Conditions: Ulcerative Colitis
Keywords: Ulcerative Colitis IMU-838 vidofludimus calcium
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 263
Healthy volunteers: no

Brief summary:
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-finding study to evaluate the efficacy and safety of IMU-838 for induction and maintenance therapy with an option for open-label treatment extension in moderate-to-severe ulcerative colitis (CALDOSE-1).

Detailed description:
The investigational medicinal product (IMP) IMU-838 (vidofludimus calcium) is a new compound that selectively inhibits the human enzyme dihydroorotate dehydrogenase (DHODH). Dihydroorotate dehydrogenase plays a major role in the de-novo pyrimidine synthesis and is specifically expressed at high levels in proliferating or activated lymphocytes. Resting lymphocytes satisfy their pyrimidine requirements through a DHODH-independent salvage pathway. Thus, IMU-838-mediated DHODH inhibition selectively affects activated, rapidly proliferating lymphocytes. The metabolic stress secondary to DHODH inhibition leads to a reduction of pro-inflammatory cytokine release including interleukin (IL)-17 (IL-17A and IL-17F) and interferon gamma (IFNγ), and to an increased apoptosis in activated lymphocytes.

This is a phase 2, multicenter, randomized, double-blind, and placebo-controlled trial in patients with moderate-to-severe UC with an option for open-label treatment extension. The study comprises a blinded induction phase to establish the optimal dose of IMU-838 to induce response and remission, a blinded maintenance phase to evaluate the potential of IMU-838 to maintain remission until Week 50, and an open-label treatment extension arm for all patients who discontinue the blinded phase as scheduled or prematurely, subject to certain restrictions. A subset of patients will undergo a pharmacokinetic (PK) period at the start of the open-label period to establish a full single-dose PK profile.

Arms:
arm 1: Two 5 mg tablets once daily of IMU-838 for 10 to 22 weeks depending on symptomatic remission at Weeks 10 or 22.

Patients will receive only half of their assigned full dose during the first week of treatment. arm 2: Two 15 mg tablets once daily of IMU-838 for 10 to 22 weeks depending on symptomatic remission at Weeks 10 or 22.

Patients will receive only half of their assigned full dose during the first week of treatment. arm 3: Two 22.5 mg tablets once daily of IMU-838 for 10 to 22 weeks depending on symptomatic remission at Weeks 10 or 22.

Patients will receive only half of their assigned full dose during the first week of treatment. arm 4: The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging. arm 5: Two 5 mg tablets once daily of IMU-838 until Week 50 or ulcerative colitis relapse. arm 6: Two 15 mg tablets once daily of IMU-838 until Week 50 or ulcerative colitis relapse. arm 7: The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of inactive ingredients, and packaging. Patients who have received placebo during the induction phase will be 're-randomized' to continue to receive placebo (in a blinded fashion). arm 8: Two 15 mg tablets once daily of IMU-838 or one 30 mg tablet IMU-838 once daily for up to 10 years and up to 3 years in UK sites

Interventions: intervention 1: IMU-838 intervention 2: Placebo
Intervention descriptions: intervention 1: IMU-838 tablet intervention 2: Tablets manufactured to mimic IMU-838 tablets

Protocol document:
Prot_SAP_000.pdf: 
 
STUDY PROTOCOL 
 
A phase 2, multicenter, randomized, double-blind, 
placebo-controlled, dose-finding study to evaluate the 
efficacy and safety of IMU-838 for induction and 
maintenance therapy in moderate-to-severe ulcerative colitis 
CALDOSE-1 
EudraCT No: 2017-003703-22 
IND No.: 134114 
 
Protocol no.: 
P2-IMU-838-UC 
Sponsor: 
Immunic AG 
Lochhamer Schlag 21 
82166 Graefelfing, Germany 
Coordinating investigator: 
Prof. Geert D’Haens 
Executive Director, Inflammatory 
Bowel Disease Centre 
Academic Medical Centre 
University of Amsterdam 
Meibergdreef 9, 1105 AZ Amsterdam,  
The Netherlands 
Protocol version and date: 
Final 6.0, 14-Dec-2021 
Previous protocol versions and date: 
Final 5.0, 26-Feb-2021 
 
Final 4.0, 17-Sep-2019 
 
Final 3.1 (UK), 23-Jan-2018 
 
Final 3.1 (PL), 01-Jun-2017 
 
Final 3.0, 21-Nov-2017 
 
Final 2.0, 24-Oct-2017 
 
Final 1.0, 16-Oct-2017 
This study protocol must be kept strictly confidential. Disclosure of the contents (in whole or part) 
to third parties is permissible only with written consent of Immunic AG. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 2 of 139 
 
Confidential 
 
 
REVISION CHRONOLOGY  
• Original version: Version 1.0, dated 16-Oct-2017 
• Version 2.0, dated 24-Oct-2017 
The following changes were included in Version 2.0 compared with Version 1.0: 
o Title page: ‘This version includes the following amendments’ was replaced by 
‘Previous protocol versions and date.’ 
o In the Schedule of assessments - induction phase (Table 1) a cross for ‘IMU-838 trough 
levels’ was included at Day 0, which was erroneously missing in protocol Version 1.0. 
o In the Schedule of assessments - open-label treatment arm (Table 3), ‘Collection of 
endoscopic assessments if available from clinical routine’ was replaced by ‘Collection 
of endoscopic results if performed during clinical routine. 
o Section 14.3: IP-10 (IFNγ induced protein) was deleted from the list of cytokines which 
will be assessed.  
• Version 3.0, dated 21-Nov-2017 
The following changes were included in Version 3.0 compared with Version 2.0: 
o Thresholds for neutrophil count and platelet count in Inclusion Criterion 6 specified in 
cells/L in addition to cell/µL or cell/mm³, respectively. 
o In Table 1 drug accountability at D7 and W2 deleted.  
o In Table 4 and Section 14.1 time windows for PK sampling time points included i.e. 
±15 minutes for each time point from 1 to 6 hours post-dose, and ±1 hour for the 24-, 
48-, and 72-hour time point.  
o Table 5 and Section 12.10 time window for EoS visit added (-3 days/+4 weeks). 
o In Section 2 and 6 responsibilities clarified: for LKF ‘biomarker’ added; IMGM 
‘genotyping and assessment of miR-122’ (no biomarkers as specified previously in 
Section 2), in Section 6 for Nuvisan packaging of IMP added. 
o Section 11.1.3: Label specification modified: 
‘The labels will contain at least the following information: route of administration, 
study code, randomization number, batch number, expiry date, as well as the following 
instructions for use: for clinical study use only, keep out of the reach of children, do 
not store above +25°C, return all unused study medication.’ 
Changed to: 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 3 of 139 
 
Confidential 
 
 
‘The labels will contain at least the following information: route of administration, 
study code, randomization number, batch number, expiry date, as well as instructions 
for storage.’ 
o Section 11.1.4: New storage condition added due to new stability data 
‘Study medication must be stored at or below +25°C (77 F) in a dry place, protected 
from direct sun light.’  
replaced by  
’In stability studies, the medicinal product was stable at ambient (25°C/60% relative 
humidity) and at accelerated storage conditions (40°C/75% relative humidity). Thus, 
IMU-838 does not require any special storage conditions. However, the tablets in 
general should be protected from direct sun light, moisture, freezing, and excessive 
heat (excessive heat is customarily defined as any temperature above 40°C [104 F]). It 
should also be advised to keep the bottle tightly closed in order to protect from 
moisture.’ 
o Section 12.5: ‘The StartOLE visit must be performed within 4 weeks of the last dose of 
the blinded treatment during the induction or maintenance phase.’ changed to ‘The 
StartOLE visit must be performed within 30 days of the last dose of the blinded treatment 
during the induction or maintenance phase’ as specified in Table 4. 
o Section 15.2.2: Lab Kits A and B, Biochemistry: ‘..magnesium chloride (MgCl),..’ 
changed to …’magnesium (Mg), chloride (Cl),..’ 
o Inconsistencies in and between Section 15.2.5 and Section 15.2.6 clarified i.e. in 
Section 15.2.5 ‘The HBcAg assay will be a combined immunoglobulin G (IgG) and 
IgM test’ changed to ‘The HBcAb assay will be a combined immunoglobulin G (IgG) 
and IgM test’, and in Section 15.2.6 under serology ‘HCV’ added. 
• Version 4.0, dated 17-Sep-2019 
The following changes were included in Version 4.0 compared with Version 3.0: 
o According to the independent DRC, the interim analysis did not show that any of the 
IMU-838 doses used in Enrollment Period 1 were likely ineffective and/or intolerable. 
Thus all 3 IMU-838 doses will be continued in Enrollment Period 2. Initially it was 
planned that Enrollment Period 2 would include only up to 2 doses of IMU-838 and 
placebo, excluding likely ineffective and/or intolerable doses based on the interim 
analysis at end of Enrollment Period 1. Enrollment Period 2 will now include 
approximately further 180 patients randomized 1:1:1:1 to oral 10 mg/day, 30 mg/day, 
45 mg/day IMU-838, or placebo (about 45 patients each) instead of the 135 patients 
planned if 2 IMU-838 doses or 150 patients if 1 IMU-838 dose would have been 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 4 of 139 
 
Confidential 
 
 
continued. In total, approximately 240 patients will be randomized into this trial in 
both, Enrollment Periods 1 and 2. The sample size calculation per se is not changed as 
for the primary endpoint analysis, on which the sample size calculation was based on, 
2 IMU-838 dose groups will be pooled and compared to the placebo groups, as already 
foreseen in the previous protocol versions. However, as Enrollment Period 2 will now 
include 3 IMU-838 treatment arms instead of the maximum planned 2 groups, an 
additional 45 need to be enrolled to ensure that 60 patients per treatment groups will 
be available for the primary analysis as stipulated in the sample size calculation (see 
Section 16.1). The following sections were adjusted accordingly: 
− 
Section 1: paragraph added to briefly describe conclusion of the interim analysis 
and consequences, primary and first secondary efficacy endpoint modified (see 
below), sample size adjusted (see below), ‘As recruitment in Enrollment Period 1 
is ongoing during the interim analysis, Enrollment Period 1 will most likely 
include a few more patients than the scheduled approximately 60 patients’ was 
deleted, Figure 1 (Study flow chart) 4 treatment arms in Enrollment Period 2 
included (instead of the possibility of 2 or 3 arms) 
− 
Section 7.2 (Study endpoints): 
 Primary endpoint. The following was adjusted:  
All patients (both, Enrollment Period 1 and Enrollment Period 2 patients) who 
were randomized to the active dose(s) selected for Enrollment Period 2 will be 
used … 
Replaced by 
All patients (both, Enrollment Period 1 and Enrollment Period 2 patients) who 
were randomized to 30 mg/day and 45 mg/day IMU-838 will be used….. 
 First secondary endpoint adjusted as follows: 
• If 2 IMU-838 doses are continued in Enrollment Period 2: proportion of patients 
with both symptomatic remission and endoscopic healing at Week 10 for the 
following comparisons: 
o the higher active dose versus placebo 
o the lower active dose versus placebo 
o the lower versus the higher active dose. 
Replaced by 
• Proportion of patients with both symptomatic remission and endoscopic healing 
at Week 10 (all individual IMU-838 doses will be compared with one 
another and to placebo).  
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 5 of 139 
 
Confidential 
 
 
− 
Section 8.1.3 (Induction phase):  
 Paragraph added to briefly describe conclusion of the interim analysis and 
consequences. 
 The following was added: ‘In total, approximately 240 patients will be 
randomized in both Enrollment Periods 1 and 2.’ 
 Paragraphs on Enrollment Period 2 adjusted accordingly. 
 ‘There will be no recruitment stop during the interim analysis. Recruitment into 
Enrollment Period 1 will continue until results of the interim analysis will be 
available and Enrollment Period 2 will be started’ deleted. 
− 
Section 8.2 (Study design rationale): Paragraph added to briefly describe 
conclusion of the interim analysis and consequences. 
− 
Section 9.1 (Sample size):  
 Sample size for Enrollment Period 2 adjusted from 135 patients, planned if 
2 IMU-838 doses were continued, or 150 patients, planned if 1 IMU-838 dose 
were continued, to 180 patients. The sample size calculation per se was, however, 
not changed (see above). 
 Included that the 30 mg/day and 45 mg/day groups will be pooled for the primary 
endpoint analysis. 
 The following was deleted: ‘Since enrollment is not stopped during interim 
analysis, a small “over-enrollment” of Enrollment Period 1 may occur. However, 
patient targets for Enrollment Period 2 will only consider the time period 
following implementation of recommendations from the interim analysis.’ 
− 
Section 11.1.5 (Treatment dose, dose selection, and administration): 
 Table 6 (Doses administered): Dosing in Enrollment Period 2 adjusted. 
 The following was included at the end of this section: ‘However, from the interim 
results the DRC concluded that none of the IMU-838 doses used in Enrollment 
Period 1 were likely ineffective and/or intolerable and the Steering Committee 
recommend continuing all 3 IMU-838 doses in Enrollment Period 2. These 
recommendations were accepted and implemented by the sponsor and thus 
Enrollment Period 2 will include all 3 IMU-838 doses.’ 
− 
Section 16.1 (Sample size calculation):  
 The possibility that 2 doses will be combined for the primary endpoint analysis 
was already implemented in the previous protocol. Now wording slightly 
modified to include that these 2 doses will be the 30 mg/day and 45 mg/day 
IMU-838.  
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 6 of 139 
 
Confidential 
 
 
 The possibility that only 1 IMU-838 dose will be continued in Enrollment 
Period 2 was deleted. 
− 
Section 16.4 (Primary efficacy analysis): adjusted and specified that the 30 mg/day 
and 45 mg/day IMU-838 will be pooled for the primary endpoint analysis and 
compared with placebo 
− 
Section 16.5 (Interim analysis): Wording slightly adjusted. 
o Section 1 (Summary and flow chart) and Section 6 (Investigators, study administrative 
structure, and study committees): 
− 
Additional countries in which the trial will be performed added i.e. Albania, 
Belarus, Bosnia-Herzegovina, North Macedonia, Norway, and Turkey. 
− 
Number of centers updated from ‘80 to 90’ to 115 
o Section 1 (Summary and flow chart) and Section 8.1.3 (Induction phase): 
To avoid confusion the following was changed: 
Section 1: 
‘All patients will receive their full dose they are randomized to starting from Week 2.’ 
replaced by ‘All patients will receive their full dose they are randomized to starting 
from Day 7.’ 
Section 8.1.3: 
‘Patients will be dosed with their full assigned dose starting Week 2 of the induction 
phase and thereafter’ replaced by ‘Patients will be dosed with their full assigned dose 
starting Day 7 of the induction phase and thereafter.’ 
o Section 1 (Summary and flow chart) and Section 9.2 (Inclusion Criteria 4): 
Additional requirement for active disease added in Inclusion Criterion 4 (Mayo rectal 
bleeding score of ≥1).  
4. Active symptoms defined as a Mayo stool frequency score of ≥2 and a modified 
Mayo endoscopy subscore of ≥2 at the screening flexible sigmoidoscopy 
(endoscopy assessed by an independent central reader blinded to screening center 
and patient information) 
replaced by 
4. Active disease defined as  
a. Mayo stool frequency score of ≥2 at Screening Visit 1  
b. Mayo rectal bleeding score of ≥1 at Screening Visit 1 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 7 of 139 
 
Confidential 
 
 
c.  modified Mayo endoscopy subscore of ≥2 at the screening flexible sigmoidoscopy 
(endoscopy assessed by an independent central reader blinded to screening center 
and patient information) 
o Section 1 (Summary and flow chart) and Section 9.3 (Exclusion Criterion 27), Section 
11.2.2 (Other prohibited and restricted medications), Appendix 1: 
Sections adapted to current version of IB and specified that care should be exercised 
when using medications that are substrates of the BCRP transport system, especially 
when the elimination of the medication depends on the BCRP transport system. Added 
that patients should be closely monitored for signs and symptoms of excessive 
exposure to these medications and that the dosing of these medications should be 
carefully considered. In addition, specified that statins should be lowered to the lowest 
possible dose and doses of rosuvastatin are not allowed to exceed 10 mg daily (during 
screening and entire study). 
o Section 1 (Summary and flow chart) and Section 9.3 (Exclusion Criterion 13), and 
Section 15.2.2: 
‘Creatinine clearance’ corrected to ‘estimated glomerular filtration rate’. 
o Section 1 (Summary and flow chart) and Section 9.3 (Exclusion Criterion 9), and 
Section 15.2.5: 
Clarified that a positive HIV-Ag/Ab test at Screening will be followed up by further 
HIV testing based on Nucleic Acid Amplification Technology (NAAT). A patient is 
only considered HIV positive when both tests are positive.  
o Section 1 (Summary and flow chart) and Section 9.3 (Exclusion Criteria for open-label 
extension arm 1 and 2): 
1. Any ongoing, clinically significant (as assessed by the investigator) treatment-
emergent (started during the IMU-838 treatment in the blinded treatment arms) 
adverse event (AE) or laboratory abnormality (including blood chemistry and 
urinalysis)*  
2. Significant treatment or study non-compliance during induction and/or 
maintenance phase (as assessed by the investigator), and/or inability or 
unwillingness to follow instructions by study personnel  
replaced by 
1. Any ongoing, clinically significant treatment-emergent (started during the IMU-
838 treatment in the blinded treatment arms) adverse event (AE) or laboratory 
abnormality (including blood chemistry and urinalysis) as assessed by the 
investigator* 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 8 of 139 
 
Confidential 
 
 
2. Significant treatment or study non-compliance during induction and/or 
maintenance phase (as assessed by the investigator), and/or inability or 
unwillingness to follow instructions by study personnel as assessed by the 
investigator 
o Section 8.1.3 (Induction phase), Section 10.3 (Maintenance of blinding during interim 
or exploratory analyses), Section 16.4 (Primary efficacy analysis) and 16.5 (Interim 
analysis): 
Time of interim analysis adjusted to what was specified in the SAP for the interim 
analysis, i.e. that the interim analysis will be conducted when in Enrollment Period 1 
approximately 60 patients have been randomized and had received at least 1 dose of 
IMP instead of ‘after approximately 60 patients had completed their W10/EoI 
assessments.’ The respective footnotes (i.e. This includes all patients who had 
completed Week 10 and those who prematurely discontinue the induction phase at 
Week 6 or between Week 6 and Week 10, for whom the Week 10/EOI assessment were 
performed at time of discontinuation) were deleted where applicable.  
o Section 1 (Summary and flow chart) and Section 23 (Study periods): 
− 
Start of trial updated from January 2018 to March 2018 
− 
Estimated end of maintenance phase changed from January 2021 to June 2022 and 
recruitment period extended from 24 months to 40 months. 
o Table 1 (Schedule of assessments - induction phase): 
− 
Screening visits identified as S1 and S2  
− 
for S1 the following footnote added: ‘Within 30 days of D0. If there is a delay in 
assessments from Screening Visit 1 or assessments need to be repeated due to 
technical difficulties, assessments from Screening Visit 1 are valid for up to 60 
days between Screening Visit 1 and randomization. If 60 days are exceeded, 
Screening Visit 1-assessments must be repeated. Note that tests can solely be 
repeated if tests are inconclusive or had technical problems. A re-screening of 
patients is not allowed (if not requested or approved by the sponsor).’ 
o Table 1 (Schedule of assessments - induction phase) and Section 13.2: 
Assessment of Mayo stool frequency score and Mayo rectal bleeding score added at 
Screening Visit 1 to allow correct calculation of Inclusion Criteria 4.  
o Table 1, Table 2, Table 3, Table 4, and Table 5 (Schedule of assessments): 
Hematology added i.e. ‘Clinical biochemistry’ replaced by ‘Clinical biochemistry and 
hematology’ and ‘CBC with differential’ deleted to be consistent with the respective 
lab kits. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 9 of 139 
 
Confidential 
 
 
o Section 2 (Addresses and responsibilities) and Section 6 (Investigators, study 
administrative structure, and study committees): 
− 
outside vendors were added for HIV testing based on the Nucleic Acid 
Amplification Technology, population PK modelling, eCRF, and emergency 
unblinding by phone 
− 
contact details were updated for IMGM Laboratories and Chiltern International 
Laboratories (now Covance) 
− 
services provided by Nuvisan were updated 
o Section 10.2 (Emergency unblinding): 
Added that emergency unblinding may be performed by an emergency phone service, 
in case the web-based system cannot be accessed for any reason. 
o Section 10.3 (Maintenance of blinding during interim or exploratory analyses), Section 
16.3 (Statistical analyses), Section 16.7 (Explorative analysis of maintenance phase) 
and Section 23 (Study report and publications): 
Because it was decided not to disclose any group level data of the interim analysis after 
Enrollment Period 1 or of the exploratory analysis of the maintenance phase to the 
Steering Committee the following was deleted in Section 10.3:  
‘However, the following selected data from the interim analysis (only group level 
averages without minimum and maximum values) could be made available to members 
of the Steering Committee, following the DRC recommendations to support their 
decision on dose continuation: 
For the interim analysis of the induction phase following Enrollment Period 1 
Percentage of patients with symptomatic response and symptomatic remission at 
Week 10 
Percentage of patients with endoscopic healing at Week 10 
Percentage of patients with any AE 
Mean CRP and mean fCP in stool 
For the exploratory analysis of the maintenance phase following data base lock for the 
final analysis of the induction phase 
Proportion of patients in symptomatic remission by visit up to Week 50 
Proportion of patients without symptomatic UC relapse until Week 50 
Proportion of patients with endoscopic healing at Week 50 
Mean CRP and mean fCP in stool’ 
In addition, as group level data are no longer disclosed it was considered appropriate 
not to finalize all SAPs before the interim analysis. The SAP for the induction phase 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 10 of 139 
 
Confidential 
 
 
that describes the primary endpoint analysis, however, was finalized before the interim 
analysis as scheduled. The following was changed: 
Section 10.3: 
‘To minimize bias, the statistical analysis plan (SAP) for all scheduled analyses i.e. 
including the interim analysis, explorative data analysis, final analysis induction phase, 
final analysis maintenance phase, and analyses for open-label phase will be finalized 
before any data will be analyzed i.e. before the interim analysis.’ 
replaced by 
‘To minimize bias, the statistical analysis plan (SAP) for the induction period (which 
includes the primary endpoint of the study) will be finalized before any data will be 
analyzed in the interim analysis.’ 
Section 16.3: 
‘A detailed description of the statistical analyses for all scheduled analyses (i.e. interim 
analysis, explorative analysis of maintenance phase, final analysis induction phase, 
final analysis maintenance phase, and analyses for the open-label phase) will be 
provided in an SAP and will be finalized before any data will be analyzed, i.e. before 
the interim analysis.’ 
replaced by  
‘A detailed description of the statistical analyses for all scheduled analyses (i.e. interim 
analysis, explorative analysis of maintenance phase, final analysis induction phase, 
final analysis maintenance phase, and analyses for the open-label phase) will be 
provided in SAPs. To minimize bias, the SAP for the induction period (which 
includes the primary endpoint of the study) will be finalized before any data will 
be analyzed in the interim analysis. 
Section 16.7: In ‘A detailed description of the analyses will be provided in the 
corresponding SAP which will be finalized before the interim analysis of the induction 
phase’ the following was deleted ’   which will be finalized before the interim analysis 
of the induction phase.’ 
Section 22: Because no groups level data will be disclosed no abbreviated report will 
be done for the interim analysis and was thus deleted in the respective paragraph. 
o Section 12.2 (Screening): 
Added that assessments from Screening Visit 1 are valid for 60 days i.e. ‘Only patients 
who have passed all eligibility criteria at Screening Visit 1 should be continued into 
Screening Visit 2 (endoscopy). If there is a delay in assessments from Screening Visit 
1 or assessments need to be repeated due to technical difficulties, assessments from 
Screening Visit 1 are valid for up to 60 days between Screening Visit 1 and 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 11 of 139 
 
Confidential 
 
 
randomization. If 60 days are exceeded, Screening Visit 1-assessments must be 
repeated. Note that tests can solely be repeated if tests are inconclusive or had technical 
problems. A re-screening of patients is not allowed (if not requested or approved by 
the sponsor).’ 
o Section 15.1.1.1 (Adverse events): 
Clarified that overdosing will not be considered an AE but must be documented as 
protocol deviation i.e. 
‘Overdose which is defined as more than twice the full randomized dose will also be 
considered AEs.’ 
replaced by 
‘Overdosing, defined as intake of more than twice the intended dose will not be 
considered an AE but must be documented as protocol deviation. However, 
symptoms associated with overdose are considered adverse drug reactions (ADR, 
for definition see Section 15.1.1.2).’ 
o Section 15.1.1.3 (Serious adverse events): 
Clarified that new malignancies that occur during the participation in the trial are 
defined as important medical events and must be reported as SAEs. 
o Section 15.2.2 (Blood chemistry, hematology, and coagulation): 
Clarified that coagulation parameters are part of Lab Kit A. 
o Section 15.2.4 (miR-122 expression): 
 ‘The exploratory biomarker miR-122…’ changed to ‘Micro RNA 122 is…’ 
o Section 15.2.6 (Screening laboratory): 
Under biochemistry ‘total bilirubin’ deleted as it was listed 2 times; eGFR (CKD-EPI) 
added as needed for eligibilty criteria. 
o Section 17 (Patient withdrawal from study participation): 
− 
To clarify that the listed reasons for withdrawal represent stopping rules for a 
patient, the following was added before the withdrawal reasons: ‘Patients must be 
withdrawn from the study for any of the following reasons.’ 
− 
For liver enzyme stopping rules, reference to Section 11.5.2 added 
o Country-specific amendments included (applicable only for the respective 
country(ies)): 
− 
Poland and UK: 
 Sections 1 (Summary and flow chart) and 9.2 (Inclusion Criterion 8):  
Inclusion criterion 8 was extended to include 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 12 of 139 
 
Confidential 
 
 
− 
that female partners of childbearing potential of sexually active male study 
participants need adequate contraception as outlined in inclusion criterion 7, 
and  
− 
that male participants whose partners are pregnant must use condoms while 
taking study medication to avoid exposure of the fetus to study medication 
(Poland only) 
 Section 11.4 (Precautions and restrictions) was modified to reflect the changes 
made to Inclusion Criterion 8 as described above. 
UK only 
 Sections 1 (Summary and flow chart), Table 3 (Schedule of assessments - open-
label treatment arm), Table 4 (Schedule of assessments - open-label treatment 
arm for PK population at designated PK centers), Sections 8.1.5 (Open-label 
treatment extension), 12.5 (Open-label treatment arm), and 23 (Study periods): 
The open-label extension treatment period was restricted to a maximum of 
3 years. The maximum study duration was changed accordingly from 10 years to 
4 years with a maximum open-label extension period of 3 years. Because the 
available data at the interim analysis were limited, the DRC did not make a 
recommendation whether the extended treatment period may be prolonged as 
specified in protocol Version 3.1 (UK). Now specified that the steering 
committee will make a recommendation after one of their future regular safety 
assessments on a potential prolongation when more safety data from the ongoing 
open-label treatment extension is available. 
o Editorial changes throughout 
• Version 5.0, dated 26-Feb-2021 
The following changes were included in Version 5.0 compared with Version 4.0: 
o Cover page and Section 2: The Sponsor address was updated. 
o Section 1 (principal investigators and study centers) and Section 6: Involved countries 
were summarized as “countries in Western and Eastern Europe and the United States 
in America”. 
o Section 1 (pharmacokinetic period), Section 8.1.6, and Section 14.1 were revised to 
clarify that the pharmacokinetic period that is scheduled at the start of the OLE period 
may be performed not only after completion of the maintenance phase but also after 
the induction or extended induction phase. Respective text in Section 9.1 was deleted 
as not considered necessary in this section. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 13 of 139 
 
Confidential 
 
 
o Section 1, Table 1, and Section 12.2: Clarified that assessments at Screening Visit 2 
may be repeated in case of technical problems within the times indicated for repetition 
of Screening Visit 1 assessments. 
o Exclusion criterion 9 (Section 1 and Section 9.3) and Section 15.2.5: It was clarified 
that any HIV, HBV, or HCV antigen or antibody screening test that shows reactive or 
borderline results (not as previously only a positive HIV-Ag/Ab test) will be confirmed 
via NAAT. If no virus specific nucleic acid is detected, and the clinical history of the 
patients, other laboratory examinations, and current clinical pictures also exclude a 
concurrent infection, the patient will not be excluded from the study. 
o Section 1, Section 11.2.2, and Appendix 1: Restricted medications were updated. 
o Section 2 and Section 6: The previous eCRF provider was replaced by ANJU Life 
Sciences Software. 
o Section 10.2 and Section 10.5: Deleted that the interactive web-based response system 
is situated within the eCRF. 
o Section 15.2: Added that clinically significantly abnormal values must be reported as 
an AE unless there are circumstances unrelated to a disease or the medication that likely 
explain the abnormal value. 
• Version 6.0, dated 14-Dec-2021 
The following changes were included in Version 6.0 compared with Version 5.0: 
o Section 1 and Section 23: Study end, study duration, actual start and recruitment period 
adjusted; maximum treatment duration in UK (blinded and open-label treatment 
combined) corrected from 3 to 4 years, as mentioned in other sections 
o Section 1 and Section 6: Number of participating centers updated 
o Added that patients in the open-label treatment extension may be transferred to a 
separate long-term follow-up trial or to commercial vidofludimus calcium (if 
applicable and patients have access). In this case the CALDOSE-1 trial will only be 
closed once all remaining patients in the open-label treatment extension have been 
transferred to the follow-up trial or commercial vidofludimus calcium. No EoS visit is 
required for patients transferring to the long-term follow-up study or commercially 
available vidofludimus calcium. The following sections were changed accordingly: 
−  Section 1 (Study duration, Methodology) 
−  Sections 8.1.1, 8.1.5, 12.5, 12.8, 12.10, and 23 
−  Section 12.9 newly added 
−  Figure 1, Table 3, Table 4, Table 5 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 14 of 139 
 
Confidential 
 
 
o The visit schedule in the open-label treatment extension after 50 weeks of overall study 
treatment was changed from a 10-week schedule to a 24-week schedule. Visit 
numbering will be kept unchanged. The time window for the OLE visits was expanded 
from ±7 days to ±14 days. The following sections were changed accordingly: 
−  Section 1 (Methodology) 
−  Table 3 and Table 4 
−  Sections 8.1.5, 11.1.3, and 12.5 
o Because of implementation of a new manufacturing process for IMU-838 tablets, a 
simplified formulation, i.e. IMU-838-RC, was introduced. This formulation contains 
fewer inactive ingredients. IMU-838-RC will be provided as 30 mg tablets packed in 
30 mL polyethylene bottles containing 85 or 100 tablets and may be used only during 
the open-label treatment extension. After switching, patients must take only 1 instead 
of 2 tablets during the open-label treatment extension. The following sections were 
changed accordingly: 
−  Section 1 (Treatments) 
−  Section 5.2.3 newly added 
− Sections 8.1.5, 11.1.1, 11.1.3, and 11.1.5 
− Table 6 
o Sections 1 (Statistical methods), 8.1.5, and 16.5: The possibility to do safety interim 
analyses during the open-label treatment extension included 
o Section 2 and Section 6: List of study personnel updated 
o During the open-label treatment extension, compliance will be assessed by the number 
of bottles dispensed and empty bottles returned (dispensed bottles must be used until 
empty and then returned; remaining tablets of in-use bottles will not be counted at every 
trial visit; patients will be advised accordingly). This differs for the EoOLE visit and 
in case of an interim safety analysis at which remaining tablets in in-use bottles will be 
counted at the last visit before the interim analysis. Patients will be advised to bring all 
IMP (including full, in-use, and empty bottles) to all visits; the empty bottles will be 
kept, the in-use and full ones will be returned to the patient (together with newly issued 
ones). The number of bottles dispensed will be up to 5 (previous formulation) or up to 
2 (simplified formulation). The following sections were changed accordingly: 
−  Sections 11.1.3, 11.1.6, 12.1, Table 3, Table 4  
o Sections 8.1.1, 11.1.3, 12.1, and Section 12.11 (newly added): contingency measures 
in case of pandemic situations introduced 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 15 of 139 
 
Confidential 
 
 
o Section 11.2.1.2 and Appendix 1 updated i.e. ‘tofacitinib’ replaced by ‘Janus kinase 
inhibitors approved for the treatment of IBD (e.g. tofacitinib)’; 
o Section 11.2.2 and Appendix 1 updated: ‘DHODH’ deleted (Section 11.2.2) as 
mentioned in Section 11.2.1.2; ‘Sphingosine-1-receptor (S1P) modulators (including, 
but not limited to fingolimod, siponimod, and ozanimod), monomethyl fumarate, and 
diroximel fumarate’ added: in Appendix 1: ‘methotrexate up to 17.5 mg/week’ deleted 
as restricted medication as methotrexate is prohibited during all phases of the study  
o Section 15.1.5: name of ‘SCRATCH Pharmacovigilance GmbH’ updated and 
‘Chiltern’ replaced by ‘sponsor’s designee’ 
o Sections 15.1.5 and 15.1.7: clarified that SAEs and pregnancies must be reported no 
later than within 24 hours to the sponsor 
o Section 15.2.3: uric acid was deleted from the urinalysis assessments (Lab Kits A, B, 
and C). The values of urine uric acid have been found to be highly variable and depend 
to a high degree on urine volumes and fluid intake by the study participants. It was seen 
that serum uric acid provides a much more reliable picture of the uric acid homeostasis 
and potential for changes caused by IMU-838. For this reason, the urine uric acid has 
been removed and the assessment will further focus on serum uric acid. 
o Section 17, the following reasons for withdrawal were added: 
− Transfer to another long-term follow-up study 
− Transfer to commercial vidofludimus calcium 
− The patient has fully completed this study 
o Section 19.1, the following reasons to halt or terminate the study were added: 
− All patients have been transferred to a long-term follow-up trial or to commercial 
supply of vidofludimus calcium 
− All patients have completed the full duration of this study 
o Section 19.2, the following reasons to close a center were added: 
− All patients of this trial center have completed the full duration of this trial, have 
been transferred or have otherwise withdrawn from this study, and investigators have 
stated in writing that they will provide answers to queries after trial site closure 
o Appendix 1: reason why BCRP substrates with a narrow therapeutic window are 
restricted added; updated according to Sections 11.2.1.2 and 11.2.2; 
o Editorial changes 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 16 of 139 
 
Confidential 
 
 
1 
Summary and flow chart 
Study code  
P2-IMU-838-UC 
Title of the study  
A phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-finding study to 
evaluate the efficacy and safety of IMU-838 for induction and maintenance therapy in moderate-to-
severe ulcerative colitis (CALDOSE-1) 
Principal investigators and study centers  
133 centers were initiated in a variety of countries in Western and Eastern Europe and the United 
States of America. 
Coordinating investigator(s): Prof. Geert D’Haens, University of Amsterdam, The Netherlands 
Clinical phase: 2 
Study duration  
Actual start: 
25-Jun-2018 (first patient in) 
Estimated end main maintenance phase: 
Oct 2022 (main part: last patient out)  
Open-label treatment:  
Not defined, but maximum treatment duration in 
this trial limited to a maximum of 10 years 
(including all phases of the trial; in UK: 
maximum of 4 years). Patients may also be 
transferred to a follow-up trial or to 
commercially available vidofludimus calcium, if 
applicable for patients with access 
Actual recruitment period: 
~41 months (24-Apr-2018 to 30-Sep-2021) 
 
Study periods  
Screening, induction phase with Enrollment Periods 1 and 2, maintenance phase, pharmacokinetics 
(PK) period, and open-label treatment extension.  
Study objectives 
Primary objective 
• To determine the optimal dose of IMU-838 to induce symptomatic remission and 
endoscopic healing in patients with moderate-to-severe ulcerative colitis (UC) 
Secondary objectives 
• To determine the optimal dose of IMU-838 to maintain clinical benefits in patients with 
moderate-to-severe UC 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 17 of 139 
 
Confidential 
 
 
• To evaluate the effects of IMU-838 on clinical and endoscopic endpoints in patients with 
moderate-to-severe UC 
• To evaluate the time course of activity and effects of IMU-838 
• To evaluate the safety and tolerability of IMU-838 in patients with moderate-to-severe UC 
• To evaluate exploratory biomarkers, disease activity biomarkers, and pharmacodynamic 
(PD) effects of IMU-838 
• To evaluate population pharmacokinetics (PK) and plasma trough levels of IMU-838 
throughout the induction period 
• To evaluate single dose PK at Week 50 for a subpopulation of patients with 
moderate-to-severe UC receiving 30 mg of IMU-838 
Methodology 
This is a phase 2, multicenter, double-blind, and placebo-controlled study including a blinded 
induction and maintenance phase, with double randomization i.e. initial randomization for 
induction and second randomization for maintenance. The study also includes an option for 
open-label treatment extension for patients discontinuing from or completing blinded treatment. A 
subset of patients will undergo a PK period at the start of the open-label period to establish a full 
single dose PK profile. Patients in the open-label treatment extension may also be transferred to 
another long-term follow-up trial or to commercially available vidofludimus calcium. Once all 
patients are transferred, the open-label treatment extension in this study will be closed. 
Induction phase 
Enrollment periods and interim analysis: The induction phase comprises Enrollment Period 1 and 
Enrollment Period 2 with an interim analysis between the 2 periods. Enrollment Period 1 will 
include approximately 60 eligible patients randomized 1:1:1:1 to oral 10 mg/day, 30 mg/day, 
45 mg/day IMU-838, or placebo (about 15 patients each). Initially it was planned that Enrollment 
Period 2 would include up to 2 doses of IMU-838 and placebo, excluding likely ineffective and/or 
intolerable doses based on an interim analysis of safety, PK, biomarker, PD and efficacy data after 
Enrollment Period 1. Because the interim analysis did not reveal a likely ineffective and/or 
intolerable dose according to the findings of the unblinded data review committee (DRC), the 
Steering Committee recommended to continue all 3 IMU-838 doses in Enrollment Period 2. These 
recommendations were accepted and implemented by the sponsor. Thus, Enrollment Period 2 will 
include approximately further 180 patients randomized 1:1:1:1 to oral 10 mg/day, 30 mg/day, 
45 mg/day IMU-838, or placebo (about 45 patients each). 
After randomization, and during the first week of study drug treatment in the induction phase, 
patients will receive only half of their assigned full dose (in both Enrollment Periods 1 and 2) i.e. 
5 mg/day, 15 mg/day, 22.5 mg/day IMU-838, or placebo, respectively. All patients will receive 
their full dose they are randomized to starting from Day 7. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 18 of 139 
 
Confidential 
 
 
Initial randomization: Eligible patients will be randomized to receive either IMU-838 (as 
applicable to the respective enrollment period) or placebo. Randomization will be stratified by prior 
use of any biologics and current use of corticosteroids. In addition, the proportion of patients who 
had received previous biologics will be limited to approximately 75% of all included patients. 
Study procedures: During the induction phase, safety, exploratory biomarkers, PD, disease activity 
biomarkers (fecal calprotectin [fCP] and C-reactive protein [CRP]), symptomatic and endoscopic 
assessments (full and partial Mayo score, and respective subscores), and trough IMU-838 blood 
levels will be regularly evaluated (see Table 1). The induction phase (both enrollment periods) will 
be at least 10 weeks, after which patients will undergo a scheduled flexible sigmoidoscopy with 
biopsy and the full Mayo score (including all subscores) will be assessed.  
Treatment after Week 10: Depending on symptomatic assessments patients will be treated as 
follows: 
• Patients who have achieved symptomatic remission at Week 10 will enter the maintenance 
phase. 
• Patients who have achieved symptomatic response but not yet in symptomatic remission 
will continue into an extended induction phase until Week 22 on the dose they were initially 
randomized to. If these patients have achieved symptomatic remission at Week 22 they will 
enter the maintenance phase.  
• Patients who do not show symptomatic response at Week 10 or symptomatic remission at 
Week 22 (if the patient had continued into the extended induction phase) will be 
discontinued from the blinded treatment but will have the option to enroll in the open-label 
treatment extension arm from Week 10 or Week 22 onwards.  
Maintenance phase 
Re-randomization: For maintenance treatment, patients who had received IMU-838 during 
induction will be re-randomized to 10 mg/day or 30 mg/day IMU-838; patients who had received 
placebo will be “re-randomized” to placebo treatment (however, their treatment assignment will 
remain blinded). Randomization will be stratified by the IMU-838 dose received in the induction 
phase.  
Study procedures during the maintenance phase: The maintenance phase will start with patients 
in symptomatic remission at Week 10 or Week 22. Patients in the maintenance phase will receive 
study medication until 50 weeks of total treatment (adding up induction, extended induction, and 
maintenance phase), or until UC relapse, whichever occurs earlier. During the maintenance phase, 
safety, disease activity biomarkers (fCP and CRP), symptomatic and endoscopic assessment (full 
and partial Mayo score, and respective subscores), and trough IMU-838 blood levels will be 
evaluated as outlined in the Schedule of events (Table 2). Patient visits will be scheduled every 4 
weeks. At Week 50 (or at time of symptomatic UC relapse, if earlier) a scheduled flexible 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 19 of 139 
 
Confidential 
 
 
sigmoidoscopy with biopsy will be performed and the full Mayo score (including all subscores) 
will be assessed.  
Treatment at the end of the maintenance phase: Depending on the symptomatic status, patients 
will be treated as follows: 
• Patients who have completed all Week 50 procedures (including the scheduled flexible 
sigmoidoscopy with biopsy) will discontinue maintenance treatment with the option to 
enroll in the open-label treatment extension arm. 
• Patients with a symptomatic UC relapse before Week 50 will be prematurely discontinued. 
At UC relapse a scheduled flexible sigmoidoscopy with biopsy will be performed and the 
full Mayo score (including all subscores) will be assessed. Patients who have completed the 
flexible sigmoidoscopy will have the option to enroll in the open-label treatment extension 
arm. 
Explorative data analysis: An explorative data analysis of the maintenance phase will be 
performed at the time of the final analysis for the induction phase (i.e. when all patients have 
completed the induction phase or if applicable extended induction phase). 
Open-label treatment extension 
Patients eligible for the open-label treatment extension arm will be treated with 30 mg IMU-838, 
once daily. Visits will be scheduled every 4 weeks for the initial 50 weeks of overall study 
treatment, and every 24 weeks thereafter. Following the implementation of Protocol Version 6.0 
the 10-week schedule, for patients in the open-label extension and with more than 50 weeks of 
overall treatment, will be changed to a 24-week schedule at the next scheduled visit. Safety, 
concomitant medication, Mayo patient-reported outcome (PRO)-2 score, fCP, and CRP, will be 
regularly assessed during clinic visits. No endoscopic assessment will be performed but results 
from such procedures will be collected when done in the course of routine clinical care. 
Treatment for a patient in the open-label extension arm will continue as long as no clinically 
significant safety issue (as assessed by the investigator) occurs, that is related to study procedures 
or study treatment, until the patient no longer receives a benefit from study treatment (as assessed 
by the investigator), until the patient withdraws consent, or until the sponsor terminates the study. 
In addition, patients in the open-label extension arm may be transferred by the sponsor to a separate 
and comparable follow-up trial in which they can continue treatment with IMU-838 or, if patients 
have access, transfer to commercially available vidofludimus calcium. Once all remaining 
participating patients have been transferred respectively, the CALDOSE-1 study will be closed. 
Patients will be allowed to receive a maximum of 10 years (not applicable for UK, see below) total 
combined treatment with study medication in this trial. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 20 of 139 
 
Confidential 
 
 
For UK the following applies: Patients will be allowed to receive a maximum of 4 years total 
combined treatment with study medication in this trial. The maximum duration of the open-label 
treatment extension is 3 years. However, if no safety concerns arise during future regular safety 
assessments and sufficient safety data are available, the steering committee may recommend 
extending the overall treatment period including all phases to a maximum of 10 years as per a 
substantial amendment. 
Pharmacokinetic period 
Across designated study centers (“PK centers”) only, the first 8 patients who completed the 
induction, extended induction or maintenance phase as scheduled and who will continue into the 
open-label phase will be included in a PK subpopulation for which a full single-dose PK profile 
(up to 72 hours post-dose) will be established. These patients will receive their first open-label dose 
of 30 mg IMU-838 at the StartOLE visit. Blood samples will be collected pre-dose and up to 72 hours 
post dose (during which period the patient will take no additional dose). On Day 3OLE, after the last 
PK blood sample has been taken, patients will continue their open-label phase with daily dosing as 
all other patients. 
Patient flow during the trial 
A chart summarizing the patient flow in this trial is included in Appendix 3. The term Baseline in 
this study defines any patient assessments done pre-dose at Day 0, or in the case of endoscopy, the 
screening endoscopy done between Day -14 to Day -3 (see Table 1). 
Treatments 
Test product 
IMU-838 (vidofludimus calcium), a small molecule inhibitor of dihydroorotate dehydrogenase 
(DHODH) 
Formulation:  
Tablets containing a specific polymorph of vidofludimus 
calcium, manufactured by wet granulation (IMU-838) or 
roller compaction (IMU-838-RC) 
Tablet strengths: 
Tablets with 5 mg, 15 mg, and 22.5 mg IMU-838, and 
30 mg IMU-838-RC (only open-label extension) 
Doses:   
Tablets will be taken once daily. 
Induction phase (tablet strengths refer to the IMU-838 formulation):  
 
Week 1: 5 mg/day (1 x 5 mg) 
Weeks 2-10 or 2-22: 10 mg/day (2 x 5 mg) 
Week 1: 15 mg/day (1 x 15 mg) 
Weeks 2-10 or 2-22: 30 mg/day (2 x 15 mg) 
Week 1: 22.5 mg/day (1 x 22.5 mg) 
Weeks 2-10 or 2-22: 45 mg/day (2 x 22.5 mg) 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 21 of 139 
 
Confidential 
 
 
All 3 IMU-838 doses will be used in Enrollment Periods 1 and 2.  
 Maintenance phase:  
10 mg/day (2 x 5 mg IMU-838) 
  
30 mg/day (2 x 15 mg IMU-838) 
 Open-label arm: 
30 mg/day (2 x 15 mg IMU-838 or 1 x 30 mg IMU-838-RC) 
Reference product 
Placebo tablets 
Number of patients (total and for each treatment) planned 
Overall about 240 patients will be enrolled: approximately 60 patients during Enrollment 
Period 1 (15 patients each) and 180 patients (45 patients each) during Enrollment Period 2 
randomized each 1:1:1:1 to oral 10 mg/day, 30 mg/day, or 45 mg/day IMU-838, or placebo. 
Inclusion criteria 
Induction phase 
1. Male and female patients, aged 18 - 80 years 
2. UC diagnosed more than 3 months before Screening (Day -30) as documented in the medical 
chart 
3. Previous treatment failure defined as:  
a. Patient had an inadequate response with, lost response to, or was intolerant to approved 
or experimental immunomodulators (azathioprine, 6-mercaptopurine, 6-thioguanine, 
methotrexate, or tofacitinib) or biologics (no more than 2 treatment failures with biologic 
drugs i.e. anti-tumor necrosis factor α antibodies [infliximab, adalimumab, golimumab 
and their biosimilars], vedolizumab, or certain experimental antibodies [ustekinumab]); 
or  
b. Patient had an inadequate response to, was intolerant to, or is corticosteroid dependent 
(corticosteroid-dependent patients are defined as i) unable to reduce steroids below the 
equivalent of prednisolone 10 mg/day within 3 months of starting steroids, without 
recurrent active disease, or ii) who have a relapse within 3 months of stopping steroids.1) 
4. Active disease defined as  
a. Mayo stool frequency score of ≥2 at Screening Visit 1  
b. Mayo rectal bleeding score of ≥1 at Screening Visit 1 
c.  modified Mayo endoscopy subscore of ≥2 at the screening flexible sigmoidoscopy 
(endoscopy assessed by an independent central reader blinded to screening center and 
patient information) 
 
1 Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, et al. Second European evidence-based 
consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis. J Crohns Colitis 
2012;6(10):965-90. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 22 of 139 
 
Confidential 
 
 
5. Endoscopic appearance typical for UC and extending >15 cm from the anal verge as 
confirmed by an independent central reader (blinded to screening center and patient 
information) 
6. Laboratory values: Neutrophil count >1500 cells/µL (> 1.5 x 10^9/L), platelet count 
≥100 000/mm3 (≥ 100 10^9/L), serum creatinine <1.5 x upper limit of normal (ULN), total 
bilirubin, alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT) 
<1.5 x ULN 
7. Female patients must   
a. Be of non-child-bearing potential i.e. surgically sterilized (hysterectomy, bilateral 
salpingectomy, bilateral oophorectomy at least 6 weeks before Screening) or 
post-menopausal (where postmenopausal is defined as no menses for 12 months without 
an alternative medical cause), or 
b. If of child-bearing potential, must have a negative pregnancy test at Screening (blood 
test) and before the first study drug administration (Day 0 urine test). They must agree 
not to attempt to become pregnant, must not donate ova, and must use a highly effective 
contraceptive method 2 months before Screening, during treatment with IMU-838, and 
at least 3 months after the last dose of study therapy 
Highly effective forms of birth control are those with a failure rate less than 1% per year 
and include: 
− 
oral, intravaginal, or transdermal combined (estrogen and progestogen containing) 
hormonal contraceptives associated with inhibition of ovulation 
− 
oral, injectable, or implantable progestogen-only hormonal contraceptives associated 
with inhibition of ovulation 
− 
intrauterine device or intrauterine hormone-releasing system 
− 
bilateral tubal occlusion 
− 
vasectomized partner (i.e. the patient’s male partner has undergone effective surgical 
sterilization before the female patient entered the clinical trial and he is the sole sexual 
partner of the female patient during the clinical trial) 
− 
sexual abstinence (acceptable only if it is the patient’s usual form of birth 
control/lifestyle choice) 
8. Male patients must agree not to father a child or to donate sperm starting at Screening and 
throughout the clinical trial and for 3 months after the last dose of study medication. Male 
patients must also either 
o abstain from sexual intercourse with a female partner (acceptable only if it is the 
patient’s usual form of birth control/lifestyle choice), Or 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 23 of 139 
 
Confidential 
 
 
o use adequate barrier contraception during treatment with IMU-838 and for at least 
3 months after the last dose of study medication 
For Poland and the UK the following additional requirement apply: 
o if male patients have a female partner of childbearing potential, the partner should use 
a highly effective contraceptive method as outlined in inclusion criterion 7 
And additionally, for Poland only: 
o if male patients have a pregnant partner, they must use condoms while taking study 
medication to avoid exposure of the fetus to study medication 
9. Ability to understand and comply with study procedures and restrictions  
10. The patient is legally competent, has been informed of the nature, the scope and the 
relevance of the study, voluntarily agrees to participation and the study’s provisions and has 
duly signed the informed consent form  
Maintenance phase 
1. Symptomatic remission achieved at Week 10 or Week 22 of the induction phase 
 
Open-label treatment extension arm 
1. Patient is in the induction phase, had received at least 6 weeks of blinded study treatment and 
completed the sigmoidoscopy (incl. biopsy) regularly scheduled at Week 10/EoI, and has 
neither reached symptomatic remission nor symptomatic response 
Or 
Patient is in the extended induction phase, had completed all Week 10 assessments, and has 
not reached symptomatic remission during or at the end of the extended induction phase,  
Or 
Patient is in the maintenance phase and discontinues from the maintenance phase due to 
symptomatic UC relapse or other reasons with a flexible sigmoidoscopy performed at 
discontinuation (if the previous sigmoidoscopy had been performed more than 4 weeks 
before discontinuation)  
Or  
Patient has completed the maintenance phase as scheduled (including all Week 50 
assessments) 
Exclusion criteria 
Gastrointestinal exclusion criteria 
1. Diagnosis of Crohn’s disease, inflammatory bowel disease type unclassified, ischemic 
colitis, microscopic colitis, radiation colitis or diverticular disease-associated colitis 
2. Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 24 of 139 
 
Confidential 
 
 
3. History of colectomy with ileorectal anastomosis or ileal-pouch anal anastomosis or 
imminent need for colectomy (i.e. colectomy is being planned) 
4. Active therapeutically uncontrollable abscess or toxic megacolon 
5. Malabsorption or short bowel syndrome  
6. History of colorectal cancer or colorectal dysplasia (with the exception of dysplasia in 
polyps which have been removed) 
Infectious disease exclusion criteria 
7. Clostridium difficile (C. difficile) infection  
o Evidence of, or treatment for C. difficile infection within 30 days before first 
randomization  
o Positive C. difficile toxin B stool assay during the screening period 
8. Treatment for intestinal pathogens other than C. difficile within 30 days prior to first 
randomization  
9. Other chronic systemic infections 
o History of chronic systemic infections including but not limited to tuberculosis, human 
immunodeficiency virus (HIV), hepatitis B or C, within 6 months before Screening 
o Positive interferon-gamma release assay (IGRAs) for Mycobacterium tuberculosis at 
Screening 
o Positive HBsAg (hepatitis B virus surface antigen), HBcAb (hepatitis B core antibody), 
positive hepatitis C virus and/or HIV-antigen-antibody (HIV-Ag/Ab) test2 at Screening 
10. Any live vaccinations within 30 days prior to study drug administration except for the 
influenza vaccine 
Other medical history and concomitant disease exclusion criteria 
11. Known history of nephrolithiasis or underlying condition with a strong association of 
nephrolithiasis, including hereditary hyperoxaluria or hereditary hyperuricemia 
12. Diagnosis or suspected liver function impairment which may cause, as assessed by the 
investigator, a potential for fluctuating liver function tests during this trial 
13. Renal impairment i.e. estimated glomerular filtration rate3 ≤60 mL/min/1.73m² 
 
2 If any HIV, HBV, or HCV antigen or antibody screening test shows reactive or borderline results, a confirmatory 
Nucleic Acid Amplification Test (NAAT) will automatically be performed for the detection of the virus by using 
the same blood draw sample. If no virus specific nucleic acid is detected, and the clinical history of the patient, 
other laboratory examinations, and current clinical pictures also exclude a concurrent infection, the patient will not 
be excluded from the study.  
3 Calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 25 of 139 
 
Confidential 
 
 
14. Serum uric acid levels at Screening >1.2 x ULN (for women >6.8 mg/dL, for men 
>8.4 mg/dL) 
15. History or clinical diagnosis of gout  
16. Known or suspected Gilbert syndrome 
17. Indirect (unconjugated) bilirubin ≥1.2 x ULN at Screening (i.e. ≥ 1.1 mg/dL) 
18. Concurrent malignancy or prior malignancy within the previous 10 years except for the 
following: adequately-treated non-melanoma skin cancer and adequately-treated cervical 
cancer 
Therapy exclusion criteria 
19. Use of any investigational product within 8 weeks or 5 x the respective half-life before first 
randomization, whatever is longer 
20. Use of the following medications within 2 weeks before first randomization: 
a. Tofacitinib 
b. Methotrexate, 
c. Mycophenolate mofetil 
d. Any calcineurin inhibitors (e.g. tacrolimus, cyclosporine, or pimecrolimus) 
e. Oral systemic corticosteroids >20 mg/day prednisolone equivalent including 
beclomethasone dipropionate (at >5 mg/day) and budesonide (multi-matrix [MMX] at 
>9 mg/day) 
f. Oral aminosalicylates (e.g. mesalazines) >4 g/day 
21. Use of the following medications within 4 weeks before first randomization: 
a. Use of intravenous corticosteroids 
b. Use of thiopurines including azathioprine, mercaptopurine and 6-thioguanine 
c. Use of any rectal and topical aminosalicylates and/or budesonide 
22. Use of oral systemic corticosteroids ≤20 mg/day prednisolone equivalent including 
beclomethasone dipropionate (at ≤5 mg/day) and budesonide (MMX at ≤9 mg/day) unless 
they have been used for at least 4 weeks before first randomization and at a stable dose for 
at least 2 weeks before first randomization  
23. Oral aminosalicylates (e.g. mesalazines) ≤4 g/day unless they have been used for at least 6 
weeks and with a stable dose for at least 3 weeks before first randomization 
24. Use of biologics as follows:  
a. anti-tumor necrosis factor α antibodies (infliximab, adalimumab, golimumab, 
including their biosimilars) within 4 weeks before first randomization 
b. vedolizumab and ustekinumab within 8 weeks before first randomization 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 26 of 139 
 
Confidential 
 
 
25. Use of the DHODH inhibitors leflunomide or teriflunomide within 6 months before first 
randomization 
26. Any use of natalizumab (Tysabri™) within 12 months before first randomization 
27. Use of the following concomitant medications is prohibited at Screening and throughout the 
duration of the trial:  
o any medication known to significantly increase urinary elimination of uric acid, in 
particular lesinurad (Zurampic™) as well as uricosuric drugs such as probenecid 
o treatments for any malignancy, in particular irinotecan, paclitaxel, tretinoin, bosutinib, 
sorafinib, enasidenib, erlotinib, regorafenib, pazopanib and nilotinib 
o any drug significantly restricting water diuresis, in particular vasopressin and 
vasopressin analogs  
o Rosuvastatin at doses ˃10 mg/day 
General exclusion criteria 
28. History of, or current serious, severe, or unstable (acute or progressive) physical or mental 
illness, or any medical condition, including laboratory anomalies or renal or hepatic 
impairment, that may require treatment or would put the patient in jeopardy if he/she was to 
participate in the study  
29. Known hypersensitivity to DHODH inhibitors (teriflunomide, leflunomide) or any 
ingredient of the investigational product 
30. Pregnancy or breastfeeding 
31. History of drug or alcohol abuse during the past year 
32. Concurrent participation in any other clinical trial using an investigational medicinal product 
or medical device 
33. An employee of an investigator or sponsor or an immediate relative of an investigator 
Exclusion criteria for open-label treatment extension arm 
1. Any ongoing, clinically significant treatment-emergent (started during the IMU-838 
treatment in the blinded treatment arms) adverse event (AE) or laboratory abnormality 
(including blood chemistry and urinalysis) as assessed by the investigator * 
2. Significant treatment or study non-compliance during induction and/or maintenance phase 
(as assessed by the investigator), and/or inability or unwillingness to follow instructions by 
study personnel as assessed by the investigator 
3. Significant protocol deviations during induction and/or maintenance phase that are assessed 
by the investigator to negatively affect further patient cooperation in this study 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 27 of 139 
 
Confidential 
 
 
* If treatment-emergent AEs are the reason for exclusion from the open-label extension arm, the eligibility can 
be re-assessed up to 30 days following the last treatment in the blinded treatment arms. 
Criteria for evaluation 
Primary 
Efficacy 
Induction phase 
• Composite endpoint: Proportion of patients with both, symptomatic remission and 
endoscopic healing at Week 10 
All patients (both, Enrollment Period 1 and Enrollment Period 2 patients) who were 
randomized to 30 mg/day and 45 mg/day IMU-838 will be used for the assessment of the 
primary efficacy endpoint (see Section 16.4 for further information). 
Secondary 
Efficacy 
Induction phase and extended induction phase 
• Proportion of patients with both symptomatic remission and endoscopic healing at Week 10 
(all individual IMU-838 doses will be compared with one another and to placebo)  
• Proportion of patients achieving symptomatic remission during the induction phase 
(including extended induction phase) 
• Time to achieving symptomatic remission within the induction/extended induction phase 
• Proportion of patients with clinical response at Week 10 
• Proportion of patients with endoscopic healing at Week 10  
• Proportion of patients with symptomatic response during the induction phase (including 
extended induction phase) 
• Time course of Mayo scores (full score, partial score, PRO-2 score) over 10 or 22 weeks 
and changes from Baseline 
• Time course of disease activity biomarkers (fCP and CRP) 
Maintenance phase  
• Proportion of patients in symptomatic remission by visit up to Week 50 
• Proportion of patients in durable symptomatic remission up to Week 50 
• Time course of Mayo PRO-2 score until Week 50 
• Time to symptomatic UC relapse 
• Proportion of patients without symptomatic UC relapse until Week 50 
• Time course of disease activity biomarkers (fCP and CRP) 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 28 of 139 
 
Confidential 
 
 
• Proportion of patients with endoscopic healing at Week 50 
• Proportion of patients with microscopic healing at Week 50 
• Corticosteroid-free remission at Week 50 in patients receiving corticosteroids at Baseline 
Open-label treatment extension arm 
• Proportion of patients with symptom control  
• Time course of disease activity biomarkers (fCP and CRP) 
Safety 
• Incidence and severity of AEs 
• Physical examination, body weight, and vital signs* 
• Electrocardiogram (12-lead ECG)* 
• Safety laboratory: hematology, clinical chemistry including liver function, coagulation 
parameters, urinalysis 
• Micro ribonucleic acid-122 (miR-122) expression (before first dose and 24 hours after first 
dose) 
* Only induction and maintenance phase. 
Pharmacokinetics 
• Plasma trough levels of IMU-838 throughout the induction period 
• Population PK analysis 
• Full single-dose PK including area under the drug concentration-time curve from time zero 
to 24 hours (AUC0-24h), AUC0-t (AUC time zero to last measurable concentration), AUC0-
inf (AUC time zero to infinity), maximum plasma concentration (Cmax), time to Cmax (Tmax) 
(in a subset of patients in designated PK centers) 
Further exploratory assessments 
Induction phase 
• Changes from Baseline in biomarker and PD parameters (blood cytokines) during induction 
up to Week 10 
• Correlation of efficacy variables at Week 10 with quartiles of IMU-838 trough levels at 
Week 2 
• Correlation of efficacy variables at Week 10 with biomarker and PD parameters up to 
Week 6 
• If feasible, estimate the relationship between IMU-838 PK and selected safety and efficacy 
parameters 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 29 of 139 
 
Confidential 
 
 
Statistical methods 
The primary endpoint for this study is the composite endpoint proportion of patients with both 
symptomatic remission and endoscopic healing at Week 10. 
All patients (both Enrollment Period 1 and Enrollment Period 2 patients) who were randomized to 
30 mg/day and 45 mg/day IMU-838 will be combined and compared with placebo. 
A stratified Cochran-Mantel-Haenszel test will be used for the analysis of the primary endpoint in 
order to adjust for the stratification factors prior use of any biologics and current use of 
corticosteroids. The primary analysis will be based on the full analysis set. 
Sample size calculation is based on the primary endpoint assessed at Week 10 during the final 
analysis of the induction phase as follows:  
With 3 dose groups (30 mg/day and 45 mg/day IMU-838 and placebo) about 49 patients per group 
are required to show a difference of 16% between the verum group and placebo assuming a placebo 
remission rate of about 10%, a significance level of 0.097, and a power of 80%. Assuming a drop-
out rate of 20%, approximately 60 patients will be required per group.  
Underlying assumptions:  
Primary endpoint: composite of symptomatic remission and endoscopic healing 
Underlying test: Chi square test 
Randomization:  Enrollment Periods 1 and 2: 
1:1:1:1 
 
The sample size is based on a comparison of the 30 mg/day and 45 mg/day 
IMU-838 treatment groups combined vs placebo.  
Power:  
80%  
Significance level: 0.097, 1-sided 
In this early stage development study, a higher α, i.e. 0.1, than the standard 
0.025 level is considered appropriate. Due to the interim analysis and to keep 
the overall α-level to 0.1, this level must be adjusted. A group sequential design 
with O’Brien-Fleming boundaries will be applied. Accordingly, the sample 
size calculation is based on a significance level of 0.097, 1-sided. 
No formal sample size calculation was performed for the sample size of the interim analysis of this 
small phase 2 study. However, and based on preliminary experiences, 15 patients per group were 
deemed sufficient to show numerical differences between placebo and verum, and between dose 
groups. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 30 of 139 
 
Confidential 
 
 
Interim analyses 
During the open-label treatment extension in addition to data review (as outlined in the Steering 
Committee Charter), safety interim analyses may be performed at the request of the sponsor or the 
Steering Committee.  
 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 31 of 139 
 
Confidential 
 
 
          10 or 22 weeksd                        10 or 22 weeksd                                          Until W50 or UC relapse  
                                                                                                               
Schedules of assessments and flow chart 
Figure 1: 
Study flow chart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a Initially it was planned that Enrollment Period 2 would include up to 2 doses of IMU-838 and placebo, excluding likely ineffective 
and/or intolerable doses based on the results of the interim analysis after Enrollment Period 1. Because the interim analysis did 
not reveal a likely ineffective and/or intolerable dose according to the unblinded DRC, the Steering Committee recommended to 
continue all 3 IMU-838 doses in Enrollment Period 2. 
b Assuming that 60% of IMU-838-treated patients in the induction phase will have a symptomatic remission. 
c Assuming that 30% of placebo-treated patients in the induction phase will have a symptomatic remission. 
d Patients who show symptomatic response but no symptomatic remission at Week 10 will continue induction treatment until 
Week 22. If the patient shows symptomatic remission at Week 22, the patient will continue with maintenance treatment.  
e If patients are transferred to another long-term follow-up study or to commercially available vidofludimus calcium, the open-
label arm will be closed early once all remaining patients are transferred. 
DRC = data review committee, IMU = IMU-838, R = randomization, UC = ulcerative colitis, W = Week. 
 
30 mg IMU-838 
Induction phase 
Maintenance phase 
Enrollment Period 1 
Enrollment Period 2a 
                              Interim analysis          Final analysis induction phase                                          Final analysis 
                                                  Explorative data analysis maintenance phase                       maintenance phase 
                                                 
Patients without any major deviations from dosing schedule or non-compliance who completed at least 
6 weeks of induction treatment and completed a sigmoidoscopy or who discontinued from the 
maintenance phase as scheduled or prematurely and have a flexible sigmoidoscopy available at 
discontinuation and wish to receive further treatment with IMU-838  
Open-label arme 
 
 
Placebo 
 
Placebo   
 
(N = 15)  
(N = 45)  
 
 
10 mg IMU 
10 mg IMU 
     
(N = 15)  
(N = 45) 
 
 
30 mg IMU 
30 mg IMU    
(N = 15)  
(N = 45) 
 
 
 
 
45 mg IMU 
45 mg IMU 
(N = 15)   
(N = 45) 
 
R
 
Placebo 
(N ~ 18c) 
10 mg IMU 
(N ~ 54) 
 
30 mg IMU 
(N ~ 54) 
 
Patients with symptomatic remission  
 at Weeks 10 or 22 
R
N ~108b  
R
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 32 of 139 
 
Confidential 
 
 
Table 1: 
Schedule of assessments - induction phase 
Assessment 
Screen. 
Induction phase 
Ext. induct.a 
 D-30 
to -5  
D-14 
to -3 
D0 
D1 
D7 
W2 
W6 W10/
EoIg 
W10 W14 W18 W22/
EoEI 
 
S1l 
S2m 
BL 
 
±1d 
±2d 
±3d ±3 d 
±3d 
±7d 
±7d 
±7d 
Signed informed consent 
x 
 
 
 
 
 
 
 
 
 
 
 
In- and exclusion criteria 
x 
 
xc 
 
 
 
 
 
 
 
 
 
Physical examination 
x 
 
x 
 
 
 
 
x 
 
 
 
x 
Height  
x 
 
 
 
 
 
 
 
 
 
 
 
Weight 
x 
 
x 
 
 
x 
x 
x 
 
x 
x 
x 
Medical + disease history 
x 
 
 
 
 
 
 
 
 
 
 
 
Concomitant medication 
x 
 
x 
x 
x 
x 
x 
x 
 
x 
x 
x 
Previous UC medication 
x 
 
x 
 
 
 
 
 
 
 
 
 
Stool frequency reference 
value 
x 
 
 
 
 
 
 
 
 
 
 
 
Partial Mayo score+PRO2 
 
 
x 
 
 
x 
x 
x 
 
x 
x 
x 
Full Mayo score 
 
 
x 
 
 
 
 
x 
 
 
 
 
Mayo stool frequency and 
rectal bleeding score 
xk 
 
 
 
 
 
 
 
 
 
 
 
Randomization 
 
 
x 
 
 
 
 
 
 
 
 
 
Sigmoidoscopy + biopsyb 
 
x 
 
 
 
 
 
x 
 
 
 
 
Central reading 
 
x 
 
 
 
 
 
x 
 
 
 
 
Geboes score 
 
x 
 
 
 
 
 
x 
 
 
 
 
Immunohistochemistry 
 
x 
 
 
 
 
 
x 
 
 
 
 
Laboratory assessments 
 
 
 
 
 
 
 
 
 
 
 
 
Central screening labs, 
incl. blood pregnancy 
test 
x 
 
 
 
 
 
 
 
 
 
 
 
Local screening labs, 
incl. Clostridium toxin 
and Tbc-IGRA 
x 
 
 
 
 
 
 
 
 
 
 
 
Blood biochemistry and 
hematology 
 
 
x 
x 
x 
x 
x 
x 
 
x 
x 
x 
Coagulationd 
 
 
x 
x 
 
x 
 
x 
 
 
 
 
Urinalysis 
 
 
x 
x 
x 
x 
x 
x 
 
xe 
xe 
x 
Blood cytokinesd 
 
 
x 
x 
 
x 
 
x 
 
 
 
 
Fecal calprotectin 
 
 
x 
 
 
x 
x 
x 
 
x 
x 
x 
Genotypingd 
 
 
x 
 
 
 
 
 
 
 
 
 
IMU-838 trough levelsd 
 
 
x 
x 
x 
xj 
x 
x 
 
 
 
 
IMU-838 plasma conc.d 
 
 
 
 
 
xj 
 
 
 
 
 
 
Local urine pregnancy 
testf 
 
 
x 
 
 
 
x 
x 
 
x 
x 
x 
mIR-122d 
 
 
x 
x 
 
 
 
 
 
 
 
 
 
continued 
 
 
 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 33 of 139 
 
Confidential 
 
 
Table 1: 
Schedule of assessments - induction phase (continued) 
Assessment 
Screen. 
Induction phase 
Ext. induct.a 
 D-30 
to -5  
D-14 
to -3 
D0 
D1 
D7 
W2 
W6 W10/EoIg W10 W14 W18 W22/ 
EoEI 
 
S1l 
S2m 
BL 
 
±1d 
±2d 
±3d 
±3 d 
±3d 
±7d 
±7d 
±7d 
Lab Kits used 
 
 
 
 
 
 
 
 
 
 
 
 
Screening lab kit 
S 
 
 
 
 
 
 
 
 
 
 
 
Study lab kit 
 
 
A 
A 
B 
A 
B 
A 
 
C 
C 
B 
Genotyping 
 
 
G 
 
 
 
 
 
 
 
 
 
Fecal calprotectin 
 
 
FC 
 
 
FC 
FC 
FC 
 
FC 
FC 
FC 
mIR-122 
 
 
BM BM 
 
 
 
 
 
 
 
 
Single PK kit  
 
 
PK1 
PK1 PK1 2xPK1j PK1 
PK1 
 
 
 
 
Biopsy kit 
 
BK 
 
 
 
 
 
BK 
 
 
 
 
Shipments to central lab 
 
 
 
 
 
 
 
 
 
 
 
 
Ambient temperature 
x 
 
x 
x 
x 
x 
x 
x 
 
x 
x 
x 
Dry ice 
 
 
 
 
 
 
 
xi 
 
 
 
 
Adverse events 
x 
x 
x 
x 
x 
x 
x 
x 
 
x 
x 
x 
Vital signs 
x 
 
x 
 
x 
x 
x 
x 
 
x 
x 
x 
ECG 
x 
 
 
 
 
 
 
x 
 
 
 
x 
Drug accountability 
 
 
 
 
 
 
x 
x 
 
x 
x 
x 
Dispense of study med. 
 
 
x 
 
 
 
x 
 
x 
x 
x 
 
Diary instruction 
 
x 
 
 
 
 
 
 
 
 
 
 
Patient diary 
 
 
 
 
 
 
 
 
 
      h       h       h 
Diary review 
 
 
x 
 
x 
x 
x 
x 
 
x 
x 
x 
a Extended induction phase: only applicable for patients with symptomatic response but not yet symptomatic remission at 
Week 10.       
b Only to be done if all other eligibility criteria assessed at the first screening visit (D-30 to -5) are met. If a full colonoscopy 
was not performed in the previous year, the screening sigmoidoscopy should be replaced by a full colonoscopy. Includes 
assessment of histological score.  
c Before randomization. 
d Samples to be stored at -20°C until next scheduled dry-ice shipment to central laboratory. 
e Urine sediment analysis will only be done when urine dipstick analysis (performed at central laboratory) was positive for 
RBC. 
f Any positive local urine pregnancy test has to be followed up with a confirmatory local blood pregnancy test. 
g These assessments have to be performed for all patients completing Week 10 and those who prematurely discontinue the 
induction phase at Week 6 or between Week 6 and Week 10. 
h Completed only during the 5 days preceding the respective visit. 
i Samples requiring dry-ice shipment will be collected throughout the induction period, stored at -20°C freezing conditions 
and then sent to the central laboratory following the Week 10 visit. 
j At Week 2, IMU-838 plasma levels will be assessed pre-dose (trough level) and 3 to 10 hours post dose (the actual time of 
the second blood collection can be chosen based on the patient’s preference but must be between 3 and 10 hours after 
dosing). 
k Will be assessed retrospectively. 
 l Within 30 days of D0. If there is a delay in assessments from Screening Visit 1 or assessments need to be repeated due to 
technical difficulties, assessments from Screening Visit 1 are valid for up to 60 days between Screening Visit 1 and 
randomization. If 60 days are exceeded, Screening Visit 1-assessments must be repeated. Note that tests can solely be 
repeated if tests are inconclusive or had technical problems. A re-screening of patients is not allowed (if not requested or 
approved by the sponsor). 
m In case of technical problems, assessments at Screening Visit 2 may be repeated within the times indicated for repetition of 
Screening Visit 1 assessments. 
BL = baseline, conc. = concentration, D = day, ECG =electrocardiogram, EoI = end-of-induction, EoEI = end-of-extended-
induction, ext. = extended, IGRA = interferon gammy release assay, incl. = including, induct. = induction phase, lab = laboratory, 
med.= medication, miR-122 = micro RNA 122, RBC = red blood cells, PK = pharmacokinetics, PRO = patient-reported outcome, 
RNA = ribonucleic acid, Screen. = screening, Tbc = tuberculosis, UC = ulcerative colitis, W = week. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 34 of 139 
 
Confidential 
 
 
Table 2: 
Schedule of assessments - maintenance phase  
 
Start 
maintenance 
phasea 
Maintenance phase 
 
W14, 18b 
W22b 
W26, 30, 34, 38, 42, 46 
W50/EoM 
 
±7d (each) 
±7d 
±7d (each) 
±7 d 
Inclusion criterion 
x 
 
 
 
 
Physical examination 
 
 
x 
 
x 
Weight 
 
x 
x 
x 
x 
Concomitant medication 
x 
x 
x 
x 
x 
Partial Mayo score+PRO-2 
 
x 
x 
x 
x 
Full Mayo score 
 
 
 
 
xd 
Randomization 
x 
 
 
 
 
Sigmoidoscopy + biopsy 
 
 
 
 
xd 
Central reading 
 
 
 
 
xd 
Geboes score 
 
 
 
 
xd 
Laboratory assessments 
 
 
 
 
 
Blood biochemistry and 
hematology 
 
x 
x 
x 
x 
Urinalysis 
 
xe 
x 
xe 
x 
Fecal calprotectin 
 
x 
x 
x 
x 
Local urine pregnancy testf 
 
x 
x 
x 
 
Lab kits used 
 
 
 
 
 
Study lab kit 
 
C 
B 
C 
B 
Fecal calprotectin 
 
FC 
FC 
FC 
FC 
Biopsy kit 
 
 
 
 
BK 
Shipments to central lab 
 
 
 
 
 
Ambient temperature 
 
x 
x 
x 
x 
Adverse events 
 
x 
x 
x 
x 
Vital signs 
 
x 
x 
x 
x 
ECG 
 
 
x 
 
x 
Drug accountability 
 
x 
x 
x 
x 
Dispense study medication 
x 
x 
x 
x 
 
Patient diary 
        c 
        c  
      c 
          c 
         c  
Diary review 
 
x 
x 
x 
x 
a At Week 10 following induction phase or Week 22 of extended induction phase, depending on when the patient enters 
the maintenance phase.       
b Only if patient has switched to maintenance phase at Week 10. 
c Completed only during the 5 days preceding the respective visit. 
d In case of early discontinuation during maintenance phase, the sigmoidoscopy and full Mayo score assessment is to be 
performed at the time of discontinuation, unless this occurs less than 4 weeks after the last sigmoidoscopy examination. 
e Urine sediment analysis will only be done when urine dipstick analysis (performed at central laboratory) was positive 
for RBC. 
f 
Any positive local urine pregnancy test has to be followed up with a confirmatory local blood pregnancy test. 
AE = adverse event, ECG =electrocardiogram, EoM = end-of-maintenance, lab = laboratory, RBC = red blood cells, 
PRO = patient-reported outcome,  W = week. 
 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 35 of 139 
 
Confidential 
 
 
Table 3: 
Schedule of assessments - open-label treatment arm  
Assessment 
Treatment period 
 
StartOLEa 
Week XOLEb 
EoOLEc 
 
 
±14d 
 
Inclusion and exclusion criteria 
xe 
 
 
Concomitant medication 
xd 
x 
x 
Mayo PRO-2 score 
xd 
x 
x 
Laboratory assessments 
 
 
 
Blood biochemistry and hematology 
xd 
x 
x 
Urinalysis 
xd,f 
xf 
xf 
Fecal calprotectin 
xd 
 
x 
Local urine pregnancy testg 
xd 
x 
x 
Lab kits used 
 
 
 
Study lab kit 
Cd 
C 
C 
Fecal calprotectin 
FCd 
 
FC 
Shipments to central lab 
 
 
 
Ambient temperature 
xd 
x 
x 
Adverse events 
xd 
x 
x 
Collection of endoscopic results if performed during clinical routineh 
 
x 
x 
Weight 
xd 
x 
x 
Vital signs 
xd 
x 
x 
Dispense study medication 
x 
x 
 
Drug accountability 
 
xi 
x 
a 
Open-label treatment has to start within 30 days of the last dose of the blinded treatment arms. 
b 
Clinic visits will be scheduled every 4 weeks (±7 days) until 50 weeks of total study participation (i.e. induction + extended 
induction, if applicable, maintenance + open-label part) and every 10 weeks (±7 days) thereafter. The visit schedule in the 
open-label treatment extension after 50 weeks of overall study treatment is changed from a 10-week schedule to a 24-week 
(±14 days) schedule after Protocol Version 6.0 comes into force. 
c 
Patients can continue treatment as long as there are no clinically significant safety issues (as assessed by the investigator), 
that are related to study procedures or study treatment, as long as the patient benefits from study treatment (as assessed by 
the investigator), until the patient withdraws consent, or until the sponsor terminates the study. In addition, if patients will be 
transferred to a long-term follow-up study or to vidofludimus calcium, the extended treatment period will be closed early 
once all remaining participants are transferred. Patients will be allowed to be treated with study medication for a maximum 
of 10 years (not applicable for UK) including all periods of the trial. For the UK the following applies: Patients will be 
allowed to be treated with open-label study medication for a maximum of 3 years (may be extended, see Section 8.1.5). 
d 
Only to be performed if the open-label treatment starts more than 3 weeks after the last regular study visit. 
e 
If continuing treatment-emergent adverse events are the reason for exclusion from the open-label extension arm, the eligibility 
can be re-assessed up to 4 weeks following the last treatment in the blinded treatment arms. 
f 
Urine sediment analysis will only be done when urine dipstick analysis (performed at central laboratory) was positive for 
RBC. 
g 
Any positive local urine pregnancy test has to be followed up with a confirmatory local blood pregnancy test. 
h  
Videotapes will not be collected and not centrally assessed. The investigator’s judgment of the endoscopy results will be 
collected in the eCRF. 
i 
During the open-label extension treatment period, dispensed bottles must be used until empty and then returned; remaining 
tablets of in-use bottles will not be counted at every study visit. Patients will be advised to bring all IMP (including full, in-
use and empty bottles) to all visits; the empty bottles will be kept, the in-use and full ones will be returned to the patient 
(together with newly issued ones). Patients will also be advised to completely use up the tablets in one bottle before starting 
a new bottle. Only the number of bottles dispensed, and number of empty bottles returned will be counted. Counting of tablets 
for any in-use bottle will only be performed for any safety interim analysis, as communicated by the sponsor. 
IMP = investigational medicinal product, Lab = laboratory, RBC = red blood cells, OLE = open-label extension, PRO = patient-
reported outcome, EoOLE = end-of-treatment open-label extension. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 36 of 139 
 
Confidential 
 
 
Table 4: 
Schedule of assessments - open-label treatment arm for PK population at 
designated PK centers 
Assessment 
Treatment period 
 StartOLEa Day 1OLE 
Day 2OLE Day 3OLE 
Week XOLEb 
EoOLEc 
 
 
 
 
 
±14d 
 
Inclusion and exclusion criteria 
xe 
 
 
 
 
 
Concomitant medication 
xd 
 
 
 
x 
x 
Mayo PRO-2 score 
xd 
x 
x 
x 
x 
x 
Laboratory assessments 
 
 
 
 
 
 
Blood biochemistry and hematol. 
xd 
 
 
 
x 
x 
Urinalysis 
xd,h 
 
 
 
xh 
xh 
Fecal calprotectin 
xd 
 
 
 
 
x 
Dosing with 30 mg IMU-838 
x 
 
 
xf 
as scheduled 
 
IMU-838 full PKi 
x 
x 
x 
x 
 
 
Local urine pregnancy testg 
xd 
 
 
 
x 
x 
Lab kits used 
 
 
 
 
 
 
Study lab kit 
Cd 
 
 
 
C 
C 
Fecal calprotectin 
FCd 
 
 
 
 
FC 
Full PK kit 
PK2 
 
 
 
 
 
Shipments to central lab 
 
 
 
 
 
 
Ambient temperature 
xd 
 
 
 
x 
x 
Dry ice shipment 
 
 
 
xf 
 
 
Adverse events 
xd 
 
 
 
x 
x 
Collection of endoscopic results if 
performed during clinical routinej 
 
 
 
 
x 
x 
Weight 
xd 
 
 
 
x 
x 
Vital signs 
xd 
 
 
 
x 
x 
Dispense study medication 
x 
 
 
 
x 
 
Drug accountability 
 
 
 
 
xk 
x 
 
a 
Open-label treatment has to start within 30 days of the last dose of the blinded treatment arms. 
b 
Clinic visits will be scheduled every 4 weeks (±7 days) until 50 weeks of total study participation (i.e. induction + extended 
induction, if applicable, maintenance + open-label part) and every 10 weeks (±7 days) thereafter. The visit schedule in the 
open-label treatment extension after 50 weeks of overall study treatment is changed from a 10-week schedule to a 24-
week (±14 days) schedule after Protocol Version 6.0 comes into force. 
c 
Patients can continue treatment as long as there are no clinically significant safety issues (as assessed by the investigator), 
that are related to study procedures or study treatment, as long as the patient benefits from study treatment (as assessed by 
the investigator), until the patient withdraws consent, or until the sponsor terminates the study. In addition, if patients will 
be transferred to a long-term follow-up study or to vidofludimus calcium, the extended treatment period will be closed 
early once all remaining participants are transferred. Patients will be allowed to be treated with study medication for a 
maximum of 10 years (not applicable for UK, see below) including all periods of the trial. For UK the following applies: 
Patients will be allowed to be treated with open-label study medication for a maximum of 3 years (may be extended, see 
Section 8.1.5). 
d 
Only to be performed if start of open-label treatment starts more than 3 weeks after the last regular study visit. 
e 
If continuing treatment-emergent adverse events are the reason for exclusion from the open-label extension arm, the 
eligibility can be re-assessed up to 4 weeks following the last treatment in the blinded treatment arms. 
f 
After last blood sample for full PK has been collected. 
g 
Any positive local urine pregnancy test has to be followed up with a confirmatory local blood pregnancy test. 
h 
Urine sediment analysis will only be done when urine dipstick analysis (performed at central lab) was positive for RBC. 
i 
Blood samples for PK will be collected pre-dose, 1, 2, 3, 4, 5, 6, 24, 48, and 72 hours post-dose (±15 min each for time 
point from 1 to 6 hours, and ±1 hour each for the 24-, 48-, and 72-hour time point). Samples to be stored at -20°C until 
next scheduled dry-ice shipment to central laboratory. 
j 
Videotapes will not be collected and not centrally assessed. The investigator’s judgment of the endoscopy results will be 
collected in the eCRF. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 37 of 139 
 
Confidential 
 
 
k 
During the open-label extension treatment period, dispensed bottles must be used until empty and then returned; remaining 
tablets of in-use bottles will not be counted at every study visit. Patients will be advised to bring all IMP (including full, 
in-use and empty bottles) to all visits; the empty bottles will be kept, the in-use and full ones will be returned to the patient 
(together with newly issued ones). Patients will also be advised to completely use up the tablets in one bottle before starting 
a new bottle. Only the number of bottles dispensed, and number of empty bottles returned will be counted. Counting of 
tablets for any in-use bottle will only be performed for any safety interim analysis, as communicated by the sponsor. 
 
IMP= investigational 
medicinal 
product, 
Lab = laboratory, 
EoOLE = end-of-treatment 
open-label 
extension, 
hematol. = hematology, lab = laboratory, OLE = open-label extension, PK = pharmacokinetics, RBC = red blood cells, 
PRO = patient-reported outcome. 
Table 5: 
Schedule of assessments - unscheduled visits and end-of-study visit 
 
Unscheduled visit 
 
EoSa 
 
due to UC 
exacerbation 
due to safety/AE 
issue 
 
 
Physical examination 
x 
x 
x 
Weight 
 
 
x 
Concomitant medication 
x 
x 
x 
Partial Mayo score+PRO-2 
x 
 
 
Laboratory assessments 
 
 
 
Blood biochemistry and 
hematology 
x 
x 
x 
Urinalysis 
xb 
x 
x 
Fecal calprotectin 
x 
 
 
Local urine pregnancy testc 
 
 
x 
Lab kits used 
 
 
 
Study lab kit 
C 
B 
B 
Fecal calprotectin 
FC 
 
 
Shipments to central lab 
 
 
 
Ambient temperature 
x 
x 
x 
Adverse events 
x 
x 
x 
Vital signs 
 
x 
x 
ECG 
 
x 
x 
Patient diary 
xd 
 
 
Drug accountability 
 
 
xe 
a Should always be done 30 days (-3 days/+4 weeks) after last study treatment (of induction, extended 
induction, maintenance, or open-label phase, whichever applies). No EoS visit is required for patients 
transferring to the long-term follow-up study or commercially available vidofludimus calcium. 
b Urine sediment analysis will only be done when urine dipstick analysis (performed at central laboratory) 
was positive for RBC. 
c  Any positive local urine pregnancy test has to be followed up with a confirmatory local blood pregnancy 
test. 
d Assessment done retrospectively. 
e Only to be performed if not done at the last treatment visit. 
AE = adverse event, ECG =electrocardiogram, EoS = end-of-study, lab = laboratory, RBC = red blood cells, 
PRO = patient-reported outcome, UC = ulcerative colitis. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 38 of 139 
 
Confidential 
 
 
To be considered for patient visits at the study center 
• At all visits, patients should arrive at the center in fasted conditions. 
• Applies only to induction phase:  
o Patients should arrive at the center without taking their study drug. 
o If patients have inadvertently taken their study drug within 1.5 hours of arriving 
at the study center, the blood samples for IMU-838 trough levels can still be 
drawn. If longer than 1.5 hours, the blood levels should not be determined. In 
either case, this should be recorded as protocol deviation. Blood samples for 
biochemistry can be collected in any case and no additional visit to collect a blood 
sample for trough IMU-838 plasma levels must be scheduled. 
• Patients need to bring to the center their study medication and their filled-out diary. 
• Visits should be scheduled at the same time in the morning so that visits are all within 
±2 hours of the Day 0 visit. 
• Patients must be advised at each visit to drink a generous amount of fluid per day to 
ensure adequate urine flow. 
 
 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 39 of 139 
 
Confidential 
 
 
2 
Addresses and responsibilities 
Sponsor’s signatory 
Dr Andreas Mühler  
Chief Medical Officer, Immunic AG 
Lochhamer Schlag 21 
82166 Graefelfing, Germany 
Office:  
 +49 89 2500 794 64 
Mobile:  
+49 176 7873 8359 
Email:  
andreas.muehler@imux.com 
 
Coordinating investigator 
Prof. Dr Geert D’Haens 
Inflammatory Bowel Disease Centre 
Academic Medical Centre, University of Amsterdam 
Meibergdreef 9, 
1105 AZ Amsterdam, The Netherlands 
Phone:  
 +31 20 56 63534 
Fax:     
+31 20 69 17033 
 
Drug safety officer 
Dr med. Dipl. Inf. Susanne Kienzle-Horn 
SCRATCH Pharmacovigilance GmbH & Co. KG 
Schlossstrasse 25 
35510 Butzbach, Germany 
Phone:  
+49 6033 74535 50 
Fax:     
+49 6033 74535 59 
Email: 
safety-immunic@scratch-pv.com  
 
CRO for project management 
and monitoring 
 
 
 
Labcorp Drug Development Inc. (formerly: Covance 
Clinical and Periapproval Services Ltd) 
Osprey House 
Westacott Way 
Maidenhead SL6 3QH, United Kingdom 
Phone:  
+44 1628 548 000 
Fax:     
+44 1628 548 234 
 
 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 40 of 139 
 
Confidential 
 
 
IMP labeling, packaging, and 
distribution 
Nuvisan GmbH 
Wegenerstrasse 13 
89231 Neu-Ulm, Germany 
Phone:  
+49 731 9840 0 
Fax:     
+49 731 9840 226  
Email: 
bdinfo@nuvisan.com 
Or 
Labeling, packaging and 
distribution 
Fisher Clinical Services UK Ltd 
Langhurstwood Road 
Horsham, RH12 4QD, West Sussex 
United Kingdom 
Or 
Labeling and packaging 
Fisher Clinical Services GmbH 
Steinbühlweg 69  
4123 Allschwil, Switzerland 
Phone:  
+41 614 852300 
Or 
Distribution  
Fisher Clinical Services GmbH 
Im Wörth 3 
79576 Weil am Rhein, Germany 
(currently not involved in supply chain, but may be 
involved in the future) 
 
Central safety laboratory, 
biomarker assessment 
LKF - Laboratorium für Klinische Forschung GmbH 
Lise-Meitner-Strasse 25-29 
24223 Schwentinental, Germany 
Phone:  
+49 4307 8276 0 
Fax: 
+49 4307 8276 79 
Email: 
office@lkf-kiel.de 
 
HIV testing based on Nucleic 
Acid Amplification Technology 
Labor Lademannbogen 
 
Lademannbogen 61 
22339 Hamburg, Germany 
Phone:  
+49 40 53805 0 
Fax: 
+49 40 53805 701 
Email: 
info@labor-lademannbogen.de 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 41 of 139 
 
Confidential 
 
 
 
Emergency phone service for 
unblinding 
ESMS Global Limited 
 
29 Long Lane 
London SE1 4PL 
Phone (admin):  
+44 207 113 7878 
Email: 
clinicaltrials@esmsglobal.com 
 
Biostatistics and data 
management 
FGK Clinical Research GmbH 
Heimeranstrasse 35 
80339 München, Germany 
Phone:  
+49 89 893 119 00 
Fax:     
+49 89 893 119 20 
 
Electronic case report form 
ANJU Life Sciences Software 
4500 S. Lakeshore Drive, Suite 620 
Tempe, AZ 85282, USA 
Phone:  
+49.228.22744.11 
Fax:      
+49.228.22744.119 
Email: eclinicalsupport@anjusoftware.com  
 
Central endoscopy reading 
Clario (formerly Bioclinica, Inc.) 
1818 Market St, Suite 2600  
Philadelphia, PA 19103, USA  
Phone:  
+1 215 972 0420 
Fax:  
+1 215 972 0414 
Email:  
P2-IMU838-UC@bioclinica.com 
 
Pharmacokinetics (IMU-838 
measurements in plasma 
samples) 
Nuvisan GmbH 
Wegenerstrasse 13 
89231 Neu-Ulm, Germany 
Phone:  
+49 731 9840 0 
Fax:     
+49 731 9840 226  
email: 
bdinfo@nuvisan.com 
 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 42 of 139 
 
Confidential 
 
 
Pharmacokinetics (population 
PK modeling) 
PharmaLex Belgium 
5 rue Belin  
1435 Mont-Saint-Guibert, Belgium 
Phone:  +32 10 46 10 10 
 
Genotyping and micro 
ribonucleic acid-122 (miR-122) 
assessment 
IMGM Laboratories GmbH 
Lochhamer Str. 29a 
82152 Martinsried, Germany 
Phone:  
+ 49 89 4524 667 0 
Fax:     
+ 49 89 4524 667 410 
 
 
Histology & 
Immunohistochemistry 
Indivumed GmbH 
Falkenried 88, Bldg. D 
20251 Hamburg, Germany 
Tel.:  
+49 40 41 33 83 0 
Fax:  
+49 40 41 33 83 14 
Email:  
info-eu@indivumed.com 
 
A complete list of study personnel will be available in the trial master file. 
 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 43 of 139 
 
Confidential 
 
 
3 
Table of contents 
 
Page 
REVISION CHRONOLOGY ................................................................................................. 2 
1 
SUMMARY AND FLOW CHART ............................................................................. 16 
2 
ADDRESSES AND RESPONSIBILITIES ................................................................. 39 
3 
TABLE OF CONTENTS ............................................................................................. 43 
4 
ABBREVIATIONS AND DEFINITION OF TERMS .............................................. 49 
5 
INTRODUCTION ........................................................................................................ 53 
5.1 
Disease background ................................................................................... 53 
5.2 
IMU-838 ...................................................................................................... 54 
5.2.1 
Mode of action ............................................................................................. 54 
5.2.2 
History.......................................................................................................... 54 
5.2.3 
Formulations of IMU-838 ............................................................................ 54 
5.2.4 
Non-clinical studies ..................................................................................... 55 
5.2.5 
Clinical studies ............................................................................................. 56 
5.3 
Rationale for the study .............................................................................. 56 
6 
INVESTIGATORS, STUDY ADMINISTRATIVE STRUCTURE, AND 
STUDY COMMITTEES .............................................................................................. 57 
7 
STUDY OBJECTIVES AND ENDPOINTS .............................................................. 58 
7.1 
Study objectives .......................................................................................... 58 
7.2 
Study endpoints .......................................................................................... 59 
8 
STUDY DESIGN AND DESIGN RATIONALE ....................................................... 61 
8.1 
Overall study design .................................................................................. 61 
8.1.1 
Design overview .......................................................................................... 61 
8.1.2 
Screening...................................................................................................... 61 
8.1.3 
Induction phase ............................................................................................ 62 
8.1.4 
Maintenance phase ....................................................................................... 63 
8.1.5 
Open-label treatment extension ................................................................... 63 
8.1.6 
Pharmacokinetics period .............................................................................. 65 
8.2 
Study design rationale ............................................................................... 66 
8.3 
Risk-benefit assessment ............................................................................. 67 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 44 of 139 
 
Confidential 
 
 
9 
PATIENT SELECTION .............................................................................................. 69 
9.1 
Sample size .................................................................................................. 69 
9.2 
Inclusion criteria ........................................................................................ 69 
9.3 
Exclusion criteria ....................................................................................... 72 
10 
RANDOMIZATION, BLINDING AND UNBLINDING PROCEDURES ............. 75 
10.1 
Blinding ....................................................................................................... 75 
10.2 
Emergency unblinding............................................................................... 76 
10.3 
Maintenance of blinding during interim or exploratory analyses ......... 76 
10.4 
Patient identification .................................................................................. 77 
10.5 
Randomization ........................................................................................... 77 
11 
TREATMENTS ............................................................................................................ 78 
11.1 
Study medication ........................................................................................ 78 
11.1.1 
IMU-838 ...................................................................................................... 78 
11.1.2 
Placebo ......................................................................................................... 78 
11.1.3 
Packaging, labeling and dispensing ............................................................. 78 
11.1.4 
Storage and stability ..................................................................................... 79 
11.1.5 
Treatment dose, dose selection, and administration .................................... 80 
11.1.6 
Drug accountability and patient compliance ................................................ 82 
11.2 
Prior and concomitant medications ......................................................... 83 
11.2.1 
UC-related treatments .................................................................................. 83 
11.2.1.1 
Allowed UC treatments ........................................................................................... 84 
11.2.1.2 
Prohibited UC-related treatments during the trial ................................................... 86 
11.2.2 
Other prohibited and restricted medications ................................................ 86 
11.3 
Oral corticosteroid tapering regimen ....................................................... 87 
11.4 
Precautions and restrictions...................................................................... 87 
11.5 
Management of clinical events .................................................................. 89 
11.5.1 
Adverse events of anticipated clinical events of UC ................................... 89 
11.5.2 
Monitoring of hepatotoxicity ....................................................................... 89 
11.5.3 
Monitoring of red blood cells in urine ......................................................... 90 
12 
STUDY SCHEDULE .................................................................................................... 90 
12.1 
Study conduct ............................................................................................. 90 
12.2 
Screening ..................................................................................................... 91 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 45 of 139 
 
Confidential 
 
 
12.3 
Induction phase .......................................................................................... 92 
12.4 
Maintenance phase..................................................................................... 93 
12.5 
Open-label treatment arm ......................................................................... 94 
12.6 
Pharmacokinetics period ........................................................................... 95 
12.7 
Unscheduled visit due to disease exacerbations or due to safety issues 
and AEs ....................................................................................................... 95 
12.8 
Premature termination .............................................................................. 95 
12.9 
Transfer into a long-term follow-up trial or to commercially available 
vidofludimus calcium ................................................................................. 96 
12.10 
End of study visit ........................................................................................ 97 
12.11 
Study conduct contingency measures ....................................................... 97 
13 
EFFICACY ASSESSMENTS AND PROCEDURES ................................................ 98 
13.1 
Demographics and other baseline assessments ....................................... 98 
13.2 
Mayo score .................................................................................................. 98 
13.3 
Sigmoidoscopy with biopsies ................................................................... 100 
13.4 
Diary completion and review .................................................................. 101 
14 
PHARMACOKINETICS AND PHARMACODYNAMICS ASSESSMENTS ..... 101 
14.1 
Pharmacokinetics ..................................................................................... 101 
14.2 
Pharmacokinetic sampling ...................................................................... 103 
14.3 
Biomarkers and blood genotyping ......................................................... 104 
14.4 
Disease activity biomarkers: fecal calprotectin and C-reactive  
protein ....................................................................................................... 104 
15 
SAFETY ASSESSMENTS ......................................................................................... 104 
15.1 
Adverse events documentation and reporting ....................................... 104 
15.1.1 
Definitions.................................................................................................. 104 
15.1.1.1 
Adverse events ....................................................................................................... 104 
15.1.1.2 
Adverse drug reactions and unexpected adverse drug reactions ........................... 105 
15.1.1.3 
Serious adverse events ........................................................................................... 106 
15.1.1.4 
Suspected unexpected serious adverse reaction (SUSAR) .................................... 107 
15.1.2 
Classification of adverse events ................................................................. 107 
15.1.3 
Adverse events of special interest .............................................................. 108 
15.1.4 
Documentation of adverse events .............................................................. 109 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 46 of 139 
 
Confidential 
 
 
15.1.5 
Documentation and reporting of immediately reportable adverse events . 110 
15.1.6 
Follow-up of adverse events ...................................................................... 111 
15.1.7 
Pregnancies ................................................................................................ 111 
15.2 
Laboratory investigations ....................................................................... 112 
15.2.1 
Pregnancy tests........................................................................................... 112 
15.2.2 
Blood chemistry, hematology, and coagulation ......................................... 112 
15.2.3 
Urine assessments ...................................................................................... 113 
15.2.4 
miR-122 expression ................................................................................... 114 
15.2.5 
Serology and stool sample for C. difficile test ........................................... 114 
15.2.6 
Screening laboratory .................................................................................. 115 
15.3 
Vital signs, physical examination, and ECG ......................................... 115 
16 
BIOSTATISTICAL METHODS ............................................................................... 116 
16.1 
Sample size calculation ............................................................................ 116 
16.2 
Analysis sets and types of analyses ......................................................... 116 
16.3 
Statistical analyses ................................................................................... 117 
16.4 
Primary efficacy analysis ........................................................................ 118 
16.5 
Interim analysis ........................................................................................ 118 
16.6 
Final analysis of induction phase ............................................................ 119 
16.7 
Explorative analysis of maintenance phase ........................................... 119 
16.8 
Final analysis of maintenance phase ...................................................... 119 
17 
PATIENT WITHDRAWAL FROM STUDY PARTICIPATION ......................... 119 
18 
ETHICAL AND LEGAL REQUIREMENTS ......................................................... 120 
18.1 
Ethical conduct of the study .................................................................... 120 
18.2 
Independent ethics committee or institutional review board .............. 121 
18.3 
Patient information and consent procedure .......................................... 121 
18.4 
Insurance coverage .................................................................................. 122 
18.5 
Submission to authorities ........................................................................ 122 
18.6 
Patient confidentiality .............................................................................. 122 
19 
CRITERIA FOR PREMATURE TERMINATION OF THE TRIAL AND 
CRITERIA FOR INITIALIZING AND CLOSING A STUDY CENTER ........... 123 
19.1 
Criteria for halting or terminating the study ........................................ 123 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 47 of 139 
 
Confidential 
 
 
19.2 
Criteria for closing a study center .......................................................... 123 
20 
STUDY PROTOCOL, DOCUMENTATION AND ARCHIVING OF DATA ..... 124 
20.1 
Amendments to the protocol ................................................................... 124 
20.2 
Protocol deviations ................................................................................... 124 
20.3 
Data retention ........................................................................................... 125 
21 
DATA COLLECTION, MONITORING AND QUALITY ASSURANCE ........... 125 
21.1 
Data collection .......................................................................................... 125 
21.2 
Monitoring ................................................................................................ 126 
21.3 
Audits and inspections ............................................................................. 126 
21.4 
Data management procedures ................................................................ 126 
22 
STUDY REPORT AND PUBLICATIONS .............................................................. 127 
23 
STUDY PERIODS ...................................................................................................... 127 
24 
REFERENCES............................................................................................................ 129 
25 
APPROVAL AND SIGNATURES............................................................................ 130 
26 
APPENDICES ............................................................................................................. 132 
Appendix 1 
Prior and concomitant treatments ............................................................ 133 
Appendix 2 
Geboes score for assessment of ulcerative colitis histologic disease 
activity ......................................................................................................... 138 
Appendix 3 
Patient flow chart P2-IMU-838-UC .......................................................... 139 
 
Table of tables 
Table 1: 
Schedule of assessments - induction phase ...................................................... 32 
Table 2: 
Schedule of assessments - maintenance phase ................................................. 34 
Table 3: 
Schedule of assessments - open-label treatment arm ....................................... 35 
Table 4: 
Schedule of assessments - open-label treatment arm for PK population at 
designated PK centers ....................................................................................... 36 
Table 5: 
Schedule of assessments - unscheduled visits and end-of-study visit .............. 37 
Table 6: 
Doses administered ........................................................................................... 81 
Table 7: 
Allowed concomitant UC-related treatments ................................................... 84 
Table 8: 
Full Mayo score ................................................................................................ 99 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 48 of 139 
 
Confidential 
 
 
Table of figures 
Figure 1: 
Study flow chart ................................................................................................ 31 
 
 
 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 49 of 139 
 
Confidential 
 
 
4 
Abbreviations and definition of terms 
AE 
Adverse event 
AESI 
AEs of special interest 
ALT 
Alanine aminotransferase 
AP 
Alkaline phosphatase 
AST 
Aspartate aminotransferase 
AUC 
Area under the drug concentration-time curve 
AUC0-24h 
Area under the drug concentration-time curve from time zero to 
24 hours 
AUC0-t 
Area under the drug concentration-time curve from time zero to last 
measurable concentration 
AUCinf 
Area under the drug concentration-time curve from time zero to 
infinity  
BCRP 
Breast cancer resistance protein  
BSEP 
Bile salt export pump 
BUN 
Blood urea nitrogen 
CA 
Competent authority 
Ca 
Calcium 
CD 
Crohn’s Disease 
C-diff toxin B 
Clostridium difficile toxin B 
CKD-EPI 
Chronic Kidney Disease Epidemiology Collaboration  
Cl 
Chloride 
Cmax 
Maximum plasma concentration  
CRP 
C-reactive protein 
CYP 
Cytochrome P450  
d or D 
Day 
DHODH 
Dihydroorotate dehydrogenase 
DRC 
Data Review Committee  
ECG 
Electrocardiogram 
eCRF 
Electronic case report form 
eGFR 
Estimated glomerular filtration rate  
Eo(E)I 
End-of-(extended)-induction 
EoM 
End-of-maintenance 
EoOLE 
End-of-open-label extension 
EoS 
End-of-study 
FAS 
Full analysis set 
fCP 
Fecal calprotectin 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 50 of 139 
 
Confidential 
 
 
GCP 
Good Clinical Practice 
GGT 
Gamma glutamyl transferase 
HBcAb 
Hepatitis B core antibody 
HBsAg 
Hepatitis B surface antigen 
HCV 
Hepatitis C virus 
HIV(-Ag/Ab) 
Human immunodeficiency virus(-antigen/antibody) 
HPF 
High powered field 
IBD 
Inflammatory bowel disease  
ICH 
International Council for Harmonisation of Technical Requirements 
for Pharmaceuticals for Human Use 
IEC 
Independent ethics committee  
IFNγ 
Interferon gamma  
IgG(M) 
Immunoglobulin G(M) 
IL 
Interleukin 
IMP 
Investigational medicinal product 
INR 
International normalized ratio 
IRB 
Institutional review board  
IWRS 
Interactive web-based response system  
K 
Potassium 
MCH 
Mean corpuscular hemoglobin 
MCV 
Mean corpuscular volume  
miR-122 
Micro ribonucleic acid-122 
MMX 
Multi-matrix 
Na 
Sodium 
OAT1(3) 
Organic anion transporters 1(3) 
OATP1B1(3) 
Organic anion transporting polypeptides 1B1(3) 
P 
Inorganic phosphate 
PD 
Pharmacodynamic(s) 
PK 
Pharmacokinetic(s) 
PP 
Per-protocol set 
PRO 
Patient-reported outcome 
RA 
Rheumatoid arthritis 
RBC 
Red blood cells 
SAE 
Serious adverse event 
SAF 
Safety analysis set 
SAP 
Statistical analysis plan 
SAR 
Serious adverse reaction 
SDV 
Source data verification 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 51 of 139 
 
Confidential 
 
 
SUSAR 
Suspected unexpected serious adverse reaction 
Tbc-IGRA 
Mycobacterium tuberculosis IFNγ-release assay  
TEAE 
Treatment-emergent adverse events 
Th 
T helper (cell) 
Tmax 
Time to maximum plasma concentration 
TNFα 
Tumor necrosis factor α 
UC 
Ulcerative colitis 
ULN 
Upper limit of normal 
URAT1 
Urate anion transporter 1 
W 
Week 
WBC 
White blood cell count 
Drugs 
 
4SC-101 
Tablet or capsule formulation containing vidofludimus free acid 
IMU-838  
Tablet formulation containing vidofludimus calcium 
 
 
Definitions  
 
Baseline 
Any assessments done pre-dose at Day 0, or in the case of endoscopy, 
the screening endoscopy done between Day -14 to Day -3 (see 
Table 1) 
Full Mayo score: 
Combined, partial (non-invasive) Mayo score and Mayo endoscopy 
score  
Partial Mayo score: 
Non-invasive Mayo subscores, i.e. stool frequency, rectal bleeding, 
and physician rating of disease activity scores 
Mayo PRO-2 score:  
Mayo patient-reported outcome score, i.e. stool frequency and rectal 
bleeding score 
Modified Mayo 
endoscopy score:  
The Mayo endoscopy score modified that a value of 1 does not 
include friability 
Symptomatic 
response: 
≥1-point decrease from Baseline in Mayo PRO-2 score 
Clinical response: 
Decrease from Baseline in the full Mayo score of at least 3 points and 
at least 30%, with an accompanying decrease in the subscore for 
rectal bleeding of at least 1 point or an absolute subscore for rectal 
bleeding of 0 or 1 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 52 of 139 
 
Confidential 
 
 
Symptomatic 
remission:  
• Mayo rectal bleeding subscore = 0, and 
• Mayo stool frequency subscore of 0 or 1 
Durable symptomatic 
remission: 
• Symptomatic remission at all but 1 visit from the time the patient 
first achieved symptomatic remission at the end of induction (i.e. 
Weeks 10 or 22) until Week 50 
Clinical remission:  
• Mayo rectal bleeding subscore = 0, and 
• Mayo stool frequency subscore of 0 or 1, and 
• Endoscopy subscore 1 or 0 on modified Mayo endoscopy score 
Endoscopic healing: 
Modified Mayo endoscopy subscore of 0 or 1 
Microscopic healing: 
Geboes score of ≤3.1 
UC relapse 
(symptomatic): 
Re-occurrence of active UC symptoms defined as an ≥2-point 
increase from the Week 10 value (or Week 22 value if the patient 
received remission only during the extended induction phase) in 
Mayo PRO-2 score for 2 consecutive visits, or the need for any 
treatment escalation as assessed by the investigator after excluding 
intermittent infections (at the investigator’s conclusion). 
Symptom control: 
Absence of symptomatic UC relapse 
 
Note: In case of inconsistencies between text in the protocol and schedules of assessments 
(Table 1 through Table 5), the schedules will predominate. 
 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 53 of 139 
 
Confidential 
 
 
5 
Introduction 
5.1 
Disease background 
Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease (IBD) affecting the 
rectum and colon. The prevalence of IBD continues to increase steadily in Western countries, and 
newly industrialized countries have a rapidly increasing incidence. [1] 
The hallmark of UC is a chronic, uncontrolled inflammation of the intestinal mucosa presumably 
caused by a dysregulated immune response to bacteria and bacterial products in a susceptible host. 
This aberrant immune response is mediated by various cytokines and small cell-signaling protein 
molecules secreted by immune and other cells. The secreted molecules stimulate the proliferation 
of antigen-specific effector cells and thereby activate the adaptive immune system with a 
consequent burst of local and systemic inflammation. This upregulation of cytokines may play 
many roles in the pathophysiology of UC. It is believed that cytokines themselves are directly 
responsible for mucosal injury and consequent tissue damage. Activated T helper 1 (Th1) cells 
produce classical proinflammatory cytokines (interferon γ [IFNγ] and tumor necrosis factor α 
[TNFα]) and interleukin [IL]-2. In addition, Th17 cells seem to be involved leading to enhanced 
synthesis of Th17 typical cytokines such as IL-17 and IL-23.  
The clinical course of UC is characterized by periods of exacerbation and remission. The latter 
may occur either spontaneously or in response to treatment. Symptoms of an UC flare-up generally 
involve diarrhea, abdominal pain and cramping, rectal pain and bleeding, fatigue, and urgent bowel 
movements. 
Several treatment options are currently available including anti-inflammatory drugs (e.g. 
corticosteroids, aminosalicylates), immunosuppressive drugs (e.g. azathioprine 6-mercaptopurine 
and 6-thioguanine), biologics (e.g. TNFα inhibitors such as infliximab, adalimumab, golimumab, 
as well as the anti-adhesion molecule vedolizumab), and other drugs to manage specific symptoms 
(e.g. antibiotics, anti-diarrheal medications, pain relievers, calcineurin inhibitors [cyclosporine, 
tacrolimus], and iron supplements). 
However, some patients respond only poorly to established treatment options or, after an initial 
response, experience flare-ups, and/or develop intolerable side effects (e.g. major infections with 
TNFα-inhibitors; myelosuppression, hepatotoxicity and dose-independent nausea, diarrhea, 
arthralgia and acute pancreatitis with thiopurines). Thus, new treatment options are needed. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 54 of 139 
 
Confidential 
 
 
5.2 
IMU-838  
A brief summary of current data is provided below. For more information please refer to the 
investigator’s brochure. 
5.2.1 
Mode of action 
The investigational medicinal product (IMP) IMU-838 (vidofludimus calcium) is a new compound 
that selectively inhibits the human enzyme dihydroorotate dehydrogenase (DHODH). 
Dihydroorotate dehydrogenase plays a major role in the de-novo pyrimidine synthesis and is 
specifically expressed at high levels in proliferating or activated lymphocytes. Resting 
lymphocytes satisfy their pyrimidine requirements through a DHODH-independent salvage 
pathway. Thus, IMU-838-mediated DHODH inhibition selectively affects activated, rapidly 
proliferating lymphocytes. The metabolic stress secondary to DHODH inhibition leads to a 
reduction of pro-inflammatory cytokine release including IL-17 (IL-17A and IL-17F) and IFNγ, 
and to an increased apoptosis in activated lymphocytes. 
5.2.2 
History 
Previously, vidofludimus free acid (SC12267) was developed by 4SC AG using capsules or tablets 
containing amorphous vidofludimus (4SC-101). Immunic AG acquired all rights and data of 
SC12267 and has developed a new pharmaceutical form containing the calcium salt of 
vidofludimus (INNM: vidofludimus calcium) in a new pharmaceutical formulation (tablets 
containing a specific polymorph).  
Both formulations depend on the same active moiety i.e. vidofludimus which is released from the 
tablets in the gut and enters the blood stream. Hence, the 2 formulations share the same mechanism 
of action, pharmacology, and toxicology. Vidofludimus calcium may exhibit, however, superior 
pharmaceutical properties compared with the former vidofludimus free acid film-coated tablet. 
5.2.3 
Formulations of IMU-838 
Clinical studies up to this point have used the formulation IMU-838 manufactured utilizing wet 
granulation. A new manufacturing process using roller compaction was developed to allow large 
scale production of tablets. This necessitated a slightly revised and simplified formulation IMU-
838-RC. The ongoing clinical trials will be stepwise transferred to the IMU-838-RC formulation, 
as well as new clinical trials will now only use the simplified IMU-838-RC formulation. 
A bioequivalence study P1-IMU-838-BE was performed between a single oral dose of one 
IMU-838-RC tablet containing 45 mg vidofludimus (test treatment) and 2 IMU-838 tablets 
containing 22.5 mg vidofludimus each (reference treatment). The formulation of IMU-838-RC was 
found to be bioequivalent to the previous IMU-838 formulation regarding the area under the plasma 
concentration time curve and only a small increase in maximum plasma concentration (Cmax) was 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 55 of 139 
 
Confidential 
 
 
found. The upper limit of the 90% confidence interval for Cmax was only slightly above the upper 
bioequivalence acceptance limit of 125%. This difference is regarded as not clinically relevant. 
5.2.4 
Non-clinical studies 
Pharmacodynamics 
As a result of the DHODH inhibition, vidofludimus strongly inhibits activated lymphocytes and 
reduces the release of pro-inflammatory cytokines and other physiologic effects of activated 
lymphocytes in in-vivo studies. In murine chronic colitis models, vidofludimus improved 
histological scores of intestinal epithelial damage and inflammatory cell infiltration similar to 
dexamethasone, and significantly reduced IFNγ and IL-17 in the colon tissue. In a rat arthritis 
model, vidofludimus effectively suppressed clinical symptoms (total arthritis score) and 
histopathological signs of arthritis (cellular infiltrate, cartilage erosion).  
The permeability through a human intestinal epithelial cell barrier (Caco-2 test) was higher for 
vidofludimus calcium than vidofludimus free acid. In line, Cmax and area und the time-
concentration curve between zero and infinity (AUCinf) of the calcium salt were 1.7 times higher 
than the Cmax and AUCinf of the free acid in rats. 
Metabolism of vidofludimus involves primarily cytochrome P450 (CYP)1A1 (about 60%), 
followed by CYP2C8 (about 20%) and CYP2E1 (about 10%). Vidofludimus was primarily 
eliminated via feces (about 70%).  
Vidofludimus mildly to moderately inhibits several transport systems, including the urate anion 
transporter 1 (URAT1), the breast cancer resistance protein (BCRP), the organic anion transporters 
1 and 3 (OAT1 and OAT3), the organic anion transporting polypeptides 1B1 and 1B3 (OATP1B1 
and OATP1B3), and the bile salt export pump (BSEP). 
Consistent with DHODH’s important role for viral replication in human cells, vidofludimus 
inhibited viral replication of hepatitis C virus (HCV) in an in-vitro assay. 
Toxicology 
Main targets of toxicity in rats and dogs included the liver (weight changes, liver enzymes, bile 
duct hyperplasia) and the thymus (signs of involution, likely due to primary pharmacodynamics of 
the test compound). Adverse reactions were completely or partly reversible during a recovery 
period. There was no indication for a remarkable hepatic injury or direct proliferative activity of 
bile duct epithelium. No signs of preneoplastic lesions were identified. Bile duct hyperplasia is 
likely a physiological compensation of slightly reduced bile flow upon initiation of treatment, 
which was possibly caused by BSEP inhibition. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 56 of 139 
 
Confidential 
 
 
5.2.5 
Clinical studies 
With the exception of two phase 1 studies performed with IMU-838, all previous clinical studies 
were performed using vidofludimus free acid (4SC-101).  
In 2 of these studies, beneficial effects of 4SC-101 were investigated in patients with rheumatoid 
arthritis (RA). 4SC-101 improved various clinical parameters versus placebo. A pronounced effect 
was observed for inflammatory parameters.  
In a small phase 2 study in patients with steroid-dependent IBD (Crohn’s disease and UC), 4SC-101 
showed beneficial effects in the remission maintenance therapy. Compared with historical placebo 
data, 4SC-101 treatment showed a significantly higher response rate (88.5% total response). At the 
end of the study (after 12 weeks of treatment) more than 50% of the steroid-dependent patients 
were in remission without any steroid intake. An additional 35% of patients could markedly reduce 
their steroid threshold dose of disease relapse indicating a strong steroid-sparing effect of 4SC-101. 
Overall mean steroid intake dropped from about 27 mg/day at Screening to 1.0 mg/day at the end 
of the study (Week 12).  
With respect to safety, no 4SC-101-associated clinically significant adverse reactions were 
observed at doses of <70 mg once daily including the potential target organs liver and kidney as 
identified in non-clinical or early clinical studies. At higher 4SC-101 doses (>70 mg/day or single 
doses of 210 mg) potential drug-related increases in urine red blood cells (RBC) and hematurias 
were observed (see also Section 8.3).  
5.3 
Rationale for the study  
As outlined above, IMU-838 selectively inhibits pyrimidine synthesis in activated cells. The 
inhibition of nucleotide synthesis seems to be a promising approach to treat IBD. Purine synthesis 
inhibitors, like 6-mercaptopurine, azathioprine and 6-thioguanine, are established products for the 
long-term treatment of IBD. The DHODH inhibitor leflunomide, currently approved for RA, was 
efficacious in small studies investigating Crohn’s Disease (CD), but was associated with diarrhea 
limiting its use in an IBD patient population.  
Based on these data and the pharmacodynamics of vidofludimus, IMU-838 may represent a novel 
and efficacious oral treatment option for IBD patients. Previous clinical studies with the 
predecessor drug 4SC-101 confirmed that vidofludimus may be beneficial in patients with steroid-
dependent IBD. Thus, Study P2-IMU-838-UC will further evaluate the dose response, as well as 
efficacy and safety of vidofludimus, using the novel formulation IMU-838, in patients with active, 
moderate-to-severe UC. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 57 of 139 
 
Confidential 
 
 
6 
Investigators, study administrative structure, and study 
committees 
The study is funded by Immunic AG and included about 133 study centers in a variety of countries 
in Western and Eastern Europe and the United States of America. 
The sponsor, Immunic AG, will be responsible for the overall supervision and administration of 
the study. Monitoring and project management will be done by Labcorp Drug Development Inc 
(formerly Covance Clinical and Periapproval Services Ltd), Maidenhead, United Kingdom (a 
contract research organization - in the following referred to as sponsor’s designee). Data 
management, statistical analysis and report writing will be done by FGK Clinical Research GmbH, 
München, Germany. 
Other vendors used in the study: 
• Nuvisan GmbH, Neu Ulm, Germany: labeling, packaging, and distribution of IMP and 
measurement of IMU-838 in plasma samples 
• PharmaLex GmbH, Mont-Saint-Guibert, Belgium: population PK modeling 
• LKF - Laboratorium für Klinische Forschung GmbH, Schwentinental, Germany: central 
clinical safety laboratory and assessment of biomarker 
• Labor Lademannbogen, Hamburg, Germany: HIV testing based on Nucleic Acid 
Amplification Technology 
• ESMS Global Limited, London, UK: emergency phone service for unblinding 
• Fisher Clinical Services UK Ltd, Horsham, UK: labeling, packaging and distribution of the 
IMP or Fisher Clinical Services GmbH, Allschwil, Switzerland: labeling and packaging of 
IMP and Fisher Clinical Services GmbH, Weil am Rhein (Rheinfelden site): distribution of 
IMP (currently not involved in supply chain, but may be involved in the future) 
• Clario (formerly Bioclinica), Philadelphia, PA, USA: central assessment of endoscopic 
results  
• SCRATCH Pharmacovigilance GmbH, Butzbach, Germany: pharmacovigilance services 
• IMGM Laboratories GmbH, Martinsried, Germany: genotyping and miR-122 assessment 
• Indivumed GmbH, Hamburg, Germany: histological and immunohistochemical assessment 
• ANJU Life Sciences Software, Tempe, AZ 85282, USA: electronic case report form 
(eCRF) and interactive web response system (IWRS) 
 
An independent data review committee (DRC) who assessed unblinded safety and efficacy data 
and was to give recommendation on the dose(s) selection for Enrollment Period 2 (see Section 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 58 of 139 
 
Confidential 
 
 
11.1.5) was appointed. A charter, which includes a detailed description of responsibilities and the 
procedures on dose selection, was implemented prior to interim data base lock and start of the 
Enrollment Period 1 interim analysis. 
Based on the recommendation of the DRC, a Steering Committee including sponsor 
representatives, the coordinating investigator, and a drug safety officer was to select the dose(s) for 
Enrollment Period 2 and make potential adjustments to safety procedures, if necessary. 
Addresses and telephone numbers of main responsible parties involved in the conduct of the trial 
are provided in Section 2. 
7 
Study objectives and endpoints 
7.1 
Study objectives 
Primary objective 
• To determine the optimal dose of IMU-838 to induce symptomatic remission and 
endoscopic healing in patients with moderate-to-severe ulcerative colitis (UC) 
Secondary objectives 
• To determine the optimal dose of IMU-838 to maintain clinical benefits in patients with 
moderate-to-severe UC 
• To evaluate the effects of IMU-838 on clinical and endoscopic endpoints in patients with 
moderate-to-severe UC 
• To evaluate the time course of activity and effects of IMU-838 
• To evaluate the safety and tolerability of IMU-838 in patients with moderate-to-severe UC 
• To evaluate exploratory biomarkers, disease activity biomarkers, and pharmacodynamic 
(PD) effects of IMU-838 
• To evaluate population pharmacokinetics (PK) and plasma trough levels of IMU-838 
throughout the induction period 
• To evaluate single dose PK at Week 50 for a subpopulation of patients with 
moderate-to-severe UC receiving 30 mg of IMU-838 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 59 of 139 
 
Confidential 
 
 
7.2 
Study endpoints 
Primary 
Efficacy 
Induction phase 
• Composite endpoint: Proportion of patients with both, symptomatic remission and 
endoscopic healing at Week 10 
All patients (both, Enrollment Period 1 and Enrollment Period 2 patients) who were 
randomized to 30 mg/day and 45 mg/day will be used for the assessment of the primary 
efficacy endpoint (see Section 16.4 for further information). 
Secondary 
Efficacy 
Induction phase and extended induction phase 
• Proportion of patients with both symptomatic remission and endoscopic healing at Week 10 
(all individual IMU-838 doses will be compared with one another and to placebo)  
• Proportion of patients achieving symptomatic remission during the induction phase 
(including extended induction phase) 
• Time to achieving symptomatic remission within the induction/extended induction phase 
• Proportion of patients with clinical response at Week 10 
• Proportion of patients with endoscopic healing at Week 10  
• Proportion of patients with symptomatic response during the induction phase (including 
extended induction phase) 
• Time course of Mayo scores (full score, partial score, PRO-2 score) over 10 or 22 weeks 
and changes from Baseline 
• Time course of disease activity biomarkers (fCP and CRP) 
Maintenance phase  
• Proportion of patients in symptomatic remission by visit up to Week 50 
• Proportion of patients in durable symptomatic remission up to Week 50 
• Time course of Mayo PRO-2 score until Week 50 
• Time to symptomatic UC relapse 
• Proportion of patients without symptomatic UC relapse until Week 50 
• Time course of disease activity biomarkers (fCP and CRP) 
• Proportion of patients with endoscopic healing at Week 50 
• Proportion of patients with microscopic healing at Week 50 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 60 of 139 
 
Confidential 
 
 
• Corticosteroid-free remission at Week 50 in patients receiving corticosteroids at Baseline 
Open-label treatment extension arm 
• Proportion of patients with symptom control  
• Time course of disease activity biomarkers (fCP and CRP) 
Safety 
• Incidence and severity of AEs 
• Physical examination, body weight, and vital signs* 
• Electrocardiogram (12-lead ECG)* 
• Safety laboratory: hematology, clinical chemistry including liver function, coagulation 
parameters, urinalysis 
• miR-122 expression (before first dose and 24 hours after first dose) 
* Only induction and maintenance phase. 
Pharmacokinetics 
• Plasma trough levels of IMU-838 throughout the induction period 
• Population PK analysis 
• Full single-dose PK including area under the drug concentration-time curve from time zero 
to 24 hours (AUC0-24h), AUC0-t (AUC time zero to last measurable concentration), AUC0-
inf (AUC time zero to infinity), maximum plasma concentration (Cmax), time to Cmax (Tmax) 
(in a subset of patients in designated PK centers) 
Further exploratory assessments 
Induction phase 
• Changes from Baseline in biomarker and PD parameters (blood cytokines) during induction 
up to Week 10 
• Correlation of efficacy variables at Week 10 with quartiles of IMU-838 trough levels at 
Week 2 
• Correlation of efficacy variables at Week 10 with biomarker and PD parameters up to 
Week 6 
• If feasible, estimate the relationship between IMU-838 PK and selected safety and efficacy 
parameters 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 61 of 139 
 
Confidential 
 
 
8 
Study design and design rationale 
8.1 
Overall study design 
8.1.1 
Design overview 
This is a phase 2, multicenter, randomized, double-blind, and placebo-controlled trial in patients 
with moderate-to-severe UC with an option for open-label treatment extension. The study 
comprises a blinded induction phase to establish the optimal dose of IMU-838 to induce response 
and remission, a blinded maintenance phase to evaluate the potential of IMU-838 to maintain 
remission until Week 50, and an open-label treatment extension arm for all patients who 
discontinue the blinded phase as scheduled or prematurely, subject to certain restrictions. A subset 
of patients will undergo a PK period at the start of the open-label period to establish a full single-
dose PK profile. Patients in the open-label treatment extension may also be potentially transferred 
to another long-term follow-up study or commercially available vidofludimus calcium. Once all 
patients have been transferred the open-label period will be closed. 
Blinding to individual treatment assignments during the blinded treatment phase will be maintained 
during the induction and maintenance phase, the interim analysis as well as the open-label 
treatment extension arm for patients, investigators, and other personnel involved in the conduct of 
this trial. An overview of the design is shown in Figure 1. 
Only during exceptional circumstances (e.g. COVID-19) some study assessments may be collected 
remotely, in case, the patients cannot attend the study visit in person. Refer to Section 12.11 for 
study conduct contingency measures. 
8.1.2 
Screening 
Patients with a confirmed diagnosis of moderate-to-severe UC will be included and randomized to 
treatment. Diagnosis of UC must have been established at least 3 months before the first 
randomization by clinical and endoscopic evidence, and endoscopic confirmation of disease 
activity (colonoscopy or flexible sigmoidoscopy at Screening with independent central reading). 
Randomization at the start of the induction phase will be stratified by prior use of any biologics 
and concurrent use of corticosteroids. In addition, the proportion of patients who had received 
previous biologics will be limited to approximately 75% of all included patients. 
 
 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 62 of 139 
 
Confidential 
 
 
8.1.3 
Induction phase 
The induction phase will have a 2-stage design: 
• In Enrollment Period 1 approximately 60 patients were to be randomized 1:1:1:1 to oral 
10 mg/day, 30 mg/day, or 45 mg/day IMU-838, or placebo (about 15 patients each). An 
interim analysis was conducted after approximately 60 patients had been randomized into 
Enrollment Period 1 and had received at least 1 dose of IMU-838. Initially it was planned 
that Enrollment Period 2 will include up to 2 doses of IMU-838 and placebo, excluding 
likely ineffective and/or intolerable doses based on an interim analysis of safety, PK, 
biomarker, PD and efficacy data after Enrollment Period 1. Because the interim analysis 
did not reveal a likely ineffective and/or intolerable dose according to the findings of the 
unblinded DRC, the Steering Committee recommended to continue all 3 IMU-838 doses in 
Enrollment Period 2. These recommendations were accepted and implemented by the 
sponsor. Thus, Enrollment Period 2 will include approximately a further 180 patients 
randomized 1:1:1:1 to oral 10 mg/day, 30 mg/day, 45 mg/day IMU-838, or placebo (about 
45 patients each). 
• Enrollment Period 2 will include approximately further 180 patients randomized 1:1:1:1 
to oral 10 mg/day, 30 mg/day, 45 mg/day IMU-838, or placebo (about 45 patients each). 
In total, approximately 240 patients will be randomized in both Enrollment Periods 1 and 2. During 
the first 7 days of treatment during the induction period in both Enrollment Period 1 and 2, patients 
will receive only half of their assigned dose i.e. 1 tablet of 5 mg/day, 15 mg/day, 22.5 mg/day 
IMU-838, or placebo, respectively. Patients will be dosed with their full assigned dose starting 
Day 7 of the induction phase and thereafter. 
During the induction phase, safety, biomarker and PD, disease activity biomarkers (fCP and CRP), 
genotyping, symptomatic and endoscopic assessments (full and partial Mayo score, and respective 
subscores), and IMU-838 plasma trough levels will be regularly evaluated (see Table 1). 
After Week 10, patients will be treated as follows: 
• Patients who have achieved symptomatic remission at Week 10 will enter the maintenance 
phase. 
• Patients who have achieved symptomatic response but not yet symptomatic remission, will 
continue into an extended induction phase until Week 22. If these patients have achieved 
symptomatic remission at Week 22 they will enter the maintenance phase.  
• Patients who do not show symptomatic response at Week 10 or symptomatic remission at 
Week 22 (if the patient had continued into the extended induction phase) will be 
discontinued from the blinded treatment but will have the option to enroll in the open-label 
treatment extension arm.  
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 63 of 139 
 
Confidential 
 
 
The final analysis of the induction period will be performed when all patients enrolled in 
Enrollment Periods 1 and 2 have completed their induction or, if applicable, extended induction 
phase, including all scheduled EoI/EoEI assessments. 
8.1.4 
Maintenance phase 
All patients with symptomatic remission at Week 10 or Week 22, will be treated as follows: 
• Patients who had received IMU-838 during induction will be re-randomized to receive 
either 10 mg/day or 30 mg/day IMU-838. 
• Patients who had received placebo will be “re-randomized” to continue to receive placebo. 
However, patients, investigator and other study personnel will remain blinded and unaware 
to this continued placebo treatment as these patients will undergo the same randomization 
procedures and study drug assignments as patients receiving IMU-838.  
• Patients will be treated until they have received IMU-838 or placebo treatment for a total 
of 50 weeks (adding up induction phase, potential extended induction phase and 
maintenance treatment) or until UC relapse, whichever occurs first. 
Randomization at the start of the maintenance phase will be stratified by the IMU-838 dose 
received in the induction phase. 
Safety and partial Mayo score (including respective patient-reported subscores, e.g. PRO-2) will 
be regularly assessed during the maintenance phase (see Table 2). Patient visits in the maintenance 
phase will be scheduled every 4 weeks. All patients who remain in the maintenance phase until 
Week 50 will undergo a scheduled flexible sigmoidoscopy with biopsy and will have the full Mayo 
score (including all subscores) assessed. Patients that experience a symptomatic UC relapse before 
Week 50 will undergo a scheduled flexible sigmoidoscopy with biopsy and will have the full Mayo 
score (including all subscores) assessed at the time of relapse (see Table 2, End of Maintenance 
[EoM]). Patients with symptomatic UC relapse will be discontinued from the maintenance phase 
with the option to enter the open-label treatment extension arm, subject to certain conditions (see 
Section 9). 
The final analysis for the maintenance phase will be performed when all patients enrolled in the 
maintenance phase have terminated maintenance treatment prematurely or as scheduled. An 
explorative data analysis for the maintenance phase will be done at the time point of final analysis 
for the induction phase. 
8.1.5 
Open-label treatment extension 
The following patients will have the option to enroll in the open-label treatment extension arm and 
will be treated with 30 mg IMU-838, once daily (however, the sponsor reserves the right to change 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 64 of 139 
 
Confidential 
 
 
the dose at any time additional information regarding safety and efficacy of IMU-838 becomes 
available): 
• Patients in the induction phase who had received at least 6 weeks of blinded study treatment 
and completed the EoI sigmoidoscopy (including biopsy) regularly scheduled at Week 10, 
and have neither reached symptomatic remission nor symptomatic response 
• Patients in the extended induction phase who had completed all Week 10 assessments 
(including EoI sigmoidoscopy), and have not reached symptomatic remission during or at 
the end of the extended induction phase  
• Patients in the maintenance phase who had discontinued from the maintenance treatment 
due to symptomatic UC relapse or other reasons with the EoM sigmoidoscopy performed 
at discontinuation (unless the previous sigmoidoscopy had been performed less than 
4 weeks before the discontinuation)  
• Patients having completed the maintenance phase as scheduled (including all 
EoM/Week 50 assessments) 
Although patients may be eligible for open-label treatment extension, those patients with 
significant protocol deviations or significant non-compliance at any time during the blinded 
treatment are not allowed to enter the open-label treatment extension arm. When patients eligible 
to enter the open-label treatment extension arm have ongoing relevant significant treatment-
emergent AEs, those patients are allowed a waiting period (including treatment suspension) of up 
to 30 days following blinded treatment and will only be allowed to enter the open-label treatment 
extension arm when such treatment-emergent AEs have subsided to levels observed at Baseline or 
have fully recovered from such AEs. 
Open-label treatment has to start within 30 days of the last dose of the blinded treatment arms, 
otherwise patients will be discontinued from this trial. 
Visits will be scheduled every 4 weeks for the initial 50 weeks of overall study treatment (i.e. 
combining treatment periods in induction, extended induction and maintenance, if applicable, and 
open-label treatment extension phases), and every 10 weeks thereafter. Following the 
implementation of Protocol Version 6.0, the 10-week schedule, for patients in the open-label 
extension and with more than 50 weeks of overall treatment, will be changed to a 24-week schedule 
at the next scheduled visit. Safety, concomitant medication, Mayo PRO-2 score, and CRP, will be 
regularly assessed during clinic visits (see Table 3). No endoscopic assessment will be performed 
but results from such procedures will be collected if done in the course of routine clinical care. 
The IMU-838 formulation (IMU-838 vs IMU-838-RC) may be changed during the open-label 
extension treatment. For more details see Section 11.1.3. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 65 of 139 
 
Confidential 
 
 
Treatment for a patient in the open-label extension arm will continue as long as no clinically 
significant safety issue (as assessed by the investigator) occurs, that is related to study procedures 
or study treatment, until the patient no longer receives a benefit from study treatment (as assessed 
by the investigator), until the patient withdraws consent, or until the sponsor terminates the study. 
In addition, patients in the open-label extension arm may be transferred by the sponsor to a separate 
and comparable follow-up study in which they can continue treatment with IMU-838 or, if patients 
have access, transfer to commercially available vidofludimus calcium. Once all remaining 
participating patients have been transferred respectively, the CALDOSE-1 study will be closed. 
Patients will be allowed to receive a maximum of 10 years (not applicable for UK, see below) total 
combined treatment with study medication in this trial. 
For the UK the following applies: With a maximum allowed treatment of 3 years in the open-label 
extension arm, patients will receive a maximum of 4 years total combined treatment with study 
medication in this trial. However, if no safety concerns arise during future regular safety 
assessments and sufficient safety data are available, the steering committee may recommend 
extending the overall treatment period including all phases to a maximum of 10 years as per a 
substantial amendment.   
The blinding of the individual randomized treatment assignments during the blinded treatment 
phase will be maintained as described in Section 10 for investigators and other study personnel, as 
well as for patients entering the open-label extension arm. When all patients have completed the 
induction phase, the individual treatment assignments for patients during induction treatment will 
be unblinded and a final data analysis for the induction phase performed, even so some patients 
may still undergo treatment in the blinded maintenance phase following the second randomization. 
During open-label treatment extension in addition to data review (as outlined in the Steering 
Committee Charter), safety interim analyses may be performed at the request of the sponsor or the 
Steering Committee. 
8.1.6 
Pharmacokinetics period 
The procedures described in this section are done in addition to population PK and IMU-838 trough 
levels done in the induction phase (see Section 8.1.3), both of which are done in all patients. This 
section only applies to the additional single-dose PK assessment in a subset of patients to be 
performed in designated PK centers only. 
Across designated study centers (“PK centers”), the first 8 patients who completed the maintenance 
phase as scheduled inclusive the EoI/Week 10 or EoM/Week 50 Visit (both, including the required 
sigmoidoscopy examinations) and who have opted to continue into the open-label treatment 
extension arm will be included in a PK subpopulation for which a full single-dose PK profile (up 
to 72 hours post-dose) will be established. These patients will receive their first open-label dose of 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 66 of 139 
 
Confidential 
 
 
30 mg IMU-838 at the StartOLE visit. Blood samples will be collected pre-dose and up to 72 hours 
post dose. No doses will be taken on Day 1OLE and Day 2OLE of the open-label period. On Day 3OLE 
and after the last PK blood sample has been taken, patients will continue daily dosing as all other 
patients (see also Sections 12.6 and 14). 
8.2 
Study design rationale 
This is a placebo-controlled, double-blind study including a double randomization (initial 
randomization for induction and second randomization for maintenance). A placebo arm is 
included due to regulatory recommendations to evaluate dose-related benefits and adverse effects 
in randomized, double-blind, placebo-controlled studies. [2,3]  
The distribution of male and female patients will be according to the natural distribution within the 
study population for this trial. No corrective measures will be taken. Because this is a phase 2 study, 
it is not planned to enrol a sufficient number of patients necessary to detect sex-related differences. 
To evaluate the time course of the clinical effects, an induction period of 10 weeks and an extended 
induction period of 22 weeks were chosen. 
To obtain a full single-dose PK profile in UC patients, a subset of patients will undergo a PK period 
at the beginning of the open-label treatment arm.  
As required by respective guidelines, [2,3] the in- and exclusion criteria ensure that only patients 
for whom a diagnosis of UC has been established by clinical and endoscopic evidence at least 
3 months before study start and for whom disease activity was confirmed at Screening by a flexible 
sigmoidoscopy with central reading will be included.  
The interim analysis after completion of Enrollment Period 1 of the induction phase was planned 
to allow to reduce the dose groups to the most appropriate dose(s) of IMU-838 and to ensure that 
patients were not unnecessarily exposed to ineffective or intolerable IMU-838 doses. However, 
because the interim analysis did not reveal a likely ineffective and/or intolerable dose 
(Section 8.1.3) all 3 IMU-838 doses will be continued in Enrollment Period 2.  
To evaluate the potential of IMU-838 to maintain remission, only patients with symptomatic 
remission are included in the maintenance phase and patients are re-randomized as 
recommended. [2] Patients with symptomatic response at the end of the initial induction phase but 
have not yet achieved symptomatic remission will continue induction treatment to Week 22 to 
evaluate if continued treatment in responders eventually leads to delayed symptomatic remission. 
This will also allow achieving sufficient patient numbers in the maintenance phase.  
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 67 of 139 
 
Confidential 
 
 
The primary endpoint at Week 10 includes a composite of both patient-reported symptomatic 
remission (i.e. stool frequency [stool frequency Mayo subscore of 0 or 1]4, rectal bleeding Mayo 
score [=0]), and endoscopic healing (modified Mayo endoscopy subscore of 0 or 1) as 
recommended. [2,3]  
The treatment period of the maintenance phase is 40 or 28 weeks (depending on the length of the 
preceding induction period) and the overall blinded treatment period is 50 weeks which is both 
considered appropriate for a phase 2 trial. 
An explorative data analysis of the maintenance phase at the time of the final analysis for the 
induction phase helps to plan for further IMU-838 development, including Phase 3 studies, and to 
evaluate if the remaining maintenance phase must be adjusted to accommodate for observed relapse 
rates. 
8.3 
Risk-benefit assessment 
Risks 
Based on pre-clinical and clinical studies with the precursor drug 4SC-101 and the single and 
multiple dose Phase 1 studies with IMU-838, no serious adverse reactions are expected with IMU-
838 at doses of <70 mg once daily. 
In clinical studies with 4SC-101, including 486 subjects of whom 299 received 4SC-101, no drug-
associated clinically relevant adverse reactions were observed at doses of <70 mg once daily. This 
included the potential target organs liver and kidney, which have been identified in animals or 
during early clinical studies. In a large placebo-controlled, randomized clinical trial of 4SC-101 in 
patients with RA, the AE profile of 35 mg/day 4SC-101 was similar to the AE profile of placebo. 
Additionally, no increased rate of infections and infestations were seen in the treatment arm as 
compared to placebo in the same study. 
At high 4SC-101 doses (≥70 mg/day or single doses of ≥210 mg) potential drug-related decreases 
in blood uric acid and increases in urine red blood cells were observed, in very rare cases presenting 
as symptomatic hematuria during the first days of treatment. Laboratory findings were consistent 
with post-renal events and de novo precipitates in the urinary tract. However, no cases of 
symptomatic hematuria were seen at daily doses of 35 mg 4SC-101, the highest therapeutic dose 
used in previous clinical trials.  
Based on results of Phase 1 studies with IMU-838, the underlying mechanism leading to increased 
RBC in urine appears to be an increased uric acid elimination during the initial days after drug 
administration. By inhibition of the urate transport system URAT1, IMU-838 may decrease the 
tubular re-uptake of uric acid in kidneys, leading to an increase in the urinary excretion of uric acid. 
 
4 Because patients must present with a stool frequency of ≥2 at Screening the stool frequency must decrease by ≥1 
as requested by respective guidelines or clinical remission. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 68 of 139 
 
Confidential 
 
 
Increased urine uric acid may in turn result in microcrystallization of uric acid in acidic urine and 
may lead to the occurrence of RBC in urine. Although this may not regularly lead to clinically 
relevant AEs or laboratory abnormalities at therapeutic doses, it may be important for patients with 
risk factors (including increased serum uric acid or higher propensity for urinary concrements) or 
for patients in whom IMU-838 metabolism is decreased potentially leading to increased drug blood 
concentrations.  
Thus, several risk mitigation measures for urinary events were implemented in this study: 
• Patients will be advised to drink sufficient fluid per day to ensure adequate urine flow.  
• Patients will receive only half of their assigned full dose during the first week of treatment 
as the main changes on uric acid urinary excretion are expected during the initial treatment 
days.  
• Regular urine dipsticks and urine sediment analysis will be performed to monitor presence 
of RBC in urine.  
• Patients with a history of renal diseases, especially those favoring or resulting in 
nephrolithiasis, with serum uric acid levels at Screening >1.2 x upper limit of normal 
(ULN), and/or history of gout or symptoms suggestive of gout will be excluded from the 
study. 
During clinical trials using the previous formulation 4SC-101, 1 serious adverse event (SAE) of 
hepatitis was reported in a patient with Gilbert syndrome receiving 35 mg 4SC-101. Gilbert 
syndrome is a genetic disease characterized by a 70–80% reduction in the glucoronidation activity 
of UGT1A1. IMU-838 is a moderate inhibitor of UGT1A1 which may have contributed to this AE. 
Patients with known or suspected Gilbert syndrome or with elevation of indirect (unconjugated) 
bilirubin above 1.2 x ULN will therefore be excluded from this clinical study. 
A thorough analysis of the clinical data did not confirm a potential adverse effect of vidofludimus 
on liver function in patients other than those with Gilbert syndrome. However, patients with liver 
impairment will be excluded from trial participation and liver enzymes and bilirubin will be 
regularly monitored throughout the trial. 
For more information please refer to the investigator’s brochure.  
Benefits 
Based on the PD of vidofludimus and the pathology of UC, patients with UC may benefit from 
IMU-838 treatment. A small uncontrolled study in patients with steroid-dependent patients with 
CD and UC confirmed the beneficial effects vidofludimus. The response rate with 4SC-101 was 
substantially higher compared with historical placebo rates and the use of steroids could be reduced 
(see also Section 5.2.5). 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 69 of 139 
 
Confidential 
 
 
Risk management 
As mentioned above, risk minimization procedures are implemented for this study to minimize and 
assess potential risks to participating patients. These include, but are not limited, to: 
• specific inclusion and exclusion criteria which ensure that patients who present with 
characteristics that may increase the risk for an adverse outcome are excluded, 
• close monitoring for RBC in urine, 
• regular monitoring of liver enzymes, 
• a 1-week initiation dose at half-dose level, and 
• an interim analysis by an independent DRC. 
Risk-benefit assessment 
Considering the known safety data, the implemented risk minimization measures, the expected 
benefits in the target population, and the medical need for further treatment in UC, the benefit-risk 
evaluation is considered favorable. 
9 
Patient selection 
9.1 
Sample size 
Overall approximately 240 patients will be enrolled: Approximately 60 patients during 
Enrollment Period 1 and approximately 180 patients in Enrollment Period 2 each randomized 
1:1:1:1 to oral 10 mg/day, 30 mg/day, or 45 mg/day IMU-838, or placebo (about 15 patients or 
45 patients each).  
The 30 mg/day and 45 mg/day IMU-838 dose groups pooled for the primary efficacy analysis will 
include about 120 patients. 
For sample size calculation see Section 16.1. 
The maximum numbers of patients enrolled will be 30 per center and 80 per country. 
9.2 
Inclusion criteria  
Induction phase 
1. Male and female patients, aged 18 - 80 years 
2. UC diagnosed more than 3 months before Screening (Day -30) as documented in the medical 
chart 
3. Previous treatment failure defined as:  
a. Patient had an inadequate response with, lost response to, or was intolerant to approved 
or experimental immunomodulators (azathioprine, 6-mercaptopurine, 6-thioguanine, 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 70 of 139 
 
Confidential 
 
 
methotrexate, or tofacitinib) or biologics (no more than 2 treatment failures with biologic 
drugs i.e. anti-tumor necrosis factor α antibodies [infliximab, adalimumab, golimumab 
and their biosimilars], vedolizumab, or certain experimental antibodies [ustekinumab]); 
or  
b. Patient had an inadequate response to, was intolerant to, or is corticosteroid dependent 
(corticosteroid-dependent patients are defined as i) unable to reduce steroids below the 
equivalent of prednisolone 10 mg/day within 3 months of starting steroids, without 
recurrent active disease, or ii) who have a relapse within 3 months of stopping steroids. 
[4]) 
4. Active disease defined as  
a. Mayo stool frequency score of ≥2 at Screening Visit 1  
b. Mayo rectal bleeding score of ≥1 at Screening Visit 1 
c.  modified Mayo endoscopy subscore of ≥2 at the screening flexible sigmoidoscopy 
(endoscopy assessed by an independent central reader blinded to screening center and 
patient information) 
5. Endoscopic appearance typical for UC and extending >15 cm from the anal verge as 
confirmed by an independent central reader (blinded to screening center and patient 
information) 
6. Laboratory values: Neutrophil count >1500 cells/µL (> 1.5 x 10^9/L), platelet count 
≥100 000/mm3 (≥ 100 10^9/L), serum creatinine <1.5 x upper limit of normal (ULN), total 
bilirubin, alanine aminotransferase (ALT), and gamma-glutamyl transferase (GGT) 
<1.5 x ULN 
7. Female patients must   
a. Be of non-child-bearing potential i.e. surgically sterilized (hysterectomy, bilateral 
salpingectomy, bilateral oophorectomy at least 6 weeks before Screening) or post-
menopausal (where postmenopausal is defined as no menses for 12 months without an 
alternative medical cause), or 
b. If of child-bearing potential, must have a negative pregnancy test at Screening (blood 
test) and before the first study drug administration (Day 0 urine test). They must agree 
not to attempt to become pregnant, must not donate ova, and must use a highly effective 
contraceptive method 2 months before Screening, during treatment with IMU-838, and 
at least 3 months after the last dose of study therapy 
Highly effective forms of birth control are those with a failure rate less than 1% per year 
and include: 
− 
oral, intravaginal, or transdermal combined (estrogen and progestogen containing) 
hormonal contraceptives associated with inhibition of ovulation 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 71 of 139 
 
Confidential 
 
 
− 
oral, injectable, or implantable progestogen-only hormonal contraceptives 
associated with inhibition of ovulation 
− 
intrauterine device or intrauterine hormone-releasing system 
− 
bilateral tubal occlusion 
− 
vasectomized partner (i.e. the patient’s male partner has undergone effective 
surgical sterilization before the female patient entered the clinical trial and he is the 
sole sexual partner of the female patient during the clinical trial) 
− 
sexual abstinence (acceptable only if it is the patient’s usual form of birth 
control/lifestyle choice) 
8. Male patients must agree not to father a child or to donate sperm starting at Screening and 
throughout the clinical trial and for 3 months after the last dose of study medication. Male 
patients must also either 
o abstain from sexual intercourse with a female partner (acceptable only if it is the 
patient’s usual form of birth control/lifestyle choice), Or 
o use adequate barrier contraception during treatment with IMU-838 and for at least 
3 months after the last dose of study medication 
For Poland and the UK the following additional requirement apply: 
o if male patients have a female partner of childbearing potential, the partner should use 
a highly effective contraceptive method as outlined in inclusion criterion 7 
And additionally, for Poland only: 
o if male patients have a pregnant partner, they must use condoms while taking study 
medication to avoid exposure of the fetus to study medication 
9. Ability to understand and comply with study procedures and restrictions  
10. The patient is legally competent, has been informed of the nature, the scope and the 
relevance of the study, voluntarily agrees to participation and the study’s provisions and 
has duly signed the informed consent form  
Maintenance phase 
1. Symptomatic remission achieved at Week 10 or Week 22 of the induction phase 
 
Open-label treatment extension arm 
1. Patient is in the induction phase, had received at least 6 weeks of blinded study treatment 
and completed the sigmoidoscopy (incl. biopsy) regularly scheduled at Week 10/EoI, and 
has neither reached symptomatic remission nor symptomatic response 
Or 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 72 of 139 
 
Confidential 
 
 
Patient is in the extended induction phase, had completed all Week 10 assessments, and has 
not reached symptomatic remission during or at the end of the extended induction phase,  
Or 
Patient is in the maintenance phase and discontinues from the maintenance phase due to 
symptomatic UC relapse or other reasons with a flexible sigmoidoscopy performed at 
discontinuation (if the previous sigmoidoscopy had been performed more than 4 weeks 
before discontinuation)  
Or  
Patient has completed the maintenance phase as scheduled (including all Week 50 
assessments) 
9.3 
Exclusion criteria 
A patient will not be eligible for inclusion if any of the following criteria applies:  
Gastrointestinal exclusion criteria 
1. Diagnosis of Crohn’s disease, inflammatory bowel disease type unclassified, ischemic 
colitis, microscopic colitis, radiation colitis or diverticular disease-associated colitis 
2. Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine 
3. History of colectomy with ileorectal anastomosis or ileal-pouch anal anastomosis or 
imminent need for colectomy (i.e. colectomy is being planned) 
4. Active therapeutically uncontrollable abscess or toxic megacolon 
5. Malabsorption or short bowel syndrome  
6. History of colorectal cancer or colorectal dysplasia (with the exception of dysplasia in 
polyps which have been removed) 
Infectious disease exclusion criteria 
7. Clostridium difficile (C. difficile) infection  
o Evidence of, or treatment for C. difficile infection within 30 days before first 
randomization  
o Positive C. difficile toxin B stool assay during the screening period 
8. Treatment for intestinal pathogens other than C. difficile within 30 days prior to first 
randomization  
9. Other chronic systemic infections 
o History of chronic systemic infections including but not limited to tuberculosis, human 
immunodeficiency virus (HIV), hepatitis B or C, within 6 months before Screening 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 73 of 139 
 
Confidential 
 
 
o Positive interferon-gamma release assay (IGRAs) for Mycobacterium tuberculosis at 
Screening 
o Positive HBsAg (hepatitis B virus surface antigen), HBcAb (hepatitis B core antibody), 
positive hepatitis C virus and/or HIV-antigen-antibody (HIV-Ag/Ab) test5 at Screening 
10. Any live vaccinations within 30 days prior to study drug administration except for the 
influenza vaccine 
Other medical history and concomitant disease exclusion criteria 
11. Known history of nephrolithiasis or underlying condition with a strong association of 
nephrolithiasis, including hereditary hyperoxaluria or hereditary hyperuricemia 
12. Diagnosis or suspected liver function impairment which may cause, as assessed by the 
investigator, a potential for fluctuating liver function tests during this trial 
13. Renal impairment i.e. estimated glomerular filtration rate (eGFR) ≤60 mL/min/1.73m²6 
14. Serum uric acid levels at Screening >1.2 x ULN (for women >6.8 mg/dL, for men 
>8.4 mg/dL) 
15. History or clinical diagnosis of gout  
16. Known or suspected Gilbert syndrome 
17. Indirect (unconjugated) bilirubin ≥1.2 x ULN at Screening (i.e. ≥ 1.1 mg/dL) 
18. Concurrent malignancy or prior malignancy within the previous 10 years except for the 
following: adequately-treated non-melanoma skin cancer and adequately-treated cervical 
cancer 
Therapy exclusion criteria 
19. Use of any investigational product within 8 weeks or 5 x the respective half-life before first 
randomization, whatever is longer 
20. Use of the following medications within 2 weeks before first randomization: 
a. Tofacitinib 
b. Methotrexate 
c. Mycophenolate mofetil 
d. Any calcineurin inhibitors (e.g. tacrolimus, cyclosporine, or pimecrolimus) 
 
5 If any HIV, HBV, or HCV antigen or antibody screening test shows reactive or borderline results, a confirmatory 
Nucleic Acid Amplification Test (NAAT) will automatically be performed for the detection of the virus by using 
the same blood draw sample. If no virus specific nucleic acid is detected, and the clinical history of the patient, 
other laboratory examinations, and current clinical pictures also exclude a concurrent infection, the patient will not 
be excluded from the study.  
6 Calculated according to the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 74 of 139 
 
Confidential 
 
 
e. Oral systemic corticosteroids >20 mg/day prednisolone equivalent including 
beclomethasone dipropionate (at >5 mg/day) and budesonide (multi-matrix [MMX] at 
>9 mg/day) 
f. Oral aminosalicylates (e.g. mesalazines) >4 g/day 
21. Use of the following medications within 4 weeks before first randomization: 
a. Use of intravenous corticosteroids 
b. Use of thiopurines including azathioprine, mercaptopurine and 6-thioguanine 
c. Use of any rectal and topical aminosalicylates and/or budesonide 
22. Use of oral systemic corticosteroids ≤20 mg/day prednisolone equivalent including 
beclomethasone dipropionate (at ≤5 mg/day) and budesonide (MMX at ≤9 mg/day) unless 
they have been used for at least 4 weeks before first randomization and at a stable dose for 
at least 2 weeks before first randomization  
23. Oral aminosalicylates (e.g. mesalazines) ≤4 g/day unless they have been used for at least 6 
weeks and with a stable dose for at least 3 weeks before first randomization 
24. Use of biologics as follows:  
a. anti-tumor necrosis factor α antibodies (infliximab, adalimumab, golimumab, including 
their biosimilars) within 4 weeks before first randomization 
b. vedolizumab and ustekinumab within 8 weeks before first randomization 
25. Use of the DHODH inhibitors leflunomide or teriflunomide within 6 months before first 
randomization 
26. Any use of natalizumab (Tysabri™) within 12 months before first randomization 
27. Use of the following concomitant medications is prohibited at Screening and throughout 
the duration of the trial:  
o any medication known to significantly increase urinary elimination of uric acid, in 
particular lesinurad (Zurampic™) as well as uricosuric drugs such as probenecid 
o treatments for any malignancy, in particular irinotecan, paclitaxel, tretinoin, bosutinib, 
sorafinib, enasidenib, erlotinib, regorafenib, pazopanib and nilotinib 
o any drug significantly restricting water diuresis, in particular vasopressin and 
vasopressin analogs  
o Rosuvastatin at doses ˃10 mg/day 
General exclusion criteria 
28. History of, or current serious, severe, or unstable (acute or progressive) physical or mental 
illness, or any medical condition, including laboratory anomalies or renal or hepatic 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 75 of 139 
 
Confidential 
 
 
impairment, that may require treatment or would put the patient in jeopardy if he/she was 
to participate in the study  
29. Known hypersensitivity to DHODH inhibitors (teriflunomide, leflunomide) or any 
ingredient of the investigational product 
30. Pregnancy or breastfeeding 
31. History of drug or alcohol abuse during the past year 
32. Concurrent participation in any other clinical trial using an investigational medicinal 
product or medical device 
33. An employee of an investigator or sponsor or an immediate relative of an investigator 
Exclusion criteria for open-label treatment extension arm 
1. Any ongoing, clinically significant treatment-emergent (started during the IMU-838 
treatment in the blinded treatment arms) adverse event (AE) or laboratory abnormality 
(including blood chemistry and urinalysis) as assessed by the investigator * 
2. Significant treatment or study non-compliance during induction and/or maintenance phase 
(as assessed by the investigator), and/or inability or unwillingness to follow instructions by 
study personnel as assessed by the investigator 
3. Significant protocol deviations during induction and/or maintenance phase that are assessed 
by the investigator to negatively affect further patient cooperation in this study 
* If treatment-emergent AEs are the reason for exclusion from the open-label extension arm, the eligibility can 
be re-assessed up to 30 days following the last treatment in the blinded treatment arms. 
10 
Randomization, blinding and unblinding procedures 
10.1 
Blinding 
Study participants, investigators, and all other personnel directly involved in the conduct of the 
study will be blinded to treatment assignments during the blinded treatment phase. If patients 
switch to the open-label treatment arm, the blind of their previous treatment assignment during 
induction and maintenance will be kept until after database hard lock for the final analysis of the 
induction and maintenance phase, respectively. The blinding for study participants, investigators, 
and all other persons directly involved in the conduct of the study will also be kept during interim 
and explorative data analyses.  
To maintain the blind, the IMU-838 as well as the placebo tablets will have identical appearance, 
shape and color, and will have identical labeling and packaging. To minimize the potential for bias, 
treatment randomization information will be kept confidential by the responsible personnel and 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 76 of 139 
 
Confidential 
 
 
will not be released to investigators, other study center personnel, or the sponsor’s designee(s) until 
after database hard lock for the final analysis of the induction and maintenance phase, respectively. 
10.2 
Emergency unblinding 
The premature breaking of the code should be restricted to emergency cases in which knowledge 
of the administered drug is necessary for treatment of clinically significant AEs. Whenever 
possible, the sponsor should be contacted before breaking the blind. Should any blind be broken, 
the respective patient will be withdrawn from further blinded treatment in the study (however, the 
patient may continue open-label treatment, if applicable) and a written explanation must be given 
by the investigator to the sponsor immediately. Emergency unblinding, if necessary, will be 
conducted via IWRS or via an emergency phone service, in cases the web-based system cannot be 
accessed for any reason. 
10.3 
Maintenance of blinding during interim or exploratory analyses 
An interim analysis was performed for the induction phase of Enrollment Period 1 and an 
exploratory analysis will be performed for the maintenance phase at the final analysis of the 
induction phase. Care will be taken to maintain the blind of patients, investigators and sponsor 
during these analyses, and to avoid introducing any biases into the study. 
After approximately 60 patients had been randomized into Enrollment Period 1 and had received 
at least 1 dose of IMU-838 an interim analysis was performed for the induction phase data.  
After all patients have completed their induction phase and, if applicable, their extended induction 
phase, the respective data base part will be hard locked, and data of the induction phase will be 
unblinded and analyzed. An exploratory analysis of the maintenance phase will be performed at 
this time. However, the blind for the maintenance phase will be kept until completion of the 
maintenance phase and hard lock of the respective data base part. 
Access to interim comparative and individual patient data will be restricted to members of the DRC 
and the independent data manager and independent biostatistician performing the interim and 
explorative data analyses. The statistical analysis will be done by the independent statistician not 
otherwise involved in the clinical trial.  
Aggregate data on accrual and drop-out rates, and reasons for ineligibility and discontinuation will 
also be made available for the Steering Committee. 
To minimize bias, the statistical analysis plan (SAP) for the induction period (which includes the 
primary endpoint of the study) was finalized before any data was analyzed in the interim analysis. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 77 of 139 
 
Confidential 
 
 
10.4 
Patient identification 
A 6-digit patient identifier consisting of 2 digits each for country (YY), center (XX) and patient 
(ZZ) i.e. YYXX-ZZ will be assigned to each screened patient.  
10.5 
Randomization 
The study includes a double randomization, i.e. initial randomization for induction, second 
randomization for maintenance.  
Eligible patients will be randomized by means of IWRS. The IWRS will assign the appropriate 
initial and all subsequent study medication kits for each patient. The sites will be supplied with 
user guides for the IWRS in English or the national language. 
The investigators will be provided with technical options and password information to selectively 
break the code for an individual patient by telephone or through electronic message transfers. For 
further information, please see Section 10.2. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 78 of 139 
 
Confidential 
 
 
11 
Treatments 
11.1 
Study medication 
All medications supplied by the sponsor will be manufactured, tested, and released according to 
current Good Manufacturing Practice guidelines and local requirements.  
11.1.1 
IMU-838  
Name: 
IMU-838  
Manufacturer: 
Immunic AG 
Active ingredient: 
Vidofludimus calcium (IM90838) 
Inactive ingredients: 
Microcrystalline cellulose, crospovidone and magnesium stearate; tablets 
manufactured by wet granulation additionally contain povidone and talc. 
Formulation: 
Tablets containing a specific polymorph of vidofludimus calcium 
manufactured by wet granulation or roller compactor (IMU-838 or IMU-
838-RC); the 2 formulations are considered bioequivalent (see 
investigator’s brochure and Section 5.2.3) 
Matrix: 
White uncoated tablets, biconvex shape, diameter of 8 mm 
Dose strengths: 
Before implementation of Protocol Version 6.0: 
5 mg, 15 mg, and 22.5 mg (IMU-838) 
Following implementation of Protocol Version 6.0: 
5 mg, 15 mg, and 22.5 mg (IMU-838), and 30 mg (IMU-838-RC, will 
only be used in the open-label treatment extension) 
 
11.1.2 
Placebo 
The placebo tablets will be identical to the IMU-838 tablets in terms of appearance, constitution of 
inactive ingredients, and packaging. 
11.1.3 
Packaging, labeling and dispensing 
All study medication will be packed and labeled according to applicable regulatory requirements.  
The labels will contain at least the following information: route of administration, study code, 
randomization number, batch number, expiry date, as well as instructions for storage. 
IMU-838 and placebo tablets will be packaged in 30 mL polyethylene bottles containing 85 tablets; 
IMU-838-RC will be packed in 30 mL polyethylene bottles containing 100 tablets.  
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 79 of 139 
 
Confidential 
 
 
Study medication (one bottle with 85 tablets) during the blinded treatment phase will be dispensed 
at D0, Week (W)6, W10, W14, W18, W22, W26, W30, W34, W38, W42, and W46, if applicable.  
Study medication during the open-label treatment will be dispensed every 4 weeks (during first 
50 weeks of treatment, one bottle will be dispensed at each visit) or every 10 weeks (after first 
50 weeks of treatment, 2 bottles will be dispensed at each visit) until Protocol Version 6.0 comes 
into force. After the Protocol Version 6.0 approval, the patient can receive at each visit 1 bottle of 
IMU-838-RC instead of 2 bottles of IMU-838. 
After implementation of Protocol Version 6.0 either up to 5 bottles of IMP (when the previous 
IMU-838 formulation is used) or up to 2 bottles of IMP (when the simplified IMU-838-RC 
formulation is used) will be dispensed every 24 weeks (until EoT). The number of bottles dispensed 
depends on the specific circumstances of the visit schedule of the patient and the amount of 
remaining IMP estimated from the currently used bottles available to the patient. During the 
extended treatment period, dispensed bottles must be used until empty and then be returned. 
Patients will be advised to bring all IMP (including full, in-use and empty bottles) to all visits; the 
empty bottles will be kept, the in-use and full ones will be returned to the patient (together with 
newly issued ones). Patients will also be advised to completely use up the tablets in one bottle 
before starting a new bottle. In-use non-empty bottles (without counting of remaining tablets) will 
be returned to the patients for continued use, unless a safety interim analysis is being performed as 
communicated by the sponsor. 
The switch from the IMU-838 to the simplified IMU-838-RC formulation will depend on the 
remaining availability of the previous formulation. The sponsor will communicate to sites when 
formulations must be switched at the next regular study visit for all patients still on treatment. After 
switching to the simplified IMU-RC formulation, patients must take only one instead of 2 tablets 
per day. The investigator and other study personnel must make patients aware of this change when 
first dispensing the IMU-838-RC formulation. 
As an exception only during any extraordinary circumstances (e.g. COVID -19 pandemic), the 
sponsor acknowledges that some organizational and/or logistical adjustments might be necessary 
at the investigational sites. Only during these exceptional circumstances sites are allowed to ship 
IMP directly to the patients.  
11.1.4 
Storage and stability 
The investigator is responsible for the safe and proper handling and storage of the study medication 
at the investigational site. The study medication must be stored in a locked facility with access 
limited to the investigator and authorized personnel. The investigator must ensure that the study 
medication is administered only to the patients enrolled in this study. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 80 of 139 
 
Confidential 
 
 
In stability studies, the medicinal product was stable at ambient (25°C/60% relative humidity) and 
at accelerated storage conditions (40°C/75% relative humidity). Thus, IMU-838 does not require 
any special storage conditions. However, the tablets in general should be protected from direct sun 
light, moisture, freezing, and excessive heat (excessive heat is customarily defined as any 
temperature above 40°C [104 F]). It should also be advised to keep the bottle tightly closed in order 
to protect from moisture. 
11.1.5 
Treatment dose, dose selection, and administration  
Doses administered are summarized in Table 6. Tablets (1 tablet per administration and day for the 
initial week of treatment, 2 tablets per administration and day thereafter; if the IMU-838-RC 
formulation is used during the open-label extension treatment only 1 tablet per day) will be taken 
once daily in the morning in the fasted state (no food after midnight, intake of water allowed) and 
taken with one glass of water approximately 15 minutes to 1 hour before breakfast. 
For treatment administration, the following must be considered: 
• At study visit days in the induction phase, medication must be taken at the study center to 
allow for pre-dose assessments (i.e. plasma IMU-838 trough levels). 
• During the entire study, patients will not be allowed to have breakfast before they arrive at 
the study center (to allow for blood chemistry). Intake of water is always allowed.  
• Patients selected for the full PK assessment for the single dose given during the open-label 
treatment must fast for a minimum of 10 hours (no food, only intake of water allowed) 
before dosing and blood drawings and 2 hours after dosing.  
 
 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 81 of 139 
 
Confidential 
 
 
Table 6: 
Doses administered 
Phase 
 
Daily dose 
[mg] 
No of tablets, 
tablet strength 
 
 
Week 1 
D0 - D6 
Weeks 2-10 or 
Weeks 2-22 
Week 1 
Weeks 2-10 or 
Weeks 2-22 
Induction and 
extended induction 
phase 
Enrollment Periods 1 
and 2 
0 
0 
1 x placebo 
2 x placebo 
5 
10 
1 x 5 mg 
2 x 5 mg 
 
15 
30 
1 x 15 mg 
2 x 15 mg 
 
 
22.5 
45 
1 x 22.5 mg 
2 x 22.5 mg 
 
 
Daily dose 
[mg] 
No of tablets, 
tablet strength 
 Maintenance phase 
 
0 
2 x placebo 
 
 
10 
2 x 5 mg 
 
 
30 
2 x 15 mg 
 
 
Daily dose 
[mg] 
No of tablets, 
tablet strength 
Open-label treatment 
 
30a 
2 x 15 mg IMU-838 
Or 1 x 30 mg IMU-838-RC 
a The sponsor may change the dose whenever additional information regarding safety and efficacy of IMU-838 becomes 
available.  
D = Day, No = number. 
 
Doses of 10 to 45 mg once daily were chosen based on 4SC-101 data where a daily dose around 
35 mg/day was safe, and based on the results of the Phase 1 studies with IMU-838 showing 
comparable plasma exposure of the free acid and calcium salt formulation of vidofludimus. The 
highest dose used in this trial will be 45 mg/day IMU-838. The area under the drug concentration-
time curve (AUC) of this dose is expected to be far lower than that of 70 mg/day 4SC-101 which 
was associated with increased RBC in urine. To further reduce the risk of increased urine RBC, 
patients will receive only half of their assigned full dose during the first week of treatment as the 
mechanism of increased uric acid excretion is thought to be more pronounced during treatment 
initiation. 
An elimination half-life of 30 hours allows a once daily administration. 
The doses used for Enrollment Period 2 are based on the interim data of Enrollment Period 1. All 
available data (PD, efficacy and safety data) were reviewed by the DRC during the interim analysis 
(see Section 6). Subsequently a maximum of 2 effective and safe IMU-838 doses were to be 
selected for Enrollment Period 2. Ineffective doses and doses with dose-limiting toxicities were to 
be discontinued. The dose selection process was based on many parameters and thus no direct and 
easy algorithm to identify the best doses existed. However, the decision was to be justified on the 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 82 of 139 
 
Confidential 
 
 
observed results. Details about the interim analysis were defined in a DRC charter finalized prior 
to data base lock for the interim analysis. However, from the interim results the DRC concluded 
that none of the IMU-838 doses used in Enrollment Period 1 were likely ineffective and/or 
intolerable and the Steering Committee recommend continuing all 3 IMU-838 doses in Enrollment 
Period 2. These recommendations were accepted and implemented by the sponsor and thus 
Enrollment Period 2 will include all 3 IMU-838 doses. 
11.1.6 
Drug accountability and patient compliance 
Study medication must not be used outside the context of this study protocol. The investigator must 
ask the patient to return excess study medication as well as all packaging materials (including 
empty containers) at all applicable visits (see Table 1, Table 2, Table 3, Table 4) for drug 
accountability. Unused study medication cannot be used outside this study. Dispensed and returned 
medication cannot be re-used for other patients in this study. 
The investigator or authorized staff must document the receipt, dispensation, and return of all study 
medication received during this study. These records will include but are not limited to dates, 
quantities, batch numbers, and patient identifiers and unique IRT codes, as applicable. The 
investigators must maintain records documenting that the patients were provided with study 
medication as outlined in the protocol. Furthermore, they should reconcile all study medication 
received from the sponsor and returned from the patient. It is the responsibility of the investigator 
to give reasons for any discrepancies in study medication accountability. Forms will be provided 
to enhance drug accountability. 
At the end of the clinical trial, or as directed, all remaining and unused study medication must be 
accurately accounted (final drug accountability) and destroyed according to the sponsor’s 
instructions, e.g. return all remaining and unused study medication to the sponsor or sponsor’s 
designee.  
During the open-label extension treatment, compliance will be assessed by the number of bottles 
dispensed and empty bottles returned (dispensed bottles must be used until empty and then 
returned; remaining tablets in in-use bottles will not be counted at every trial visit). This differs for 
the EoT visit and in case of an interim safety analysis (see Section 16.5) at which remaining tablets 
of in-use bottles will be counted. 
 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 83 of 139 
 
Confidential 
 
 
11.2 
Prior and concomitant medications 
11.2.1 
UC-related treatments 
All previous medications administered within 1 month before randomization must be documented 
in the corresponding section of the eCRF. In addition, all UC-related therapies since UC diagnosis 
will be documented in the eCRF. 
All medications taken by the patients at entry into the study and all treatments given in addition to 
the study medication during the study are regarded as concomitant treatments and must be 
documented in the eCRF. 
An overview on allowed and prohibited prior and concomitant therapies is also provided in 
Appendix 1. 
 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 84 of 139 
 
Confidential 
 
 
Table 7: 
Allowed concomitant UC-related treatments 
 
Induction phase 
Maintenance 
phase 
Open-label 
extension 
Oral corticosteroids  
Stable dose of 
≤20 mg/day prednisolone 
equivalent allowed, if a 
stable dose was given for 
at least 2 weeks  before 
randomization 
No initiation 
allowed, doses of 
≤20 mg/day 
prednisolone 
equivalent 
alloweda 
Initiation 
allowed, doses of  
≤20 mg/day 
prednisolone 
equivalent 
allowed 
Oral budesonide MMX 
Stable dose of ≤9 mg/day 
allowed, if a stable dose 
was given for at least 2 
weeks before 
randomization 
No initiation 
allowed, stable 
doses of 
≤9 mg/day 
alloweda 
Initiation 
allowed, 
doses of 
≤9 mg/day 
Oral beclomethasone 
dipropionate 
Stable dose of ≤5 mg/day 
allowed, if same stable 
dose was given for at 
least 2 weeks before 
randomization 
No initiation 
allowed, stable 
doses of 
≤5 mg/day 
alloweda 
Initiation 
allowed, 
doses of 
≤5 mg/day 
Oral aminosalicylates (e.g. 
mesalazines) 
Stable dose ≤4 g/day 
allowed, if same stable 
dose was given for at 
least 3 weeks before 
randomization 
No initiation, 
stable doses of 
≤4 g/day allowed 
Initiation 
allowed, 
doses of ≤4 g/day 
Rectal and topical 
aminosalicylates and/or 
budesonide 
Not allowed 
Not allowed 
Allowed 
Biologics 
Not allowed 
Not allowed 
Allowed 
Antiobiotics (oral or 
systemic) 
Not allowed 
Not allowed 
Allowed 
a Tapering must be initiated (see Section 11.3). 
MMX = multi-matrix 
 
11.2.1.1 
Allowed UC treatments 
Allowed treatments during Screening and Induction 
• Oral systemic corticosteroids (at or below 20 mg/day prednisolone equivalent), including 
budesonide (multi-matrix [MMX] formulation, at or below 9 mg/day) and beclomethasone 
dipropionate (at or below 5 mg/day), will be allowed if they had been used for at least 4 
weeks and with a stable dose for at least 2 weeks before first randomization, however: 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 85 of 139 
 
Confidential 
 
 
Cannot be initiated during induction, allowed only if already taken at stable doses of 
≤20 mg/day (budesonide at ≤9 mg/day, beclomethasone dipropionate ≤5 mg/day) for at 
least 2 weeks before first randomization 
Doses should be stable throughout the induction phase 
• Oral aminosalicylates (e.g. mesalazine) ≤4 g/day will be allowed if they had been used for 
at least 6 weeks and at a stable dose for at least 3 weeks before first randomization 
Cannot be initiated during induction phase, allowed only if already taken at stable doses for 
at least 3 weeks before first randomization 
Doses should be stable throughout induction phase 
Allowed treatments during Maintenance 
• Oral systemic corticosteroids, including budesonide (MMX formulation, at or below 
9 mg/day) and beclomethasone dipropionate (at or below 5 mg/day), can be used during the 
maintenance phase: 
− 
Dose can be changed during maintenance phase but must be maintained at 
≤20 mg/day 
(≤9 mg/day 
for 
budesonide, 
≤5 mg/day 
for 
beclomethasone 
dipropionate) 
− 
Weaning should be initiated (see Section 11.3) 
• Oral aminosalicylates (e.g. mesalazine) can be used during the maintenance phase 
Doses can be changed during maintenance phase but must be maintained ≤4 g/day 
Allowed treatments during open-label extension 
• Oral 
systemic 
corticosteroids 
including 
budesonide 
(MMX 
formulation) and 
beclomethasone dipropionate treatment can be continued or newly initiated during open-
label extension, however must be maintained at ≤20 mg/day (budesonide at ≤9 mg/day, 
beclomethasone dipropionate ≤5 mg/day) 
• Oral aminosalicylates (e.g. mesalazine) treatment can be newly initiated, however must be 
maintained at ≤4 g/day 
• Biologics such as anti-TNFα antibodies (infliximab, adalimumab, golimumab including 
their biosimilars), vedolizumab and ustekinumab (if licensed in your country for the 
treatment of UC) can be newly initiated during the open-label extension 
• Topical treatments (enemas or suppositories) containing aminosalicylates and/or 
budesonide  
• Oral and/or systemic antibiotic treatments used for treatment of a Clostridium difficile 
infection or other bacterial infections 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 86 of 139 
 
Confidential 
 
 
11.2.1.2 
Prohibited UC-related treatments during the trial 
Any UC-related medication not listed under allowed treatments or any doses of allowed 
medications not listed under UC-related medications are not allowed during the trial (oral systemic 
corticosteroids >20 mg/day prednisolone equivalent, budesonide >9 mg/day, and beclomethasone 
dipropionate >5 mg/day are allowed to treat UC flares only during the open-label treatment 
extension). The following medications or treatments are prohibited during the entire trial: 
• Thiopurines including azathioprine, 6-mercaptopurine and 6-thioguanine  
• Janus kinase inhibitors approved for the treatment of IBD (e.g. tofacitinib) 
• Intravenous corticosteroids  
• Use of the DHODH inhibitors leflunomide or teriflunomide  
• Any use of natalizumab (Tysabri™)  
• Use of methotrexate 
• Use of mycophenolate mofetil 
• Use of any calcineurin inhibitors (e.g. tacrolimus, pimecrolimus cyclosporine)  
11.2.2 
Other prohibited and restricted medications 
Prohibited medications 
• Any investigational product within 8 weeks or 5 x the respective half-life before the first 
randomization  
• Any medication known to significantly increase urinary elimination of uric acid, in 
particular lesinurad (Zurampic™) as well as uricosuric drugs such as probenecid 
• Treatments for any malignancy, in particular irinotecan, paclitaxel, tretinoin, bosutinib, 
sorafinib, enasidenib, erlotinib, regorafenib, pazopanib, and nilotinib 
• Any drug significantly restricting water diuresis, in particular vasopressin and vasopressin 
analogs 
• Rosuvastatin at ˃10 mg/day 
• Life vaccines 
• Sphingosine-1-receptor (S1P) modulators (including, but not limited to fingolimod, 
siponimod, and ozanimod), monomethyl fumarate, and diroximel fumarate 
 
Restricted medications 
Restricted concomitant medications are not generally prohibited (Appendix 1), but use should be 
restricted in terms of dose and treatment duration, if possible. In accordance with the prescribing 
information, the lowest effective dosage for the shortest duration should be applied based on the 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 87 of 139 
 
Confidential 
 
 
individual patient treatment goals whenever possible. Alternatives to these drugs should be 
considered and patients should be carefully monitored for any indication of overdose and/or 
toxicity. 
Care should be exercised when using medications that are substrates of the BCRP transport system, 
especially when the elimination of the medication depends on the BCRP transport system. Patients 
should be closely monitored for signs and symptoms of excessive exposure to these medications 
and dosing of these medications should be carefully considered. Statins should be lowered to the 
lowest possible dose and doses of rosuvastatin are not to exceed 10 mg daily. 
11.3 
Oral corticosteroid tapering regimen 
At the start of the maintenance phase (at Weeks 10 or 22) a corticosteroid tapering regimen should 
be initiated for patients receiving oral steroids. For prednisone, the dose should be reduced at a rate 
of 5 mg (or equivalent) every 2 weeks. For beclomethasone dipropionate and budesonide other 
suitable tapering regimen should be used according to the investigator’s discretion.  
11.4 
Precautions and restrictions 
Female patients must   
• Be of non-child-bearing potential i.e. surgically sterilized (hysterectomy, bilateral 
salpingectomy, bilateral oophorectomy at least 6 weeks before Screening) or 
post-menopausal (where postmenopausal is defined as no menses for 12 months without an 
alternative medical cause), or 
• If of child-bearing potential, must have a negative pregnancy test at Screening (blood test) 
and before the first study drug administration (Day 0 urine test). They must agree not to 
attempt to become pregnant, must not donate ova, and must use a highly effective 
contraceptive method 2 months before Screening, during treatment with IMU-838, and at 
least 3 months after the last dose of study therapy 
Highly effective forms of birth control are those with a failure rate less than 1% per year 
and include: 
o oral, intravaginal, or transdermal combined (estrogen and progestogen containing) 
hormonal contraceptives associated with inhibition of ovulation 
o oral, injectable, or implantable progestogen-only hormonal contraceptives associated 
with inhibition of ovulation 
o intrauterine device or intrauterine hormone-releasing system 
o bilateral tubal occlusion 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 88 of 139 
 
Confidential 
 
 
o vasectomized partner (i.e. the patient’s male partner has undergone effective surgical 
sterilization before the female patient entered the clinical trial and he is the sole sexual 
partner of the female patient during the clinical trial) 
o sexual abstinence (acceptable only if it is the patient’s usual form of birth 
control/lifestyle choice) 
Male patients must agree not to father a child or to donate sperm starting at Screening and 
throughout the clinical trial and for 3 months after the last dose of study medication. Male patients 
must also either 
• abstain from sexual intercourse with a female partner (acceptable only if it is the patient’s 
usual form of birth control/lifestyle choice), Or 
• use adequate barrier contraception during treatment with IMU-838 and for at least 3 months 
after the last dose of study medication 
If male patients do have a female partner of childbearing potential, it is recommended that the 
female partner should also use an effective contraceptive method.  
For Poland and the UK the following applies additionally: 
If male patients have a female partner of childbearing potential, the female partner must use an 
effective contraceptive or other effective birth control method (see above) throughout the study and 
for 3 months after the last dose of study medication.  
And additionally, for Poland only: 
If male patients have a pregnant partner, they must use condoms while taking the study medication 
to avoid exposure of the fetus to the study medication. 
For restrictions concerning the administration of study medication see Section 11.1.5. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 89 of 139 
 
Confidential 
 
 
11.5 
Management of clinical events 
11.5.1 
Adverse events of anticipated clinical events of UC 
UC-related intestinal symptoms such as diarrhea and rectal bleeding that were present at Screening 
and fluctuate based on the individual patient’s disease history during the course of the study are 
considered anticipated clinical events of the underlying condition and will not be collected as AEs. 
These disease characteristics will be regularly captured in the Mayo score (and respective 
subscores). 
Any worsening of intestinal UC disease symptoms should only be recorded as an AE if their course 
is abnormally severe or significant or unexpected. New UC typical extra-intestinal manifestations 
which have never been seen before in this particular patient should also be recorded as AEs. 
The terms “UC exacerbations” or “UC relapse” will not be considered as AEs. Symptomatic UC 
relapses (for definition see Section 4) will be separately documented in the eCRF.  
11.5.2 
Monitoring of hepatotoxicity 
Patients will be monitored throughout the study for evidence of hepatotoxicity with regular 
assessments (every 4 weeks) of liver enzymes e.g. aspartate aminotransferase (AST), alanine 
aminotransferase (ALT), alkaline phosphatase (AP), gamma-glutamyl transferase (GGT) and total 
and indirect bilirubin. In addition, the exploratory biomarker miR-122 of drug-induced liver injury 
will be assessed pre-dose and at 24 hours after the first dose of study drug in the induction phase.  
In case of an increase in ALT, GGT or AST to >3 × ULN, or indirect or total bilirubin >2 × ULN 
during dosing with study medication, testing of all liver parameters (ALT, AST, GGT, total and 
indirect bilirubin) will be repeated within 48 to 72 hours. Patients will also be asked about 
symptoms. Concomitant medication will be checked for hepatotoxic medications. 
If repeat testing still shows ALT or AST to be >3 × ULN, or bilirubin >2 ×ULN close monitoring 
of the respective patient will be initiated (including but not limited to repeating liver enzymes and 
serum bilirubin tests 2 or 3 times weekly, detailed evaluation of medical history and concomitant 
drug use, ruling out other cause of liver enzyme increases, further liver function tests as considered 
appropriate by the investigator). 
Study medication will be discontinued if at least one of the following applies 
• ALT or AST >8 x ULN 
• ALT or AST >5 x ULN for more than 2 weeks 
• ALT or AST >3 x ULN and total bilirubin >2 x ULN or international normalized ratio 
(INR) >1.5 x ULN 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 90 of 139 
 
Confidential 
 
 
• ALT or AST >3 x ULN with appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia 
• Indirect bilirubin >3 x ULN 
11.5.3 
Monitoring of red blood cells in urine 
Plasma uric acid levels and urinalysis (microscopic examination of urinary sediment) will be 
regularly assessed throughout the initial 10 weeks of study treatment. Urinary screening during 
continued treatment beyond 10 weeks will be performed with urine dipstick assessments for RBC 
in urine. A positive dipstick assessment will trigger a full urine sediment analysis. In addition, 
plasma uric acid will be regularly monitored throughout the entire trial. Assessment of RBC in 
urine and hematuria as laboratory abnormality and/or AE should be based solely on findings from 
the microscopic examination of urinary sediment and not on dipstick readings only.[5] For further 
information please see Section 15.1.3. 
12 
Study schedule 
12.1 
Study conduct 
An overview on the study conduct is provided in the schedules of assessments (Table 1, Table 2, 
Table 3, Table 4, and Table 5). Patients will be given a patient’s identification card at Screening 
stating the patient’s name, that the patient is participating in a clinical trial, and the name, address 
and telephone number of the investigator. Patients must be advised to carry this identification card 
along with them throughout the entire trial. 
Visits in the induction and maintenance phase should be scheduled at the same time in the morning 
so that visits are all within ±2 hours of the Day 0 visit. 
Patients should be advised to bring to the specified visits their diary cards. Patients will also be 
advised to completely use up the tablets in one bottle before starting a new bottle. Patients will also 
be advised to bring all IMP (including full, in-use, and empty bottles) to every trial visit; the empty 
bottles will be returned to the site, the started in-use and full ones will be returned to the patient 
(together with newly issued ones). In case of a safety interim analysis during the extended treatment 
period (see Section 16.5), a full compliance will be performed at the respective last visit before the 
scheduled interim analysis i.e., at this visit tablets of started in-use bottles will be counted, and the 
patient will receive a complete new set of bottles. In addition, patients must be advised at each visit 
to drink a generous amount of fluid per day to ensure adequate urine flow. 
During the induction phase patients will be asked to withhold study medication on days of clinic 
visits. Patients will take study drug at the clinic. Patients will also be asked to fast overnight before 
all clinic visits as specified in Section 11.1.5.  
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 91 of 139 
 
Confidential 
 
 
Patients will rest quietly for at least 5 min before any blood for laboratory assessments is drawn (if 
applicable) or vital signs are measured. 
At all visits (except the end-of-study visit), patients will be asked to return to the trial site according 
to the schedule listed in Table 1, Table 2, Table 3, and Table 4 for the following visit. However, 
patients should also be instructed to contact the trial site at any time if they experience a pronounced 
deterioration of their disease. Patients must be advised to inform the investigator in case of any 
emergency.   
For study conduct contingency measure during exceptional circumstances (e.g. COVID-19 
pandemic) see Section 12.11. 
12.2 
Screening  
Patients for whom written informed consent (for consent procedures see Section 18.3) has been 
obtained will undergo the assessments listed in Table 1. Patients will be screened for eligibility 
based on the study’s inclusion and exclusion criteria. Only patients who have passed all eligibility 
criteria on Screening Visit 1 should be advanced to Screening Visit 2 (endoscopy). If there is a 
delay in assessments from Screening Visit 1 or assessments need to be repeated due to technical 
difficulties, assessments from Screening Visit 1 are valid for up to 60 days between Screening 
Visit 1 and randomization. If 60 days are exceeded, Screening Visit 1-assessments must be 
repeated. Note that tests can solely be repeated if tests are inconclusive or had technical problems. 
A re-screening of patients is not allowed (if not requested or approved by the sponsor). 
If a full colonoscopy was not performed in the previous year, a colonoscopy must be performed 
during Screening. If results of a full colonoscopy from the previous year are available, a flexible 
sigmoidoscopy with biopsy will be performed.  
A sigmoidoscopy or full colonoscopy will only be scheduled if all other eligibility criteria assessed 
at Screening Visit 1 (see Table 1) are met and randomization should be performed within 14 to 
3 days of Screening Visit 2. An independent central reading of the completed screening 
sigmoidoscopy or colonoscopy will be performed to confirm eligibility of the patient. The patient 
can only be randomized following confirmation of eligibility by the central reader. A central 
endoscopy manual which was finalized before study initiation at the first study center describes 
more details. In case of technical problems, assessments at Screening Visit 2 may also be repeated 
within the times indicated for repetition of Screening Visit 1 assessments. 
Diary cards will be completed for the 5 days before initial randomization. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 92 of 139 
 
Confidential 
 
 
12.3 
Induction phase 
Visit Day 0 
Patients will undergo the assessments and procedures listed in Table 1 and will be randomized to 
treatment. Before a patient will be randomized, endoscopic eligibility must have been confirmed 
by an independent central reader. Following randomization, the patient will take the first dose of 
study medication at the site. 
Visits Days 1, and 7 of Week 1, Weeks 2 and 6 
Patients will undergo the assessments and procedures listed in Table 1. 
At Week 2, IMU-838 plasma levels will be assessed pre-dose (trough level) and 3 to 10 hours post 
dose (the actual time of the second blood collection can be chosen based on the patient’s preference, 
but must be between 3 and 10 hours after dosing). 
Visit Week 10/EoI 
Patients will undergo the assessments and procedures listed in Table 1. 
Patients will be assessed for symptomatic response and symptomatic remission. Based on these 
results patients will be further treated as follows: 
• Patients who have achieved symptomatic remission will enter the maintenance phase. 
• Patients who have achieved symptomatic response, but not yet symptomatic remission will 
continue into an extended induction phase until Week 22.  
• Patients who do not show symptomatic response at Week 10 will be discontinued from the 
blinded treatment but will have the option to enroll in the open-label treatment extension 
arm.  
In case of an early termination from the induction phase at or after Week 6 but before Week 10, 
the assessments and procedures outlined for the Week 10/EoI visit should be performed. Patients 
discontinuing from the study before Week 6 should perform the EoS visit 30 days after their last 
intake of study medication. 
Extended induction phase: Visits Weeks 14, 18, and 22/EoEI 
Patients who have achieved symptomatic response but not yet symptomatic remission at Week 10 
will continue into an extended induction phase until Week 22 with assessments at Weeks 14, 18, 
and 22. All assessments and procedures as listed in Table 1 will be performed. 
Patients will be assessed for symptomatic remission at Week 22. Based on these results patients 
will be further treated as follows: 
• Patients who have achieved symptomatic remission will enter the maintenance phase. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 93 of 139 
 
Confidential 
 
 
• Patients who do not show symptomatic remission at Week 22 will be discontinued from the 
blinded treatment but will have the option to enroll in the open-label treatment extension 
arm.  
For eligibility criteria to enter the open-label treatment arm see Section 9. 
In case of an early termination from the extended induction phase the assessments as outlined for 
the Week 22/EoEI visit should be performed. 
12.4 
Maintenance phase 
Start of maintenance phase (Week 10 or Week 22) 
This visit corresponds to the last visit of the induction phase or extended induction phase at which 
the patient reaches symptomatic remission. Patients entering the maintenance phase will be re-
randomized and treated as follows: 
• Patients who had received IMU-838 during induction will be re-randomized to 10 mg/day 
or 30 mg/day IMU-838. 
• Patients who had received placebo will be “re-randomized” but will continue placebo 
treatment. 
Visits Week 14, 18, and 22  
Patients who entered the maintenance phase at Week 10 will have the assessments and procedures 
listed in Table 2 performed. Patients who are in the extended induction phase will have the 
assessments performed as described in Table 1. In addition, for those achieving symptomatic 
remission at Week 22, the assessments and procedures described under start of maintenance phase 
(see above and Table 2) will be performed. 
Visits Weeks 26, 30, 34, 38, 42, and 46 
All patients in the maintenance phase will have the assessments and procedures performed as listed 
in Table 2. 
Visit Week 50/EoM  
The maintenance phase and blinded treatment period will stop when the patient has received study 
treatment for a total of 50 weeks during induction and maintenance, or the patient experiences a 
UC relapse. In both cases, the assessments and procedures as listed in Table 2 for Week 50/EoM 
will be performed.  
In case of an early termination from the maintenance phase the assessment as outlined for the 
Week 50/EoM visit should be performed. 
Patients who discontinue the maintenance phase either as scheduled or prematurely and have a 
sigmoidoscopy performed at their last visit of blinded treatment (if the previous sigmoidoscopy 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 94 of 139 
 
Confidential 
 
 
had been performed more than 4 weeks before discontinuation) will have the option to continue 
into the open-label treatment arm. 
For eligibility criteria to enter the open-label treatment arm see Section 9. 
12.5 
Open-label treatment arm 
Visit StartOLE 
The StartOLE visit must be performed within 30 days of the last dose of the blinded treatment during 
the induction or maintenance phase.  
If ongoing TEAEs are the reason for exclusion from the open-label extension arm, the eligibility 
can be re-assessed up to 4 weeks following the last treatment in the blinded treatment arms. 
The assessments and procedures as listed in Table 3 will be performed. If the visit occurs within 
3 weeks of the last visit of the induction or maintenance phase only inclusion and exclusion criteria 
will be checked and study medication dispensed. The first open-label study drug intake will be 
performed while the patient is on site.  
Visit Week XOLE  
Clinic visits will be scheduled every 4 weeks until 50 weeks of total study participation (i.e. 
induction + maintenance + open-label part) and every 10 weeks thereafter. Following the 
implementation of Protocol Version 6.0 the 10-week schedule, for patients in the open-label 
extension and with more than 50 weeks of overall treatment, will be changed to a 24-week schedule 
at the next scheduled visit. During these visits the assessments and procedures as listed in Table 3 
will be performed. 
Patients can continue treatment as long as there are no clinically significant safety issues (as 
assessed by the investigator), that are related to study procedures or study treatment, as long as the 
patient benefits from study treatment (as assessed by the investigator), until the patient withdraws 
consent, or until the sponsor terminates the study. In addition, patients in the open-label extension 
arm may be transferred by the sponsor to a separate and comparable follow-up study in which they 
can continue treatment with IMU-838 or, if patients have access, transfer to commercially available 
vidofludimus calcium. Once all remaining participating patients have been transferred respectively, 
the CALDOSE-1 study will be closed. Patients will be allowed to be treated with study medication 
for a maximum of 10 years (not applicable for UK, see below) including all periods of the trial. 
For UK the following applies: Patients will be allowed to be treated with open-label treatment for 
a maximum of 3 years (may be extended, see Section 8.1.5). 
EoOLE 
At the last visit of a patient’s participation in the open-label phase, the assessments and procedures 
as listed in Table 3 for the EoOLE visit will be performed. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 95 of 139 
 
Confidential 
 
 
12.6 
Pharmacokinetics period 
The PK period is part of the open-label treatment arm and will include 8 patients at designated PK 
centers (see Section 8.1.6). 
Visit StartOLE, Day 1OLE, Day 2OLE, and Day 3OLE 
Patients will undergo the assessments and procedures listed in Table 4. Before a patient will be 
dosed, eligibility for the open-label treatment period must have been confirmed. Patients will take 
the first open-label single dose and a full PK profile up to 72 hours post-dose will be obtained 
(during this period the patient will take no additional dose). At StartOLE patients will stay at the site 
for at least 6 hours for blood sample collections for PK assessments. After Day 3OLE the patients in 
the PK subpopulation will follow the schedule of assessments of the open-label phase (Table 3) as 
all other patients participating in the open-label phase. 
12.7 
Unscheduled visit due to disease exacerbations or due to safety issues and AEs 
Patients who visit the study center at any time outside the protocol-specified visit schedule (i.e. an 
unscheduled visit) due to disease exacerbation or safety issues will undergo the assessments as 
listed in Table 5.  
If a serious disease exacerbation is identified at an unscheduled visit during the induction phase, 
the investigator will assess if the patient should be withdrawn from further blinded drug treatment. 
If the patient is withdrawn at Week 6 or thereafter see Section 12.8 for further details. 
If a symptomatic UC relapse is identified at an unscheduled visit during the maintenance phase the 
patient must be withdrawn from the maintenance phase. For further details see Section 12.8.  
If a symptomatic UC relapse is identified at an unscheduled visit during the open-label phase, the 
investigator will assess if the patient should be withdrawn. If the patient is withdrawn see Section 
12.8 for further details. 
12.8 
Premature termination 
If a patient prematurely discontinues the trial (for reasons, see Section 17) or blinded treatment the 
following should be performed depending on when the patient discontinues: 
• If the patient discontinues during the induction phase before Week 6, the patient should 
perform an EoS visit 30 days after the last intake of study medication. 
• If the patient discontinues during the induction phase at or after Week 6 up to Week 10, the 
current visit (as scheduled or unscheduled) should be performed and documented as 
Week10/EoI visit (at the earliest opportunity), including the EoI sigmoidoscopy. If the 
patient does not switch to the open-label extension arm, an EoS visit at 30 days after the 
last intake of study medication should be performed. If the patient is eligible and switches 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 96 of 139 
 
Confidential 
 
 
to the open-label extension the visit schedule as outlined in Table 3 should be followed, 
after the Week10/EoI assessments have been performed. 
• If the patient discontinues during the extended induction phase, the current visit (as 
scheduled or unscheduled) should be performed and documented as Week22/EoEI visit (at 
the earliest opportunity) and, if the patient does not switch to the open-label extension arm, 
an EoS visit, 30 days after the last intake of study medication. If the patient is eligible and 
switches to the open-label extension the visit schedule as outlined in Table 3 should be 
followed, after the Week22/EoEI assessments have been performed. 
• If the patient discontinues during the maintenance phase, the current visit (as scheduled or 
unscheduled) should be performed and documented as Week50/EoM visit (at the earliest 
opportunity), including EoM sigmoidoscopy (if discontinuation occurs less than 4 weeks 
after the EoI endoscopic examination, the Week 50/EoM sigmoidoscopy does not need to 
be performed). If the patient does not switch to the open-label extension arm, an EoS visit 
at 30 days after the last intake of study medication will be performed. If the patient is 
eligible and switches to the open-label extension the visit schedule as outlined in Table 3 
should be followed, after the Week50/EoM assessments have been performed. 
• If the patient discontinues during the open-label phase, the current visit (as scheduled or 
unscheduled) should be performed and documented as an EoOLE visit at the last day of 
study medication, followed by an EoS visit at 30 days after the last intake of study 
medication. No EoS visit is required for patients transferring to the long-term follow-up 
study or commercially available vidofludimus calcium. 
All patients withdrawing consent for further study participation should be encouraged to complete 
the EoS examination documenting patient status at 30 days following last study treatment.  
In case of premature withdrawal either from blinded treatment or the trial, reasons, circumstances 
and findings should be fully described on the "Early Termination" page in the eCRF respecting the 
patient’s rights.  
12.9 
Transfer into a long-term follow-up trial or to commercially available 
vidofludimus calcium  
The sponsor may set up a separate long-term follow-up study for patients who are currently on 
IMU-838 treatment. Once this study is initiated, all remaining patients in the open-label treatment 
extension of the CALDOSE-1 study will be transferred to this follow-up trial. In case patients are 
transferred to the follow-up trial, no EoS visit is required. The transfer to another long-term follow-
up trial can occur during any regular visit, and the long-term follow-up trial should be started for 
the patient at the same visit the patient discontinues the CALDOSE-1 study. The reason for 
termination of a patient from this study will be recorded as “transfer to another IMU-838 long-term 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 97 of 139 
 
Confidential 
 
 
follow-up study”. Any ongoing AEs and/or clinically significant laboratory abnormalities will be 
marked as “unresolved” and then followed up in the follow-up trial. 
At any time of the study, the sponsor may also decide to transfer patients who have access to 
commercially available vidofludimus calcium (defined as regulatory approval and reimbursement 
available) to commercially available vidofludimus. The transfer to commercially available 
vidofludimus calcium can occur at any regular trial visit and no EoS visit is required in this case. 
When such transition occurs the same rules as for transfer into the long-term follow-up trial apply 
and the reason for termination of the respective patient will be recorded as “transfer to 
commercially available vidofludimus calcium”. This will be an individual decision per patient by 
the sponsor based on the patient’s access situation. Such transition to commercially available 
vidofludimus calcium (patients with access) may also occur during and in parallel to the transfer 
of patients to the long-term follow-up trial (for patients without access). Ongoing AEs at the time 
of transition should be marked as “unresolved” in this trial and then be followed up during regular 
clinical care.  
Medically important AEs, defined as new malignancies within 6 months or SAEs within 28 days 
after transferring patients to a follow-up trial or to commercially available IMU-838, must still be 
reported within this clinical study. 
12.10 
End of study visit 
Patients who discontinue the treatment (blinded or open-label) will be asked to return to an EoS 
visit 30 days (-3 days/+4 weeks) after their last treatment dose with assessments as listed in 
Table 5. Please see also Section 15.1.6 for follow-up of adverse events. No EoS visit is required 
for patients transferring to the long-term follow-up study or commercially available vidofludimus 
calcium. 
12.11 
Study conduct contingency measures 
As an exception and only during extraordinary circumstances (e.g. COVID-19 pandemic), the 
sponsor acknowledges that some organizational and/or logistical adjustments might be necessary 
at the investigational sites. 
Deviations from this protocol that might arise in case of exceptional circumstances must be 
documented and discussed with the sponsor without delay. Every effort should be made to ensure 
the continuity of this study as per this study protocol and to avoid delays, treatment, 
discontinuation, missing assessments, and study dropout.  
Some study assessments may be collected remotely, in case, the patients cannot attend the study 
visit in person due to pandemic measures. The site will obtain basic safety information by phone, 
such as AEs, any worsening of UC and concomitant medication. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 98 of 139 
 
Confidential 
 
 
Patients are provided with clinical study supplies (i.e. IMP) for this study. As an exception only 
sites are allowed to ship IMP directly to the patients. The investigator must be confident to be able 
to oversee patient safety appropriately and ensure high-quality data can be collected. 
In addition, to ensure the quality of clinical study data and to protect the rights, safety and well-
being of the patients, remote source data verification (SDV) can be used in this clinical study. 
Remote SDV will be considered only during extraordinary situations (e.g. the COVID-19 
pandemic) related to public health crises, if the Clinical Research Associate is not allowed to visit 
the clinical site and as far as this is in line with EU and national law (or temporary national 
emergency measures). 
Remote SDV will focus on the quality control of critical data such as primary efficacy data and 
important safety data. Important secondary efficacy data may be monitored simultaneously, 
provided this does not result in a need to access additional documents and therefore in an increased 
burden for study site staff. The sponsor will determine the extent and nature of remote SDV that 
they consider needed for this study under such exceptional circumstances (e.g. COVID-19 
situation). Principal investigators should make their own determination as to whether or not the 
situation at their clinical site allows options for remote SDV according to applicable guidelines. 
13 
Efficacy assessments and procedures  
13.1 
Demographics and other baseline assessments 
During Screening, demographics (including sex, age, and race), tobacco use, a complete medical 
history including a detailed UC history and the reference stool frequency as well as reference blood 
in stool will be collected. 
13.2 
Mayo score 
The full, partial, and PRO-2 Mayo score will be regularly assessed during the study as specified in 
the schedules of assessments (Table 1, Table 2, Table 3, Table 4). The Mayo stool frequency and 
rectal bleeding scores will be assessed at the first screening visit. 
The full Mayo score is composed of 4 categories (bleeding, stool frequency, physician assessment, 
and endoscopic appearance) each rated from 0 to 3 that are added up to give a total score that ranges 
from 0 to 12. Throughout the study the endoscopy subscore will be modified such that a value of 
1 does not include friability. 
The partial Mayo score includes only the non-invasive Mayo subscores, i.e. stool frequency, rectal 
bleeding, and physician’s global assessment, the Mayo PRO-2 score only the patient-reported 
outcomes i.e. stool frequency and rectal bleeding score. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 99 of 139 
 
Confidential 
 
 
Table 8: 
Full Mayo score 
Stool frequencya 
 0 = Normal number of stools for this patient 
 1 = 1–2 stools more than normal 
 2 = 3–4 stools more than normal 
 3 = 5 or more stools more than normal 
Rectal bleedingb 
 0 = No blood seen 
 1 = Streaks of blood with stool less than half the time 
 2 = Obvious blood with stool most of the time 
 3 = Blood alone passed 
Findings of flexible proctosigmoidoscopyc 
 0 = Normal or inactive disease 
 1 = Mild disease (erythema, decreased vascular pattern, [mild friability]) 
 2 = Moderate disease (marked erythema, absent vascular pattern, [any]c friability, 
erosions) 
 3 = Severe disease (spontaneous bleeding, ulceration) 
Physician’s global assessmentd 
 0 = Normal 
 1 = Mild disease 
 2 = Moderate disease 
 3 = Severe disease 
a Each patient serves as his/her own control to establish the degree of abnormality of the stool frequency. 
b The daily bleeding score represent the most severe bleeding of the day. 
c In the study the modified Mayo endoscopic subscore will be used i.e. friability will not be included in 1; any friability is 
considered 2. 
d The physician’s global assessment acknowledges the 3 other criteria, the patient’s daily record of abdominal discomfort 
and general sense of well-being, and other observations, such as physical findings and the patients’ performance status. 
Extracted from [6]. 
 
Patients will be provided standardized instructions for recording the number of stools and their 
worst rectal bleeding over a 24-hour period as described below. The instructions will be 
incorporated into the diary. 
Definition of stool frequency 
Patients will be instructed that a stool is defined as a trip to the toilet when the patient has either a 
bowel movement, or passes blood alone, blood and mucus, or mucus only. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 100 of 139 
 
Confidential 
 
 
Reference remission stool frequency (over 24 hours) 
• The patient will be asked to identify at the screening visit how many stools he or she had in 
a 24-hour period when in remission from UC. 
• If the patient does not report that he or she has ever achieved remission, then the patient 
will be asked to identify the number of stools he or she had per day before initial onset of 
signs and symptoms of UC. 
Patients will be instructed to indicate the most severe category that describes the amount of blood 
in their stools for a given day following the categories given in Table 8. If they do not pass stool 
during a given day, patients are instructed to select “no blood seen”. 
Patients will be instructed to capture their rectal bleeding and stool frequency assessments in their 
daily diaries  
• for every day during the induction period and for 5 days before the first study drug 
administration at Day 0, and 
• for 5 days before each visit during the extended induction phase and maintenance phase. 
It will be recorded in the eCRF if the reference remission stool frequency is based on reported stool 
frequency when the patient was in remission or reported stool frequency before initial onset of 
signs and symptoms of UC. Both the remission and pre-UC stool frequency should be collected at 
Screening. This allows exploration of the natural history of pre-diagnosis stool frequency versus 
remission stool frequency. 
Investigational sites will be provided instructions for calculations of stool frequency and rectal 
bleeding scores. The stool frequency and rectal bleeding scores will be based on the average 
(rounded up) of the most recent 3-day consecutive period within the week before the visit. 
13.3 
Sigmoidoscopy with biopsies 
A sigmoidoscopy including biopsy will be performed at the visits as specified in the schedules of 
assessments (Table 1, Table 2, Table 3). The screening sigmoidoscopy will be replaced with a full 
colonoscopy if results of a full colonoscopy from the previous year are not available.  
The flexible sigmoidoscopy or colonoscopy will be done with video-endoscopes, and all 
examinations will be videotaped. All sigmoidoscopy examinations (and the screening colonoscopy 
assessment if applicable) will be evaluated by an independent central reader blinded to the local 
reader’s assessment. The central reader will also assess the modified Mayo endoscopy score and 
will confirm endoscopic eligibility, before a patient will be randomized. 
The Central Endoscopy Manual will standardize procedures, video recordings/equipment, and 
assessment of endoscopy and will allow the local endoscopist to request more information on the 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 101 of 139 
 
Confidential 
 
 
central reader’s assessment, if necessary. The central reader’s assessments will be used for patient 
eligibility and for efficacy assessments. 
Biopsies 
The area from which the biopsies will be taken should be between 15 to 25 cm above the anal 
verge. The investigator should try to consistently perform the biopsies at the same location 
independent of disease activity of ulcerations visible at this particular patient. Two biopsy 
specimens will be taken during each sigmoidoscopy and those will be fixed in formalin/ethanol for 
histological and, if applicable, immunohistochemical assessments. Standardized protocols for 
biopsy collection, fixation, and staining will be provided. 
At the discretion of investigators, additional biopsies may be taken for extraction of tissue RNA 
and determination of tissue RNA expression profiles. 
Histological activity of UC will be assessed with the Geboes score (see Appendix 2). 
13.4 
Diary completion and review 
Patients will be given a diary card to record stool frequency and rectal bleeding (see also 
Section 13.2). At Screening, patients will be instructed and trained on how to complete the diary 
and one diary card. At the screening endoscopy visit patients will receive a diary and asked to 
record data for the 5 days before the Day 0 visit.  
Diaries will be completed daily during the induction phase until Week 10. During the extended 
induction phase and maintenance phase the diary will only be completed for the 5 days preceding 
a clinic visit.  
Diaries will be reviewed at each visit for completeness and legibility, and if needed the patient will 
be re-educated on how to complete the diary. 
Diary entries preceding each study visit will be used to calculate the Mayo score. Because the 
flexible sigmoidoscopy may interfere with clinical parameters diary data from days on which the 
sigmoidoscopy was performed will not be used for calculation of the Mayo score.  
14 
Pharmacokinetics and pharmacodynamics assessments 
14.1 
Pharmacokinetics 
IMU-838 plasma concentrations will be determined by a validated direct liquid chromatography 
tandem-mass spectrometry (LC-MS/MS) technique. This method determines the concentration of 
the active blood moiety vidofludimus contained in IMU-838. Details of the assay will be described 
in a separate bioanalytical report.  
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 102 of 139 
 
Confidential 
 
 
Plasma samples for analytical assay will be collected by venous puncture or indwelling venous 
catheter and will be assessed for IMU-838 plasma trough levels centrally. Samples will be collected 
and subsequently stored at -20°C at the site, and shipped to the central laboratory as frozen sample, 
as appropriate. Investigators will be provided with detailed written instructions how to collect, 
handle, store, and ship the samples.  
Plasma trough levels of IMU-838  
Blood samples to assess IMU-838 plasma trough values will be collected in all patients as specified 
in the schedule of assessments for the induction phase (Table 1).  
Patients are required to withhold dosing of IMU-838 at each visit until the blood collection has 
been completed. If the patient had inadvertently taken the IMU-838 dose at such days, blood for 
trough levels should only be taken within 1.5 hours of the time of dosing. Otherwise, no blood for 
trough levels should be collected. In both cases, this should be recorded as protocol deviation. 
Trough levels of IMU-838 (trough level quartiles) will be correlated with selected safety and 
efficacy variables. 
Population PK 
If feasible all PK concentrations measured in the study, possibly in combination with IMU-838 PK 
concentration data collected in different studies, will be evaluated using a non-linear mixed effects 
modeling. A correlation with safety and efficacy might be evaluated if warranted by the data. 
Full single-dose PK profile 
A full single-dose PK profile will be assessed in the first 8 consecutive patients completing the 
induction, extended induction or maintenance phase as scheduled and opted to continue into the 
open-label treatment arm at the centers selected for full PK assessment (designated as PK centers). 
Patients in the PK subpopulation will receive one single dose of the open-label 30 mg IMU-838 
dose at the StartOLE visit. Blood samples for full PK will be collected on  
• Day 0OLE: pre-dose, and 1, 2, 3, 4, 5, and 6 hours (±15 min) post PK dose 
• Day 1OLE: 24 hours (±1 hour) post PK dose 
• Day 2OLE: 48 hours (±1 hour) post PK dose 
• Day 3OLE: 72 hours (±1 hour) post PK dose 
On Day 3OLE, after the last PK blood sample has been collected, patients will continue with daily 
dosing like other patients in the open-label treatment arm. 
The following non-compartmental PK parameters will be calculated from the individual blood 
concentration-time data of IMU-838: 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 103 of 139 
 
Confidential 
 
 
AUC0-t 
Area under the drug concentration-time curve, calculated using linear 
trapezoidal summation from time zero to time tlast, where tlast is the time of 
the last measurable concentration (Ct).  
AUC0-24h 
Area under the drug concentration-time curve, calculated using linear 
trapezoidal summation from time zero to 24 hours.  
AUC0-inf 
Area under the drug concentration-time curve from time zero to infinity, 
AUC0-inf = AUC0-t + Ct/λz, where λz is the apparent terminal elimination rate 
constant.  
Cmax 
Maximum observed drug concentration. 
λz 
Apparent terminal rate constant, calculated by linear regression of the 
terminal linear portion of the log concentration vs time curve, where  
λz =-slope.   
t1/2 
Apparent terminal elimination half-life, calculated as ln(2)/λz.  
tmax 
Time of the maximum drug concentration (obtained without interpolation). 
If the maximum value occurs at more than one time point, tmax is defined as 
the first time point with this value.  
CL/f 
Apparent total clearance, calculated as dose/AUC0-inf 
Vz/f 
Apparent volume of distribution at the terminal phase, calculated as 
(CL/f)/λz. 
Samples will be collected and stored at -20°C at the site, and shipped to the central laboratory, as 
appropriate. 
14.2 
Pharmacokinetic sampling 
Pharmacokinetic sampling for all patients is done only during the induction phase as specified in 
Table 1. An additional single dose PK is performed in a subset of patients in designated PK centers 
as described in Section 8.1.6. 
Throughout the induction phase, all patients will have blood samples taken for determination of 
blood plasma concentrations of IMU-838.  
There are two types of blood samples taken for PK measurements: 
• Plasma trough levels: taken pre-dose at D0, D1, D7, W2, W6 and W10 (patients should 
arrive at the center at those days before taking their dose, have their blood drawn and only 
then are allowed to have their dose taken), and 
• 1 additional blood plasma level: taken post-dose at W2 (the blood sample should be taken 
at 3-10 hours following oral dosing by the patient). 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 104 of 139 
 
Confidential 
 
 
For plasma trough levels, if patients have inadvertently taken their study drug within 1.5 hours of 
arriving at the study center, the blood samples for IMU-838 trough levels can still be drawn. If 
longer than 1.5 hours, the blood levels should not be determined.  
Plasma PK samples will be stored at -20°C at the site before being shipped to the central laboratory 
following Week 10 assessments. 
14.3 
Biomarkers and blood genotyping 
Blood cytokines will be collected as specified in Table 1. The cytokines assessed will include IL-17 
and IFNγ.  
At Day 0 before dosing, a single blood sample per patient will be collected for genotyping. These 
include assessment of gene and single nucleotide mutations for genes coding for metabolizing 
enzymes, transporter proteins, and for the target protein DHODH.  
Samples for cytokines and genotyping will be collected and stored at -20°C at the site, and shipped 
to the central laboratory, as appropriate. Investigators will be provided with detailed written 
instructions how to collect, handle, store, and ship the respective samples. Samples will be 
evaluated centrally. 
14.4 
Disease activity biomarkers: fecal calprotectin and C-reactive protein 
A stool sample to measure fCP, a biomarker of intestinal inflammatory activity, will be collected 
at specific time points as listed in the schedules of assessments (Table 1, Table 2, Table 3, Table 4, 
Table 5). Investigators will be provided with detailed written instructions how to collect, handle, 
store, and ship the respective samples. Samples will be evaluated centrally. 
CRP will be analyzed from the blood samples taken for clinical chemistry analysis.  
15 
Safety assessments 
15.1 
Adverse events documentation and reporting 
15.1.1 
Definitions 
15.1.1.1 
Adverse events 
An AE is any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product, which does not necessarily have a causal relationship with 
this treatment. An AE can therefore be any unfavorable and unintended sign (including an 
abnormal laboratory finding), symptom, or disease temporally associated with the use of a 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 105 of 139 
 
Confidential 
 
 
medicinal (investigational) product, whether or not related to the medicinal (investigational) 
product. 
Overdosing, defined as intake of more than twice the intended dose will not be considered an AE 
but must be documented as protocol deviation. However, symptoms associated with overdose are 
considered adverse drug reactions (ADR, for definition see Section 15.1.1.2). 
Untoward medical experiences occurring during drug-free pre-treatment periods do not meet the 
above-mentioned definition of AE. Nevertheless, they have to be documented in the same way as 
AEs, if they occur in the safety monitoring period. Should they already be present at the screening 
visit, they will be documented as medical history. 
A surgery or procedure scheduled to occur during the study will not be considered an AE if the 
surgery or procedure will be performed for a pre-existing condition and the surgery or procedure 
was pre-planned prior to study entry. However, if the pre-existing condition deteriorates 
unexpectedly during the study (e.g. surgery performed earlier than planned), then the deterioration 
of the condition for which the surgery or procedure is being done will be considered an AE. 
Diagnostic, medical or non-surgical procedures, including endoscopy will not be considered as 
AEs. Hospital admission for social or convenience reasons will also not be recorded as AE. 
AEs that occur between signing the informed consent form and the time when the patient first 
administers the study medication (Day 0) are defined as pre-treatment AEs. 
Treatment-emergent adverse events (TEAEs) are defined as any event not present prior to the 
first intake of study medication or any event already present that worsens in either intensity or 
frequency following exposure to study medication. 
A continuous event with changing intensities will be considered as one event of the most severe 
intensity documented. A continuous event with a changing seriousness will also be considered as 
one event, but the start and stop date of the time the event is serious must be separately documented. 
Clearly separated episodes of an event will be considered as separate events. 
For AEs of special interest (AESI) see Section 15.1.3. 
15.1.1.2 
Adverse drug reactions and unexpected adverse drug reactions 
An adverse drug reaction (ADR) is defined as any untoward and unintended response to an IMP 
related to any dose administered, i.e. there are facts or arguments to suggest a causal relationship 
between the administration of the IMP and the occurrence of the event. 
An unexpected ADR is an adverse reaction, the nature or severity of which is not consistent with 
the applicable product information (e.g. Investigator’s Brochure for an unapproved investigational 
product or package insert or summary of product characteristics for an approved product). Reports 
which add significant information on specificity or severity of a known, already documented AE 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 106 of 139 
 
Confidential 
 
 
constitute unexpected AEs, too. For example, an event more specific or more severe than described 
in the reference document would be considered ‘unexpected’. Specific examples would be: acute 
renal failure as a labeled AE with a subsequent new report of interstitial nephritis or hepatitis with 
a first report of a fulminant hepatitis. 
15.1.1.3 
Serious adverse events 
An SAE is any untoward medical occurrence that, at any dose: 
• results in death 
• is life-threatening 
• requires in-patient hospitalization or prolongation of existing hospitalization 
• results in persistent or significant disability or incapacity 
• results in a congenital abnormality or birth defect 
NOTE: The term "life-threatening" in the definition of "serious" refers to an event in which the 
subject was at risk of death at the time of the event; it does not refer to an event, which 
hypothetically might have caused death, if it were more severe. 
Medical and scientific judgment should be exercised in deciding whether expedited reporting is 
appropriate in other situations, such as important medical events that may not be immediately life-
threatening or result in death or hospitalization, but may jeopardize the subject or may require 
intervention to prevent one of the other outcomes listed in the definition above. These should 
usually also be considered serious. 
Examples of such events are intensive treatment in an emergency room or at home for allergic 
bronchospasm; blood dyscrasias or convulsions that do not result in hospitalization; or 
development of drug dependency or drug abuse. In addition, new malignancies that occur during 
the participation in the trial are defined as important medical events and must be reported as SAEs. 
An SAE requires that the underlying event is considered an AE as defined in Section 15.1.1.1. 
Hospitalizations due to a surgery or procedure during the trial will not be considered an SAE if the 
surgery or procedure will be performed for a pre-existing condition and the surgery or procedure 
was pre-planned prior to study entry. However, if the pre-existing condition deteriorates 
unexpectedly during the study (e.g. surgery performed earlier than planned), then the deterioration 
of the condition leading to hospitalization will be considered an SAE. Hospital admission for social 
or convenience reasons will also not be recorded as SAE. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 107 of 139 
 
Confidential 
 
 
15.1.1.4 
Suspected unexpected serious adverse reaction (SUSAR) 
A suspected unexpected serious adverse reaction (SUSAR) is a serious adverse reaction (SAR) 
that is unexpected or for which the development is uncommon (unexpected issue) observed during 
a clinical trial and for which there is a relationship with the experimental drug. 
15.1.2 
Classification of adverse events 
Classification of AEs will be performed by the investigator. 
Causality 
The causal relationship of the AE and the administration of the study medication will be assessed 
as follows: 
• Related: 
Implies a reasonable possibility of a causal relationship between the 
event and the study medication. This means that there are facts 
(evidence) or arguments to suggest a causal relationship. 
• Not 
related: 
Implies no reasonable possibility of a causal relationship between the 
event and the study medication. This means that there are neither facts 
(evidence) nor arguments to suggest a causal relationship. 
 
Severity 
Severity is a clinical observation and describes the intensity of the event. 
• Mild: 
Any symptom, of which the patient is aware, but which is easily tolerated 
• Moderate: 
Any symptom, which is discomforting enough to cause interference with 
a patient’s usual activity 
• Severe: 
Any symptom, which causes a patient’s inability to perform usual 
activity 
For the severity classification of hematurias please see Section 15.1.3. 
Outcome categories 
• Recovered: 
The patient has fully recovered from the event or the condition has 
returned to the level observed at Baseline 
• Recovering: 
The patient has recovered from the event, but the condition has not 
returned to the level observed at Baseline; 
• Not recovered: 
The event is ongoing at the time of reporting and the patient has still 
not recovered 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 108 of 139 
 
Confidential 
 
 
• Recovered 
with sequelae: 
As a result of the AE, the patient suffered persistent and significant 
disability/incapacity (e.g. became blind, deaf or paralyzed) 
• Fatal: 
The patient died due to the event. If the patient died due to other 
circumstances than the event, the outcome should be stated 
otherwise (e.g. not recovered or recovering) 
• Unknown: 
If outcome is not known or not reported 
15.1.3 
Adverse events of special interest 
The following AEs are defined as AESI if these events are different from any pre-existing 
conditions or a result from known conditions: 
• RBC urine positive (as defined below), at least of moderate intensity 
• Hematuria (as defined below) 
• Retroperitoneal colicky pain in connection with suspected or confirmed nephrolithiasis 
Evaluation and assessments of RBC in urine 
Evaluation of RBC in urine should be based solely on findings from microscopic examination of 
urinary sediment and not from dipstick reading only.[5] Therefore all conspicuous dipstick 
readings should be followed up by a microscopic examination of urinary sediment. All findings of 
RBC in urine per high-powered field (HPF) will be listed as urinalysis abnormalities but not as an 
AE when assessed by the investigator of not being clinically significant. The investigator should 
also assess any increased RBC in urine as not clinically significant when there are more probable 
alternatives to explain this finding. The following alternate explanations of RBC in urine high 
should be considered:  
• The urine sample was not properly collected (random midstream clean-catch collection) or 
there is evidence of contamination (e.g. by finding of bacteria or an unusual number of 
epithelial cells in urine sediment not explained by other conditions).  
• There is evidence of infection not considered secondary to a drug-induced damage.  
• There are likely benign causes, such as menstruation, vigorous exercise, viral illness, 
trauma, and infection. 
If any finding of RBC in urine high is assessed by the investigator as clinically significant, this 
finding will be reported as an AE of RBC urine positive.  
Evaluation and assessment of hematuria 
Any occurrence of RBC urine positive will only be defined as an AE of hematuria when at least 
one of the following 2 conditions are met:  
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 109 of 139 
 
Confidential 
 
 
• five or more RBCs per HPF were found in at least 2 consecutive, properly collected 
urinalysis specimens,[7] and/or 
• the finding of RBC urine positive had diagnostic or therapeutic consequences. 
Severity assessment of hematurias 
Severity is a clinical observation and describes the intensity of the event. 
The severity of hematurias is classified as follows:  
• Mild: 
Asymptomatic hematuria; clinical or diagnostic observations only 
• Moderate: 
Symptomatic hematuria; e.g. with moderate flank pain (and including 
short-term*, standard dose therapy with oral nonsteroidal anti-
inflammatory drugs, oral acetaminophen or oral aspirin), interfering with 
but not limiting activities of daily living 
• Severe: 
Gross or macrohematuria 
Any hematuria in connection with severe flank pain limiting activities of 
daily living. 
Any hematuria requiring additional treatment (e.g. oral anti-emetics or 
muscle relaxants, around the clock narcotic analgesics, use of narcotics or 
any intravenous treatment) or procedures for maintaining adequate urinary 
flow (e.g. urinary catheter or bladder irrigation). 
* Defined as treatment for less than 24 hours. 
 
15.1.4 
Documentation of adverse events 
All AEs that occur after the patient has signed the informed consent form until 30 days after the 
patient’s last study medication must be recorded. Information on AEs will be derived by 
non-directive questioning of the patients in general terms at each visit (e.g. "How do you feel?” or 
“How have you been feeling since the last questioning?"), by patients’ spontaneous reports, or by 
observation. Adverse events also may be detected when they are volunteered by the patient during 
or between visits or through physical examination, laboratory test, or other assessments. 
All AEs which occur during the observation period of the study as described above will be recorded 
in the patient’s AE section of the eCRF and will include the following information: a description, 
date of onset and resolution, severity, relationship to study medication, relationship to study 
procedure, action taken, and outcome. For SAEs, the SAE form must also be completed (see 
Section 15.1.5). 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 110 of 139 
 
Confidential 
 
 
15.1.5 
Documentation and reporting of immediately reportable adverse events 
Any AESI (see Section 15.1.3), any unexpected AE that could adversely affect the safety of the 
patients or the conduct of the study and any SAE, which occurs during the course of this study, 
will be reported (via the "Adverse Event of Special Interest Form" or the "Serious Adverse Event 
Form") to the sponsor immediately (i.e. no later than within 24 hours). The information will 
comprise at least the following data: 
• Name, address, and telephone number of the reporting investigator 
• Investigational product(s) 
• Study code 
• Patient identification number, sex, and date of birth 
• Description of the AE, measures taken and outcome (at the time of reporting) 
• Likelihood of drug causation of the AE assessed by the investigator 
Reports will be addressed to:  
SCRATCH Pharmacovigilance GmbH & Co. KG 
Schlossstrasse 25, D-35510 Butzbach 
E-mail: 
safety-immunic@scratch-pv.com 
Telephone: +49 6033 7453 550 
Fax: 
+49 6033 7453 559 
The sponsor ensures that all relevant information about SUSARs that are fatal or life threatening 
is recorded. Reporting of SUSARs to the independent ethics committee (IEC) or institutional 
review boards (IRBs), and regulatory authorities will follow pertinent national legislation. 
The sponsor will inform as soon as possible and following national pertinent national legislation 
the regulatory authorities, and the IECs or IRBs about any event which necessitates reconsideration 
of the benefit-risk-ratio of the investigational drug. These events are in particular: 
• single cases of expected SARs with an unexpected outcome, 
• an increased incidence of expected SARs which is considered clinically significant, 
• SUSARs occurring after a concerned person has completed the study, 
• events related to the conduct of the study or the development of the drugs possibly affecting 
the safety of the concerned persons. 
All additional measures deemed necessary through new findings and taken by the sponsor or the 
investigator to protect the safety of the persons concerned and their triggering circumstances will 
be reported as soon as possible to the concerned regulatory authorities, and the IECs or IRBs, if 
applicable. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 111 of 139 
 
Confidential 
 
 
Periodic safety reporting to regulatory authorities, and the IECs or IRBs will follow pertinent 
national legislation. 
In the event of a fatality, the "Study participant’s insurer" will be informed by the sponsor’s 
designee within 24 hours after the fatality has come to the sponsor’s designee knowledge. In case 
of other SAEs, the "Study participant’s insurer" has to be informed promptly. 
15.1.6 
Follow-up of adverse events 
All SAEs judged to be related to the study medication must be followed by the investigator until 
the patient has recovered, recovered with sequelae, died, or until the investigator determines that 
the patient’s condition is stable, whichever occurs first. All other (S)AEs must be followed by the 
investigator until the conditions mentioned above are met or until the end of the safety follow-up 
period (30 days after last study medication) whichever comes first, and until all AE-related queries 
for the patient have been resolved. The investigator will take all appropriate and necessary 
therapeutic measures required for resolution of the AE, if applicable. All efforts to collect follow-
up information must be documented in the source data. 
Follow-up information should be supplied on the respective forms of the eCRF.  
During and following a patient’s participation in this trial, the investigator has to ensure that 
adequate medical care is provided to a patient for any AEs, including clinically significant 
laboratory values, related to the trial. 
15.1.7 
Pregnancies 
Should a pregnancy occur in a female patient, or in a female partner of a male patient, it must be 
reported to the sponsor immediately, i.e. no later than within 24 hours of the first awareness of the 
event and be recorded on the appropriate pregnancy form. Patients who become pregnant during 
the study after signing the informed consent should discontinue the study immediately. 
A pregnancy in itself is not regarded an AE unless there is a suspicion that the study medication 
may have interfered with the effectiveness of a contraceptive method. Whenever possible, the 
outcome of all pregnancies (spontaneous miscarriage, elective termination, normal birth or 
congenital abnormality, maternal and/or new-born complications) must be followed up and 
documented even if the patient was discontinued from the study. All reports of congenital 
abnormalities or birth defects are SAEs. Spontaneous miscarriages should also be reported and 
handled as SAEs. Elective abortions without complications should not be handled as AEs. 
Pregnancy follow-up should be recorded on the pregnancy form and should include an assessment 
of the possible relationship of the study medication to any pregnancy outcome. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 112 of 139 
 
Confidential 
 
 
15.2 
Laboratory investigations 
Clinical laboratory tests will be performed at the times indicated in the schedules of assessments 
(Table 1, Table 2, Table 3, Table 4, Table 5). 
All laboratory samples have to be clearly and fully labeled according to the central laboratory 
manual. The laboratory reports received from the central laboratory via email or fax will be printed, 
reviewed, signed, and dated by the investigator, and filed at the center. The laboratory results will 
be additionally imported into the eCRF.  
Abnormal results will be assessed by the investigator and classified as clinically significant 
(yes/no). Clinically significantly abnormal values must be reported as AEs, unless already 
clinically significantly abnormal at Baseline (pre-dose on Day 0) or Screening Visit 1, or unless 
there are known circumstances unrelated to a disease or the medication (such as patient activities 
or sample handling) that are a likely explanation for the abnormal value. 
Persistent clinically significant abnormal values must be followed up using local laboratory values 
until the cause is determined or until they return to normal or to pre-dose value. 
15.2.1 
Pregnancy tests 
Female patients of childbearing potential, i.e. not postmenopausal (where postmenopausal state is 
defined as no menses for 12 months without an alternative medical cause) or not surgically sterile, 
must have a negative pregnancy test before the first intake of study medication. A blood pregnancy 
test is required at Screening. A local blood pregnancy test must be performed at any time in case 
of a positive urine pregnancy test. 
Additional urine pregnancy tests will be performed at the centers throughout the trial at the times 
indicated in the schedules of assessments (Table 1, Table 2, Table 3, Table 4, Table 5) for all 
female patients of childbearing potential. 
For instructions in case of pregnancy, see Section 15.1.7. 
15.2.2 
Blood chemistry, hematology, and coagulation 
Blood chemistry, hematology and coagulation assessments will be performed using Lab Kits A, B 
and C as indicated in the schedules of assessments (Table 1, Table 2, Table 3, Table 4, Table 5) 
including the following parameters: 
Lab Kits A and B 
• Hematology: 
Erythrocytes, leucocytes, differential leucocyte count (neutrophils, 
eosinophils, basophils, lymphocytes, monocytes), hemoglobin, 
hematocrit, mean corpuscular volume (MCV), mean corpuscular 
hemoglobin (MCH), platelets 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 113 of 139 
 
Confidential 
 
 
• Biochemistry: 
Liver function monitoring: AST, ALT, AP, GGT, total bilirubin, 
unconjugated (indirect) and conjugated (direct) bilirubin.  
Renal function monitoring: creatinine, uric acid, blood urea 
nitrogen (BUN). eGFR will be calculated according to the Chronic 
Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 
Other parameters: Sodium (Na), potassium (K), magnesium (Mg), 
chloride (Cl), inorganic phosphate (P), calcium (Ca), creatine 
phosphokinase, lactate dehydrogenase, amylase, lipase, C-reactive 
protein 
(CRP), 
total 
protein, 
albumin, 
glucose, 
HbA1c, 
triglycerides, cholesterol 
Lab Kit C 
• Hematology: 
Erythrocytes, leucocytes, hemoglobin, hematocrit, MCV, MCH, 
platelets 
• Biochemistry: 
Liver function monitoring: AST, ALT, AP, GGT, total bilirubin, 
unconjugated (indirect) and conjugated (direct) bilirubin.  
Renal function monitoring: 
creatinine, uric acid, BUN. eGFR 
will be calculated according to CKD-EPI equation.  
Other parameters: Na, K, Cl, P, Ca, CRP, total protein, amylase, 
lipase, albumin, glucose, triglycerides, cholesterol 
Coagulation (inlcuded in Lab Kit A) 
Coagulation parameters will be assessed at the time points indicated in the schedules of assessments 
(Table 1) including the following parameters: prothrombin time, activated partial thromboplastin 
time, and INR. 
Blood chemistry, hematology, and coagulation analyses will be done centrally (see Section 6). 
Abnormal results will be classified as clinically significant (yes/no). Clinically significantly 
abnormal values, which were not clinically significantly abnormal at Baseline, must be reported as 
AE. 
Blood samples will be collected, handled and stored according to the instructions provided by the 
central laboratory. Coagulation samples will be collected and stored at -20°C at the site, and 
shipped to the central laboratory, as appropriate.  
15.2.3 
Urine assessments 
Urinalysis assessments will be performed using Lab Kits A, B, and C as indicated in the schedules 
of assessments (Table 1, Table 2, Table 3, Table 4, Table 5) including the following parameters: 
 
 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 114 of 139 
 
Confidential 
 
 
Lab Kits A and B 
• pH, nitrites, hemoglobin, protein, albumin, glucose, ketones, creatinine 
• microscopic examination of the urine sediment: RBC, white blood cells, epithelial cells, 
bacteria, casts, crystals (including identification of crystals, if possible) 
Lab Kits C 
• pH, nitrites, hemoglobin, protein, albumin, glucose, ketones, creatinine 
• a dipstick analysis, including the assessment of RBC in urine, performed and read centrally7 
• if the dipstick is positive for RBC in urine, a urine sediment analysis will be performed: 
RBC, white blood cells, epithelial cells, bacteria, casts, crystals (including identification of 
crystals, if possible) 
Urinalysis will be done centrally (see Section 6). Abnormal results will be classified as clinically 
significant (yes/no). Clinically significantly abnormal values must be reported as AE, if not already 
clinically significantly abnormal at Baseline. 
Details on urine sampling and handling of urine samples will be given in the Laboratory Manual. 
15.2.4 
miR-122 expression 
MicroRNA-122 is an early indicator of drug induced liver injury. Blood samples to assess miR-
122 will be collected at time points given in Table 1. Samples for miR-122 will be collected and 
stored at -20°C at the site, and shipped frozen to the central laboratory, as appropriate. 
15.2.5 
Serology and stool sample for C. difficile test  
Tests for hepatitis B surface antigen (HBsAg), hepatitis B core antibody (HBcAb), HCV, and 
human immunodeficiency virus (HIV) antigen-antibody (Ag/Ab) combined test, and a 
Mycobacterium tuberculosis IFNγ-release assay (Tbc-IGRA) will be performed during Screening. 
The HBcAb assay will be a combined immunoglobulin G (IgG) and IgM test. In case of a positive 
result, IgM will be evaluated separately. 
If any HIV, HBV, or HCV antigen or antibody screening test shows reactive or borderline results, 
a confirmatory Nucleic Acid Amplification Test (NAAT) will automatically be performed for the 
detection of the virus by using the same blood draw sample. If no virus specific nucleic acid is 
detected, and the clinical history of the patient, other laboratory examinations, and current clinical 
pictures also exclude a concurrent infection, the patient will not be excluded from the study. 
A stool sample will be collected at Screening to test for Clostridium difficile (C. difficile) toxin B. 
 
7 The dipstick as well as the urine sample (to be included for potential urine sediment analysis) will be shipped to 
the central laboratory. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 115 of 139 
 
Confidential 
 
 
The Tbc-IGRA and C. difficile toxin B will be done at the local laboratory, all other screening tests 
will be performed centrally. 
15.2.6 
Screening laboratory 
The Screening Panel includes:  
• Blood pregnancy test 
• Blood biochemistry: Neutrophils, platelets, serum creatinine, ALT, AST, and GGT, total, 
direct and indirect bilirubin, uric acid, eGFR (CKD-EPI) 
• Serology: C. difficile toxin B, Tbc-IGRA, HCV, HIV-Ag/Ab, HBsAg, HBcAb IgG/IgM 
The screening tests for Tbc-IGRA and C. difficile toxin B will be done locally at the study site. All 
other tests will be done centrally and are included in the central Screening Lab Kit S. 
15.3 
Vital signs, physical examination, and ECG  
Vital signs, routine physical examinations, and ECG will be performed at the times indicated in the 
schedules of assessments (Table 1, Table 2). 
Vital signs 
Vital signs will include blood pressure and heart rate, and should be obtained seated, after at least 
5 minutes at rest. Changes in vital signs judged by the investigator as clinically significant will be 
reported as an AE. 
Physical examination 
Physical examinations will include height (only at Screening) and weight, and cover the following 
body systems: general appearance, skin, neck (including thyroid), throat, lungs, heart, abdomen, 
back, lymph nodes, extremities, vascular, neurological systems, and, if applicable, others. Any new 
clinically significant finding compared to Screening must be documented as AE in the eCRF. 
Any clinically significant finding at Screening must be documented in the medical history section 
of the eCRF. 
12-lead electrocardiogram 
The 12-lead ECG (I, II, III, aVR, aVL, aVF, V1-V6) will be recorded in supine position after at 
least 5 min rest using the site’s own standard ECG machine. The ECG will be analyzed 
qualitatively by the investigator (normal or abnormal). The heart rate, PQ-, QRS-, and 
QT-intervals, as well as the heart rate-corrected QTc interval (according to Bazett’s formula) will 
be determined. The detailed procedure used will be according to local practice. Any findings from 
ECGs collected after study drug administration will be captured as AEs if, in the opinion of the 
investigator, there has been a clinically significant change from Screening. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 116 of 139 
 
Confidential 
 
 
16 
Biostatistical methods 
16.1 
Sample size calculation 
Sample size calculation is based on the final analysis of the induction phase as follows:  
With 3 dose groups (2 IMU-838 doses and placebo) about 49 patients per group are required to 
show a difference of 16% between the verum group and placebo assuming a placebo remission rate 
of about 10%, a significance level of 0.097, and a power of 80%. Assuming a drop-out rate of 20%, 
approximately 60 patients will be required per group.  
Underlying assumptions:  
Primary endpoint: composite of symptomatic remission and endoscopic healing 
Underlying test: Chi square test 
Randomization:  Enrollment Periods 1 and 2: 
1:1:1:1  
 
The sample size is based on a comparison of the 30 mg/day and 45 mg/day 
IMU-838 doses combined vs placebo.  
Power:  
80%  
Significance level: 0.097, 1-sided 
In this early stage development study a higher α, i.e. 0.1, than the standard 
0.025 level is considered appropriate. Due to the interim analysis and to keep 
the overall α-level to 0.1, this level must be adjusted. A group sequential design 
with O’Brien-Fleming boundaries will be applied. Accordingly, the sample 
size calculation is based on a significance level of 0.097, 1-sided. 
No formal sample size calculation was performed for the sample size of the interim analysis of this 
small phase 2 study. However, and based on preliminary experiences, 15 patients per group were 
deemed sufficient to show numerical differences between placebo and verum, and between dose 
groups. 
16.2 
Analysis sets and types of analyses 
Safety analysis set 
The safety analysis set (SAF) will consist of all randomized patients who have received at least one 
dose of study medication, i.e. any dose of IMU-838 or placebo. If it is uncertain if the patient has 
received any study medication, the patient will be included in the SAF. The analyses based on the 
SAF will be conducted on an “as treated” basis, i.e. all patients will be analyzed by the treatment 
they have actually received. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 117 of 139 
 
Confidential 
 
 
Full analysis set 
The full analysis set (FAS) will consist of all randomized patients who have received at least one 
dose of study medication, i.e. any dose of IMU-838 or placebo. The analyses based on the full 
analysis set will be conducted on an intention-to-treat procedure, i.e. all patients will be analyzed 
by the groups to which they were randomized to (“intention-to-treat”). 
Per-protocol set 
All patients of the FAS will also be included in a per-protocol (PP) set if they do not violate any 
major protocol criteria. Protocol deviations will be identified and classified for each patient during 
a blind data review. 
Pharmacokinetic set 
All patients of the FAS will also be included in the PK set, if they have completed at least two of 
the scheduled PK samples. 
Assignment of analysis sets to analyses and allocation of patients 
All efficacy analyses will be based on the FAS. The primary efficacy endpoint only will be 
additionally analyzed for the PP set. The analysis of the primary efficacy endpoint using the FAS 
will be considered confirmatory. All other analyses will be exploratory. Safety analyses will be 
based on the SAF. 
The allocation of patients to the analysis sets for the final analysis of the induction and maintenance 
phase will be done separately during a blind data review meeting for the induction and maintenance 
phase, respectively. The allocation of patients to the PP set needs only to be done for the induction 
phase since the primary endpoint belongs to the induction phase. The analysis sets to be used for 
the interim analysis between the 2 enrollment periods, for the explorative analysis of the 
maintenance phase, and for the analysis of the open-label treatment extension will be defined in 
the corresponding SAPs. 
16.3 
Statistical analyses 
For qualitative variables, the frequencies (absolute and relative) will be calculated. Quantitative 
parameters will be described by declaring the mean value, standard deviation, minimum, first 
quartile, median, third quartile, and maximum. The different treatment groups will be separately 
tabulated. A detailed description of the statistical analyses for all scheduled analyses (i.e. interim 
analysis, explorative analysis of maintenance phase, final analysis induction phase, final analysis 
maintenance phase, and analyses for the open-label phase) will be provided in respective SAPs. To 
minimize bias, the SAP for the induction period (which includes the primary endpoint of the study) 
was finalized before any data was analyzed in the interim analysis. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 118 of 139 
 
Confidential 
 
 
16.4 
Primary efficacy analysis 
The primary endpoint for this study is the composite endpoint of proportion of patients with both, 
symptomatic remission and endoscopic healing at Week 10. 
All patients (both, Enrollment Period 1 and Enrollment Period 2 patients) who were randomized to 
30 mg/day or 45 mg/day IMU-will be pooled and compared with placebo. 
A stratified Cochran-Mantel-Haenszel test will be used for the analysis of the primary endpoint to 
adjust for the stratification factors prior use of any biologics and current use of corticosteroids.  
In this early stage development study a higher α, i.e. 0.1, than the standard 0.025 level is considered 
appropriate. Due to the interim analysis (conducted after approximately 60 patients had been 
randomized into Enrollment Period 1 and had received at least 1 dose of IMU-838) and to keep the 
overall α-level to 0.1, this level must be adjusted. A group sequential design with O’Brien-Fleming 
boundaries will be applied. Accordingly, a significance level of 0.097, 1-sided, will be used for the 
primary efficacy analysis. 
Patients discontinuing from the study during the induction phase due to the underlying disease will 
be counted as "treatment failures" (i.e. not achieving the primary endpoint), if these patients had at 
least 2 valid assessments of the Mayo PRO-2 score post-baseline, and had received at least 6 weeks 
of treatment without any major protocol deviations of the dosing schedule (as defined in the SAP), 
and had the Week 10/EoI sigmoidoscopy performed at the time of discontinuation (when 
discontinuation occurred before Week 10). Any discontinuation for other reasons or patients not 
fulfilling these criteria will be considered “dropouts” for the primary efficacy analysis. For 
dropouts between Week 6 and Week 10, the EoI value will be carried forward. In case that the 
corresponding information is missing or that the patient drops out before Week 6, the patient will 
constitute a missing value for the primary efficacy analysis. 
16.5 
Interim analysis 
An interim analysis was conducted after approximately 60 patients had been randomized into 
Enrollment Period 1 and had received at least 1 dose of IMU-838. The aim of this interim analysis 
was to identify ineffective and/or intolerable IMU-838 dose(s).  
An independent DRC assessed unblinded safety and efficacy data and gave recommendation on 
the dose(s) selection for Enrollment Period 2. A charter, which includes a detailed description of 
responsibilities and the procedures on dose selection, was implemented prior to data base lock for 
this interim analysis. 
Safety interim analyses may be performed during the open-label treatment extension at the request 
of the sponsor or the Steering Committee to support regulatory filings or as part of intended 
program-wide safety evaluations of IMU-838. This safety analysis will summarize any safety and 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 119 of 139 
 
Confidential 
 
 
tolerability data (including laboratory data) specifically for the extension period only. These safety 
assessments may be supplemented by complementary data regarding the clinical and disease status 
of patients. No unblinding is required as the interim analyses will be performed during the open-
label part of the extended treatment period. 
16.6 
Final analysis of induction phase 
The final analysis of the induction phase will be conducted when all patients in both enrollment 
periods have either completed or discontinued the induction phase (including extended induction 
phase, if applicable). A data base closure will be performed prior to this analysis. All parameters 
belonging to the induction phase will be checked, as specified in the data validation plan, and all 
queries resolved before data base closure and analysis. A blind data review will be conducted prior 
to unblinding for the induction phase based on all data to check for protocol deviations and to 
allocate the patients to the analysis sets. 
16.7 
Explorative analysis of maintenance phase 
An exploratory analysis of the maintenance phase will be conducted at the time of the final analysis 
of the induction phase. It will be based on the parameters belonging to the maintenance phase that 
are available at that time point. A detailed description of the analyses will be provided in the 
corresponding SAP. 
16.8 
Final analysis of maintenance phase 
The final analysis of the maintenance phase will be conducted when all corresponding patients 
have either completed or discontinued the maintenance phase. A data base closure will be 
performed prior to this analysis. All parameters belonging to the maintenance phase will be 
checked, as specified in the data validation plan, and all queries will be resolved before data base 
closure and analysis. A blind data review will be conducted prior to unblinding for the maintenance 
phase based on all data to check for protocol deviations and to allocate the patients to the analysis 
sets. 
17 
Patient withdrawal from study participation 
Participation in the study is voluntary and patients may withdraw from the study at any time and 
for any reason. However, all patients should be encouraged to complete the study. If a patient 
withdraws or is withdrawn from study, the patient should return to the clinic as outlined in 
Section 12.8. All patients withdrawing from the study should also be encouraged to complete the 
EoS assessment 30 days after the last intake of study drug.  
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 120 of 139 
 
Confidential 
 
 
Patients must be withdrawn from the study for any of the following reasons (the primary reason 
leading to patient withdrawal should be documented):  
• Patient withdraws consent due to 
o AE(s) 
o UC relapse, disease exacerbation, and/or ongoing disease activity 
o other reason (to be specified) 
• Investigator decision due to  
o AE(s), which in the opinion of the investigator may jeopardize the patient’s health or 
may compromise the study objectives 
o relevant non-compliance with the protocol, which in the opinion of the investigator 
may jeopardize the study integrity or scientific goals of the study 
o reasons other than AE or non-compliance (to be specified) 
• Pregnancy 
• Stopping criteria regarding liver enzymes (Section 11.5.2) 
• Treatment with prohibited concomitant medication 
• Transfer to another long-term follow-up study 
• Transfer to commercial vidofludimus calcium 
• The patient has fully completed this study 
The primary reason for discontinuation from the study is to be recorded in the source documents 
and on the eCRF. 
Patients who prematurely discontinue the study will be treated according to the investigator’s 
discretion and standard treatment guidelines, irrespective of the reason for withdrawal. 
Reasonable efforts should be made to contact any patient lost to follow up, to complete assessments 
(including an EoS assessment) and to retrieve any outstanding data and study medication and 
supplies. 
Patients who prematurely discontinue the study will not be replaced.  
18 
Ethical and legal requirements 
18.1 
Ethical conduct of the study 
The study will be conducted in a manner consistent with all applicable regulatory authority and 
IRB/IEC regulations (e.g. ICH Guideline for Good Clinical Practice [GCP, CPMP/ICH/135/95], 
the Declaration of Helsinki [in its currently acknowledged version], IRBs [21 CFR 56], and 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 121 of 139 
 
Confidential 
 
 
Obligations of Clinical Investigators [21 CFR 312]) as well as in keeping with applicable local 
law(s) and regulation(s). The investigator must also comply with all applicable privacy regulations 
(e.g. Health Insurance Portability and Accountability Act of 1996 [HIPAA], European Union Data 
Protection Directive 95/46/EC). 
Financial disclosure by the investigator(s) pursuant to 21 CFR Part 54 will be obtained. 
18.2 
Independent ethics committee or institutional review board 
Before the initiation of the clinical trial, the final protocol, any amendments if applicable, the 
patient information sheet and consent form, as well as any additional documents which are required 
by national regulations and the IEC or IRB will be submitted to the competent IEC or IRB for 
review. A favorable opinion for the clinical trial must be obtained from the IEC or IRB before any 
patient is enrolled at a center.  
If appropriate, any additional requirements imposed by the IEC or IRB will be followed. 
Amendments to the study documents will be notified to, or approved by, the IEC or IRB before 
implementation, if applicable. 
18.3 
Patient information and consent procedure 
Before any clinical study-related activities are performed, the investigator (or authorized designee) 
must review the informed consent form and explain the study to potential study participants. The 
investigator must ensure that the patient is fully informed about the aims, procedures, potential 
risks, any discomforts, and expected benefits of the clinical trial. Before consenting, the patient 
must be left with ample time to consider and ask questions. It must be emphasized that participation 
is voluntary and that the patient has the right to withdraw from the clinical trial at any time without 
prejudice. The patient and the investigator must then sign and date the consent form before the 
conduct of any study procedures.  
A copy of the patient information and informed consent form will be given to the patients for their 
records. The rights and welfare of the patients will be protected by emphasizing to them that the 
quality of their medical care will not be adversely affected if they decline to participate in this 
clinical trial. 
If amendments to the final study protocol affect the patient’s participation in the clinical trial (e.g. 
a change in any procedure), the patient information and informed consent form must be updated to 
incorporate this modification, and patients must agree to sign the amended form indicating that 
they re-consent to participate in the clinical trial. 
For sites in the United States of America: The investigator will comply with all applicable state 
and federal requirements, including the requirement of the HIPPA Privacy Rule. The authorization 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 122 of 139 
 
Confidential 
 
 
to use and disclose protected health information for research is part of the informed consent form, 
and a signed copy of the informed consent form must be placed in the study record. 
18.4 
Insurance coverage 
Insurance coverage for damages emerging from the clinical trial will be provided according to 
applicable legal requirements. During the informed consent procedure, the investigator must 
inform the patient accordingly. Insurance details will be provided to the patient within the patient 
information sheet. 
18.5 
Submission to authorities 
Documents required for the study application will be submitted to the responsible competent 
authority (CA). The study will not start until this authority has authorized the study. Amendments 
to the study protocol or to any other documents that must be reviewed by the CA will also be 
submitted to the CA in accordance with the regulatory requirements. If applicable, approval of the 
amendment must be awaited before implementing any changes. 
18.6 
Patient confidentiality 
The study protocol, documentation, data, and all other information generated will be held in strict 
confidence. No information concerning the clinical trial or the data will be released to any 
unauthorized third party without prior written approval of the sponsor. 
Personal patient data will be kept confidential in compliance with the European Data Protection 
Directive [8] (or General Data Protection Regulation [9] whichever applies), the HIPPA Privacy 
Rule, and other applicable international and national requirements.  
The investigator must ensure that the pseudonymity of study participants will be maintained and 
that their identities are protected from unauthorized parties. In eCRFs, compensation 
documentation, or any other documents submitted to the sponsor or sponsor’s designee, patients 
must be identified only by their identification codes; it is not allowed to use their names, addresses, 
telephone numbers, or similar information. The investigator will keep the original of the Patient 
Identification Log (including complete name and date of birth of each patient) in his/her file. The 
investigator must maintain these documents in strict confidence. 
To allow compliance with GCP, all patients will be asked for consent regarding the access to their 
personal clinical study-related data for monitoring, audits, and inspections as well as regarding 
transmission and storage of their pseudonymous data; a respective statement will be part of the 
informed consent form. Professionals getting access to source data for monitoring, audits and 
inspections are bound to preserve strict confidentiality. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 123 of 139 
 
Confidential 
 
 
19 
Criteria for premature termination of the trial and criteria for 
initializing and closing a study center 
19.1 
Criteria for halting or terminating the study 
The sponsor reserves the right to halt or terminate the study at any time. Reasons for termination 
include but are not limited to: 
• Potential health risk for the patients 
• High withdrawal rate 
• New scientific knowledge becomes available that makes the objectives of the study no 
longer feasible/valid 
• Insufficient enrollment of patients 
• All patients have been transferred to a long-term follow-up trial or to commercial supply of 
vidofludimus calcium 
• All patients have completed the full duration of this study 
19.2 
Criteria for closing a study center 
A study center may be closed for the following reasons: 
• The center is unable to recruit sufficient patients within the agreed time frame 
• The center does not respond to study management requests 
• Repeated protocol deviations or non-compliance 
• The approval of the IEC or IRB in charge of the clinical trial is irrevocably revoked 
• Additional local criteria might be established by written agreements between the sponsor 
and the study center 
• All patients of this trial center have completed the full duration of this trial, have been 
transferred or have otherwise withdrawn from this trial, and investigators have stated in 
writing that they will provide answers to queries after trial site closure 
The sponsor will notify the relevant CA, IEC(s), IRBs, and investigator(s) in writing about 
termination of individual centers or the whole study. 
The investigator may terminate his/her participation prematurely. If the investigator decides to 
terminate his/her participation before the trial is completed, he/she will notify the sponsor in writing 
stating the reasons for early termination. In terminating the study, the sponsor and the investigator 
will ensure that adequate consideration is given to the protection of the patients’ interests.  
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 124 of 139 
 
Confidential 
 
 
The investigator will notify the relevant CAs, IEC(s), or IRBs in writing if required, submit a copy 
of this notification to the sponsor and return the entire study medication and all related study 
material, as applicable, to the sponsor. Concerned eCRFs will be archived at the site. Authorization 
to access and edit the eCRF will be removed from the investigator and all authorized delegates. 
20 
Study protocol, documentation and archiving of data 
20.1 
Amendments to the protocol 
Any change to the protocol concerning the purpose of the study, the study design, or the patient’s 
eligibility can only be made in the form of a written amendment to the study protocol. Such 
amendments have to be discussed and signed by the sponsor and the investigator before 
implementation.  
Substantial amendments, i.e. amendments which are likely to affect to a significant degree 
• the safety or physical or mental integrity of the patients of the study 
• the scientific value of the study 
• the conduct or management of the study, or 
• the quality or safety of any IMP used in the study 
will be submitted to the CA and IEC or IRB for an approval and favorable opinion as required by 
applicable regulations. If such amendments affect the patient’s participation in the clinical study 
(e.g. a change in any procedure), the patient information and informed consent form must be 
updated to incorporate this modification, and currently enrolled patients must re-consent to 
participate in the clinical trial. 
Non-substantial changes, e.g. minor corrections of administrative nature and/or rephrasing, which 
do not meet the above criteria for being substantial are considered editorial changes. The IEC/IRB 
and CA do not need to be notified of such minor corrections. Non-substantial amendments will be 
signed by the sponsor only. 
If new events occur related to the conduct of the study or the development of the study medication, 
which may affect the safety of the patients, the sponsor and the investigator will take appropriate 
safety measures to protect the patients against any immediate hazard. The sponsor will immediately 
inform the CA and IEC or IRB of the new events and the measures taken. 
20.2 
Protocol deviations 
A protocol deviation is a failure to follow, intentionally or unintentionally, the requirements of the 
protocol. As required by national regulation or guidelines, reports of deviations will be provided 
to the IEC or IRB. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 125 of 139 
 
Confidential 
 
 
Under emergency circumstances deviations from the protocol may proceed without prior approval 
by the sponsor and favorable opinion of the IEC or IRB if the rights, safety and well-being of the 
patients need to be protected. Such deviations will be documented and reported to the sponsor and 
the IEC or IRB as soon as possible in accordance with national regulations. 
All protocol deviations will be listed and if the patients concerned will be evaluable for analysis 
will be discussed in a data review meeting prior to the statistical analyses. 
20.3 
Data retention 
The study center, the sponsor or sponsor’s designee(s) should maintain all study records according 
to ICH GCP and applicable regulatory requirement(s). Records will be retained until at least 2 years 
after the last approval of a marketing application in an ICH region, until there are no pending or 
contemplated marketing applications in an ICH region, until at least 2 years have elapsed since the 
formal discontinuation of clinical development of the tested study medication, and at least 15 years 
after the end of the trial, whichever period is longer. The final report will be kept for another 5 years 
after the drug was taken off the market according to the legal stipulations. The documents should 
however, be archived for a longer period if required by the applicable regulatory authorities or if 
agreed with the sponsor. It is the responsibility of the sponsor to inform the investigators when 
these documents are no longer needed to be retained. 
The medical files of study patients must be retained in accordance with local legislation and in 
accordance with the maximum period of time permitted by the hospital, institution or private 
practice. 
21 
Data collection, monitoring and quality assurance 
21.1 
Data collection 
All data will be collected on an eCRF and provided for each patient. eCRFs will be provided as a 
regulatory compliant, electronically secure and protected web-based database, and should be 
handled in accordance with the instructions provided. An audit trail will record all entries and 
corresponding changes. 
The study sites will be provided with secure access to and training on the eCRF. 
All data generated after the patient has given informed consent must be recorded in the eCRF. The 
investigator is responsible for ensuring accurate and proper completion of the eCRF. 
Only investigators and authorized designees will enter and edit the data via a secure network and 
a secure access system. Completed data for each visit will be approved by the investigator or 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 126 of 139 
 
Confidential 
 
 
authorized designee using an electronic signature to confirm the accuracy of the data. Any change 
or addition will be recorded by an electronic audit trail system. 
The investigator or designee has to carefully answer queries issued by data management. 
21.2 
Monitoring 
The extent of monitoring and source data verification will be specified in a monitoring plan. 
The study center must not enroll any patient before the initiation visit. During the study further 
monitoring visits will be performed according to ICH GCP, the sponsor’s designee’s standard 
operating procedures, and local regulations. eCRFs will be reviewed against source data for 
adherence to the study protocol and ICH GCP, as well as for completeness, accuracy, and 
consistency of data. Additionally, the monitor will check the progress of enrolment, and will ensure 
that the study drug is being stored, dispensed and accounted for according to specifications. Key 
study personnel must be available to assist the monitor during these visits. 
The investigators must permit the monitors access to the patient’s medical records and all 
applicable source documents. Throughout the study, all data captured in the eCRF will only be 
identified by patient number. The data will be blinded correspondingly in all data analyses. 
It is the investigators’ obligation to assure documentation of all relevant data in the patient’s file, 
such as medical history and concomitant diseases, date of study enrolment, visit dates, results of 
examinations, administrations of medication, and AEs. 
21.3 
Audits and inspections 
During the study, audits may be performed by independent auditors. Audits of clinical research 
activities will be performed in accordance with corresponding standard operating procedures to 
ensure compliance with the principles of GCP. 
Regulatory authorities may wish to conduct an inspection. If an inspection is requested, the 
investigator must inform the sponsor or sponsor’s designee immediately. 
The investigator must allow auditors or inspectors access to source data and documents and will 
answer any questions. 
21.4 
Data management procedures 
All data management activities will be conducted by FGK Clinical Research following their 
standard operating procedures. 
Details on data handling will be described in the data management plan. Data entered into the eCRF 
will be validated through online edit checks and offline checks run by the data manager according 
to the data validation plan. For all identified discrepancies, the data manager will raise a query in 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 127 of 139 
 
Confidential 
 
 
the electronic data capture application. The appropriate investigational personnel will answer the 
queries in the eCRF, which will be audit trailed by the electronic data capture application. 
The sponsor’s designee will handle the data cleaning process, query process, and coding. 
For the final analyses of the induction and maintenance phase as well as after termination of the 
open-label phase, the respective database will be locked when it is considered complete and 
accurate and after all changes following the data review meeting (if applicable) are included (i.e. 
all data cleaning activities performed). All changes will be tracked (audit trail). Sponsor approval 
prior to database lock is mandatory. For other analyses (interim analysis, explorative analysis of 
maintenance phase, and regular analyses for open-label phase), a soft lock will be performed to 
preserve the status of the database used for the corresponding analyses. 
22 
Study report and publications 
The results of the final analyses of the induction phase will be summarized in a clinical study report 
according to the ICH E3 Note for guidance on structure and content of clinical study reports. 
Results of the exploratory data reviews, and final analysis of the maintenance phase will be reported 
in respective abbreviated reports. Short summaries will be provided for the regular analyses of the 
open-label treatment. 
The reports will be submitted to investigators as well as to regulatory authorities and IECs, as 
appropriate, within the timeframes defined per national regulation or by the IEC.  
The preparation and submission of abstracts of manuscripts including the study results must be in 
line with the process specified in the investigator’s clinical trial agreement. The publication or 
presentation of any study results shall comply with all applicable privacy laws, for example, the 
HIPAA. 
23 
Study periods 
Actual start: 
25-Jun-2018 (first patient in) 
Estimated end main maintenance phase: 
Oct 2022 (main part: last patient out)  
Open-label treatment:  
Not defined, but maximum treatment duration in 
this trial limited to a maximum of 10 years 
(including all phases of the trial; in UK: 
maximum of 4 years). Patients may also be 
transferred to a follow-up trial or to 
commercially available vidofludimus calcium, if 
applicable for patients with access 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 128 of 139 
 
Confidential 
 
 
Actual recruitment period: 
~41 months (24-Apr-2018 to 30-Sep-2021) 
 
The end of the study is defined as last patient visit in any participating center. 
 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 129 of 139 
 
Confidential 
 
 
24 
References 
1. 
Kaplan GG, Ng SC. Understanding and Preventing the Global Increase of Inflammatory 
Bowel Disease. Gastroenterology 2017;152(2):313-21.e2. 
2. 
EMA. Guideline on the development of new medicinal products for the treatment of 
Ulcerative Colitis.[Online]. 2016. Available from: 
 
http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2016/07/
WC500211431.pdf. 
3. 
FDA. Ulcerative Colitis: Clinical Trial Endpoints. Guidance for Industry.[Online]. 2016. 
Available from: 
 
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guid
ances/UCM515143.pdf. 
4. 
Dignass A, Eliakim R, Magro F, Maaser C, Chowers Y, Geboes K, et al. Second European 
evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: 
definitions and diagnosis. J Crohns Colitis 2012;6(10):965-90. 
5. 
Grossfeld GD, Wolf JS, Jr., Litwan MS, Hricak H, Shuler CL, Agerter DC, et al. 
Asymptomatic microscopic hematuria in adults: summary of the AUA best practice policy 
recommendations. Am Fam Physician 2001;63(6):1145-54. 
6. 
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for 
mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 
1987;317(26):1625-9. 
7. 
AUA. Guideline: Diagnosis, evaluation and follow up of asymptomatic mircrohematuria 
(AMH) 
in 
adults.[Online]. 
2012. 
Available 
from: 
http://www.auanet.org/guidelines/asymptomatic-microhematuria. 
8. 
EU. Directive 95/46/EC of the European Parliament and of the Council of 24 October 1995 
on the protection of individuals with regard to the processing of personal data and on the 
free movement of such data.[Online]. Available from:  http://eur-lex.europa.eu/legal-
content/EN/TXT/?uri=CELEX%3A31995L0046. 
9. 
EU. Regulation 2016/679 on the protection of natural persons with regard to the processing 
of personal data and on the free movement of such data, and repealing Directive 95/46/EC 
(General Data Protection Regulation).  2016;[Online]. Available from: http://eur-
lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:32016R0679. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 130 of 139 
 
Confidential 
 
 
25 
Approval and signatures 
 
Protocol agreed to by sponsor:  
 
 
 
 
Sponsor’s signatory name (print) 
 
 
 
 
 
 
 
Sponsor’s signatory signature 
 
Date 
 
 
Protocol agreed to by coordinating investigator: 
 
 
 
 
 
Coordinating investigator name (print) 
 
 
 
 
 
 
 
Coordinating investigator signature 
 
Date 
 
 
             

          
      



P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 131 of 139 
 
Confidential 
 
 
Principal investigator agreement page for the protocol 
I agree: 
• 
To assume responsibility for the proper conduct of the clinical study at this site, and to 
conduct the study in compliance with national law, the valid version of the Declaration of 
Helsinki, the GCP-guidelines, the present study protocol including its amendments, and 
with any other study conduct procedures provided by the sponsor or authorized 
representatives. 
• 
Not to implement any deviations from or changes to the protocol (including protocol 
amendments) without agreement from the sponsor and prior review and favorable opinion 
from the ethics committee or institutional review board and approval from the competent 
authority, if applicable, except where necessary to eliminate an immediate hazard to the 
patient(s), or for administrative aspects of the clinical study (where permitted by all 
applicable regulatory requirements). 
• 
That I am familiar with the appropriate use of the investigational medicinal product as 
described in this protocol and any other information provided by the sponsor including, but 
not limited to, the current investigator’s brochure or equivalent document provided by the 
sponsor. 
• 
To ensure that all persons assisting me with the clinical study are adequately informed about 
the investigational medicinal product and of their study-related duties and functions. 
• 
That I have been informed that certain regulatory authorities require the sponsor to obtain 
and supply details about the investigator’s ownership interest in the sponsor or the study 
product, and more generally about his/her financial ties with the sponsor. The sponsor will 
use and disclose the information solely for the purpose of complying with regulatory 
requirements. 
 
 
 
 
 
Principal investigator name (print) 
 
 
 
 
 
 
 
 
Principal investigator signature 
 
Date 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021  
Page 132 of 139 
 
Confidential 
 
 
26 
Appendices 
 
 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021 
Page 133 of 139 
 
Confidential 
 
 
Appendix 1 
Prior and concomitant treatments 
 
Withdrawal 
before 
Random. 
Induction phase 
Maintenance phase 
Open-label 
extension 
UC treatments 
 
 
 
 
Oral systemic corticosteroids 
>20 mg/day prednisolone equivalent 
including beclomethasone dipropionate 
(at >5 mg/day) and budesonide (MMX 
at >9 mg/day)  
2 weeks 
Not allowed 
Not allowed 
Not allowed 
(short course of 
no more than 6 
weeks allowed to 
treat UC flares) 
Oral systemic corticosteroids 
≤20 mg/day prednisolone equivalent 
including beclomethasone dipropionate 
(at ≤5 mg/day) and budesonide (MMX 
at ≤9 mg/day)  
- 
Allowed if already used for at 
least 4 weeks and at a stable 
dose of ≤20 mg/day (≤9 mg/day 
for budesonide and and ≤5 
mg/day for beclomethasone 
dipropionate) for at least 2 
weeks before first 
randomization; dose must be 
stable throughout induction 
phase 
Allowed if already used for at least 
4 weeks and at a stable dose of 
≤20 mg/day (≤9 mg/day for 
budesonide or ≤5 mg/day for 
beclomethasone diproprioniate) for 
at least 2 weeks before first 
randomization; dose can be 
changed but must be ≤20mg/day 
(≤9 mg/day for budesonide, and 
(≤5 mg/day for beclomethasone 
diproprioniate). 
Tapering must be initiated (see 
Section 11.3) 
Allowed, can be 
initiated  
Oral aminosalicylates (e.g. mesalazines) 
>4 g/day 
2 weeks 
Not allowed 
Not allowed 
Not allowed 
 
 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021 
Page 134 of 139 
 
Confidential 
 
 
Prior and concomitant treatments (continued) 
 
Withdrawal 
before 
Random. 
Induction phase 
Maintenance phase 
Open-label 
extension 
Oral aminosalicylates (e.g. mesalazines) 
≤4 g/day 
 
Allowed if they had been used 
for at least 6 weeks and with a 
stable dose for at least 3 weeks 
before first randomization, dose 
must be stable throughout 
induction phase at ≤4 g/day 
Allowed if they had been used for 
at least 6 weeks and with a stable 
dose for at least 3 weeks before first 
randomization and during 
induction; dose can be changed but 
must be maintained ≤4 g/day 
Can be initiated 
at stable doses  
Biologics to treat UC: 
Anti-TNFα antibodies (infliximab, 
adalimumab, golimumab, including 
their biosimilars)  
Vedolizumab and ustekinumab  
 
 
 
4 weeks 
8 weeks 
 
 
 
Not allowed 
Not allowed 
 
 
 
Not allowed 
Not allowed 
 
 
 
Allowed 
Allowed (if 
licensed for UC) 
Rectal or topical treatments (enemas or 
suppositories) containing 
aminosalicylates and/or budesonide  
4 weeks 
Not allowed 
Not allowed 
Allowed 
Oral and/or systemic antibiotic 
treatments used for a Clostridium 
difficile infection or other bacterial 
infections 
30 days 
Not allowed 
Not allowed 
Allowed 
Intravenous corticosteroids 
4 weeks 
Not allowed 
Not allowed 
Not allowed 
Janus kinase inhibitors approved for 
the treatment of IBD (e.g. tofacitinib) 
2 weeks 
Not allowed 
Not allowed 
Not allowed 
Thiopurines (e.g. azathioprine, 
6-mercaptopurine, 6-thioguanine)  
4 weeks 
Not allowed 
Not allowed 
Not allowed 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021 
Page 135 of 139 
 
Confidential 
 
 
Prior and concomitant treatments (continued) 
 
Withdrawal 
before 
Random. 
Induction phase 
Maintenance phase 
Open-label 
extension 
Use of other DHODH inhibitor (i.e. 
leflunomide or teriflunomide)  
6 months 
Not allowed 
Not allowed 
Not allowed 
Natalizumab (Tysabri™) 
12 months 
Not allowed 
Not allowed 
Not allowed 
Methotrexate, mycophenolate mofetil, or 
any calcineurin inhibitors (e.g. 
tacrolimus, cyclosporine or 
pimecrolimus) 
2 weeks 
Not allowed 
Not allowed 
Not allowed 
Other treatments 
 
 
 
 
Any investigational product  
8 weeks or 
5 x the 
respective 
half-life 
Not allowed 
Not allowed 
Not allowed 
Any drug significantly restricting water 
diuresis, in particular vasopressin and 
vasopressin analogs 
- 
Not allowed 
Not allowed 
Not allowed 
Any medication known to significantly 
increase urinary elimination of uric acid, 
in particular lesinurad (Zurampic™) as 
well as uricosuric drugs such as 
probenecid 
- 
Not allowed 
Not allowed 
Not allowed 
Rosuvastatin ˃10 mg/day 
Not allowed 
during 
Screening 
Not allowed 
Not allowed 
Not allowed 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021 
Page 136 of 139 
 
Confidential 
 
 
Prior and concomitant treatments (continued) 
 
Withdrawal 
before 
Random. 
Induction phase 
Maintenance phase 
Open-label 
extension 
Any active treatments for malignant 
disease (in particular irinotecan, 
paclitaxel, tretinoin, bosutinib, sorafinib, 
enasidenib, erlotinib, regorafenib, 
pazopanib and nilotinib) 
- 
Not allowed 
Not allowed 
Not allowed 
Life vaccine 
30 
Not allowed 
Not allowed 
Not allowed 
Sphingosine-1-receptor (S1P) 
modulators (including, but not limited to 
fingolimod, siponimod, and ozanimod), 
monomethyl fumarate, and diroximel 
fumarate 
- 
Not allowed 
Not allowed 
Not allowed 
Restricted medications 
Restricted concomitant medications are not generally prohibited, but use should be restricted in terms of 
dose and treatment duration, if possible. In accordance with the prescribing information, the lowest 
effective dosage for the shortest duration should be applied based on the individual patient treatment goals 
whenever possible. Alternatives to these drugs should be considered and patients should be carefully 
monitored for any indication of overdose and/or toxicity. 
CYP2C8 strong inducers: rifampicin, 
barbiturates (e.g. phenobarbital), 
carbamazepine, ritonavir 
- 
Potentially decrease exposure to IMU-838 and may thus decrease efficacy. 
CYP2C8 strong inhibitors: gemfibrozil, 
clopidogrel 
- 
Potentially increase exposure to IMU-838 and may thus increase the risk for AEs; however 
uncertain due to alternative metabolic pathways of IMU-838. 
BCRP substrates with a narrow 
therapeutic window: rosuvastatin 
(maximum dose: 10 mg/day), 
mitoxantrone, sulfasalazine, topotecan, 
daunorubicin, doxorubicin, warfarin 
- 
IMU-838 may inhibit transport of BCRP substrates and lead to increased exposure in 
plasma and/or hepatocytes and thus increased risk for substrate’s side effects. 
Patients should be closely monitored for signs and symptoms of excessive exposure to 
these medications and dosing of these medications should be carefully considered. Statins 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021 
Page 137 of 139 
 
Confidential 
 
 
Prior and concomitant treatments (continued) 
 
Withdrawal 
before 
Random. 
Induction phase 
Maintenance phase 
Open-label 
extension 
(Note: methotrexate is not allowed, see 
above) 
should be lowered to the lowest possible dose. See also rosuvastatin which is not allowed at 
doses >10 mg daily. 
BCRP strong inducers: DMARDs such 
as sulfasalazine (Note: methotrexate is 
not allowed, see above) 
- 
Potentially decrease exposure to IMU-838 and may thus decrease efficacy. 
BCRP strong inhibitors: 
immunosuppressants (cyclosporine A, 
tacrolimus, sirolimus), azole anti-fungals 
(ketoconazole, itraconazole, 
fluconazole), proton pump inhibitors 
(omeprazole, pantoprazole), NSAIDs 
(ibuprofen, naproxen, salicylates) 
- 
Potentially increase exposure to IMU-838 and may thus increase the risk for AEs. 
UGT1A1 inhibitors: atazanavir, 
canagliflozin, pazopanib, regorafenib, 
sorafenib, tocilizumab, tranilast 
- 
Combination therapy of IMU-838 and other UGT1A1 inhibitors may lead to disturbance of 
the bilirubin metabolism and subsequently to hyperbilirubinemia. 
BCRP = breast 
cancer 
resistance 
protein, 
CYP = cytochrome 
P450, 
DHODH = dihydroorotate 
dehydrogenase, 
DMARD = disease-modifying 
anti-rheumatic 
drug, 
MMX = MMX = multi-matrix, NSAID = non-steroidal anti-inflammatory drug, rando. = randomization, TNFα = tumor necrosis factor α, UC = ulcerative colitis. 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021 
Page 138 of 139 
 
Confidential 
 
 
Appendix 2 
Geboes score for assessment of ulcerative colitis histologic 
disease activity 
Grade 0 
Structural (architectural changes) 
Subgrades 
0.0 
No abnormality 
0.1 
Mild abnormality 
0.2 
Mild or moderate diffuse or multifocal abnormalities 
0.3 
Severe diffuse or multifocal abnormalities 
Grade 1 
Chronic inflammatory infiltrate 
Subgrades 
1.0 
No increase 
1.1 
Mild but unequivocal increase 
1.2 
Moderate increase 
1.3 
Marked increase 
Grade 2 
Lamina propria neutrophils and eosinophils 
2A Eosinophils 
2A.0 No increase 
2A.1 Mild but unequivocal increase 
2A.2 Moderate increase 
2A.3 Marked increase 
2B Neutrophils 
2B.0 No increase 
2B.1 Mild but unequivocal increase 
2B.2 Moderate increase 
2B.3 Marked increase 
Grade 3 
Neutrophils in epithelium 
Subgrades 
3.0 
None 
3.1 
<5% Crypts involved 
3.2 
<50% Crypts involved 
3.3 
>50% Crypts involved 
Grade 4 
Crypt destruction 
Subgrades 
4.0 
None 
4.1 
Probable-local excess of neutrophils in part of crypt 
4.2 
Probable-marked attenuation 
4.3 
Unequivocal crypt destruction 
Grade 5 
Erosion or ulceration 
Subgrades 
5.0 
No erosion, ulceration, or granulation tissue 
5.1 
Recovering epithelium+ adjacent inflammation 
5.2 
Probable erosion focally stripped 
5.3 
Unequivocal erosion 
5.4 
Ulcer or granulation tissue 
 
             


P2-IMU-838-UC (CALDOSE-1) 
Study protocol  
Final 6.0, 14-Dec-2021 
Page 139 of 139 
 
Confidential 
 
 
Appendix 3 
Patient flow chart P2-IMU-838-UC 
 
CM concomitant medication, D = day, EC = exclusion criteria, EoI = end-of-induction (phase), EoM = end-of-maintenance (phase), IC = inclusion criteria, ICF = informed consent 
form, PK = pharmacokinetics, W = week, UC = ulcerative colitis. 
            